STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 119109

TO: Sean McGarry
Location: REM-2D19/2C18
Art Unit: 1635
Thursday, April 08, 2004
Case Serial Number: 10/002491

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: (571)272-2527

paul.schulwitz@uspto.gov

Search Notes

Examiner McGarry,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2527

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 8, 2004, 15:27:30 ; Search time 0.001 Seconds
(without alignments)
456.908 Million cell updates/sec

Title: us-10-002-491-3
Perfect score: 2218
Sequence: 1 acgagactctctcctcctcc.....aaaaaaaaaaaaaaaaaaa 2218

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 8 seqs, 103 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		12.4	0.6	14	1	CF279993	ACCESSION:CF279993
c 2		11	0.5	13	1	BQ587101	ACCESSION:BQ587101
c 3		10.4	0.5	12	1	BQ587288	ACCESSION:BQ587288
c 4		10.4	0.5	12	1	BQ587706	ACCESSION:BQ587706
5		10.4	0.5	13	1	BQ589768	ACCESSION:BQ589768
c 6		10.4	0.5	13	1	BQ594714	ACCESSION:BQ594714
7		10.4	0.5	13	1	CF299609	ACCESSION:CF299609
8		10.4	0.5	13	1	CF300659	ACCESSION:CF300659
c 9		9.8	0.4	14	1	CF279993	ACCESSION:CF279993
c 10		8.4	0.4	13	1	BQ589768	ACCESSION:BQ589768
11		8.2	0.4	13	1	BQ594714	ACCESSION:BQ594714
c 12		8.2	0.4	13	1	CF299609	ACCESSION:CF299609
c 13		7.8	0.4	13	1	CF300659	ACCESSION:CF300659
14		7.2	0.3	12	1	BQ587288	ACCESSION:BQ587288
15		7.2	0.3	12	1	BQ587706	ACCESSION:BQ587706
16		7.2	0.3	13	1	BQ587101	ACCESSION:BQ587101

ALIGNMENTS

RESULT 1
CF279993
LOCUS CF279993 14 bp mRNA linear EST 14-AUG-2003
DEFINITION 14ETL--06-I01.g1 Rice etiolated leaf plasmid cDNA library (14ETL) Oryza sativa cDNA clone 14ETL--06-I01, mRNA sequence.
ACCESSION CF279993
VERSION CF279993.1 GI:33657379
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 14)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .14
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="14ETL--06-I01"
/tissue_type="leaf"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 0.66;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1164 AATAAAATTTTAAA 1177
              || ||||||||||||
Db          1 AAAAAAATTTTAAA 14
```

RESULT 2
BQ587101/c
LOCUS BQ587101 13 bp mRNA linear EST 06-DEC-2002
DEFINITION E012350-024-011-K22-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone 024-011-K22 5-PRIME, mRNA sequence.
ACCESSION BQ587101
VERSION BQ587101.1 GI:26116683
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 13)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 13 Std Error: 0.00
Plate: 11 row: K column: 22
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .13
/organism="Beta vulgaris"
/mol_type="mRNA"

```
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:185760"
                     /db_xref="taxon:161934"
                     /clone="024-011-K22"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match              0.5%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 2.1;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1396 TGGAAGAAAGA 1406
             ||||||||||| |
Db         12 TGGAAGAAAGA 2


RESULT 3
BQ587288/c
LOCUS       BQ587288                  12 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012340w-024-010-G19-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA
            clone 024-010-G19 5-PRIME, mRNA sequence.
ACCESSION   BQ587288
VERSION     BQ587288.1  GI:26116870
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 12   Std Error: 0.00
            Plate: 10  row: G  column: 19
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:185570"
                     /db_xref="taxon:161934"
                     /clone="024-010-G19"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match              0.5%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 3.6;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1396 TGGAAGAAAGAA 1407
             ||||||||| ||
Db         12 TGGAAGAAAAAA 1


RESULT 4
BQ587706/c
LOCUS       BQ587706                  12 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012340-024-010-G19-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone
            024-010-G19 5-PRIME, mRNA sequence.
ACCESSION   BQ587706
VERSION     BQ587706.1  GI:26117288
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 12   Std Error: 0.00
            Plate: 10  row: G  column: 19
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:185160"
                     /db_xref="taxon:161934"
                     /clone="024-010-G19"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match              0.5%;  Score 10.4;  DB 1;  Length 12;
```

Best Local Similarity 91.7%; Pred. No. 3.6;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1396 TGGAAGAAAGAA 1407
              ||||||||| ||
Db         12 TGGAAGAAAAAA 1
```

RESULT 5
BQ589768
LOCUS BQ589768 13 bp mRNA linear EST 06-DEC-2002
DEFINITION E012680-024-020-D03-SP6 MPIZ-ADIS-024-storage root Beta vulgaris cDNA clone 024-020-D03 5-PRIME, mRNA sequence.
ACCESSION BQ589768
VERSION BQ589768.1 GI:26119351
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 13)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 13 Std Error: 0.00
Plate: 20 row: D column: 03
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .13
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:190356"
/db_xref="taxon:161934"
/clone="024-020-D03"
/tissue_type="storage root"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-storage root"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.4;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1581 CCACTTCTTGAT 1592
              || |||||||||
Db          2 CCTCTTCTTGAT 13
```

RESULT 6
BQ594714/c
LOCUS BQ594714 13 bp mRNA linear EST 06-DEC-2002
DEFINITION E012441-024-024-I23-SP6 MPIZ-ADIS-024-developing root Beta vulgaris cDNA clone 024-024-I23 5-PRIME, mRNA sequence.
ACCESSION BQ594714
VERSION BQ594714.1 GI:26124297
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 13)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 13 Std Error: 0.00
Plate: 24 row: I column: 23
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .13
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:192139"
/db_xref="taxon:161934"
/clone="024-024-I23"
/tissue_type="developing root"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-developing root"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 0.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.4;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1188 AGTGCAGAAGAA 1199
              || |||||||||
Db         12 AGAGCAGAAGAA 1
```

RESULT 7
CF299609
LOCUS CF299609 13 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--03-L04.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza sativa cDNA clone 7LEAF--03-L04, mRNA sequence.
ACCESSION CF299609
VERSION CF299609.1 GI:33671370
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

```
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Oryza sativa"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:4530"
                     /clone="7LEAF--03-L04"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.4;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1167 AAAATTTTAAAA 1178
              ||||||| ||||
Db          1 AAAATTTAAAAA 12


RESULT 8
CF300659
LOCUS       CF300659                 13 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-D14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa cDNA clone 7LEAF--05-D14, mRNA sequence.
ACCESSION   CF300659
VERSION     CF300659.1  GI:33672420
KEYWORDS    EST.
SOURCE      Oryza sativa
  ORGANISM  Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Oryza sativa"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:4530"
                     /clone="7LEAF--05-D14"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.5%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 3.4;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1167 AAAATTTTAAAA 1178
              |||| |||||||
Db          1 AAAAATTTAAAA 12


RESULT 9
CF279993/c
LOCUS       CF279993                 14 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ETL--06-I01.g1 Rice etiolated leaf plasmid cDNA library (14ETL)
            Oryza sativa cDNA clone 14ETL--06-I01, mRNA sequence.
ACCESSION   CF279993
VERSION     CF279993.1  GI:33657379
KEYWORDS    EST.
SOURCE      Oryza sativa
  ORGANISM  Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Oryza sativa"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:4530"
                     /clone="14ETL--06-I01"
                     /tissue_type="leaf"
                     /dev_stage="14 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice etiolated leaf plasmid cDNA library
                     (14ETL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             0.4%;  Score 9.8;  DB 1;  Length 14;
  Best Local Similarity   84.6%;  Pred. No. 4.8;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        419 TGAAAATTTATTT 431
              | ||||||| |||
Db         13 TTAAAATTTTTTT 1


RESULT 10
BQ589768/c
LOCUS       BQ589768                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  EO12680-024-020-D03-SP6 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-020-D03 5-PRIME, mRNA sequence.
ACCESSION   BQ589768
VERSION     BQ589768.1  GI:26119351
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
```

```
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13  Std Error: 0.00
            Plate: 20  row: D  column: 03
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:190356"
                     /db_xref="taxon:161934"
                     /clone="024-020-D03"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.4%;  Score 8.4;  DB 1;  Length 13;
  Best Local Similarity   90.0%;  Pred. No. 11;
  Matches    9;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1487 TCAAGAGGAG 1496
              |||||| |||
Db         12 TCAAGAAGAG 3


RESULT 11
BQ594714
LOCUS       BQ594714                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012441-024-024-I23-SP6 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-024-I23 5-PRIME, mRNA sequence.
ACCESSION   BQ594714
VERSION     BQ594714.1  GI:26124297
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13  Std Error: 0.00
            Plate: 24  row: I  column: 23
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:192139"
                     /db_xref="taxon:161934"
                     /clone="024-024-I23"
                     /tissue_type="developing root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-developing root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             0.4%;  Score 8.2;  DB 1;  Length 13;
  Best Local Similarity   76.9%;  Pred. No. 12;
  Matches   10;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       258 TTCTTCTGGACAT 270
             ||||||| | |
Db         1 TTCTTCTGCTCTT 13


RESULT 12
CF299609/c
LOCUS       CF299609                 13 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-L04.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa cDNA clone 7LEAF--03-L04, mRNA sequence.
ACCESSION   CF299609
VERSION     CF299609.1  GI:33671370
KEYWORDS    EST.
SOURCE      Oryza sativa
  ORGANISM  Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Oryza sativa"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
```

/db_xref="taxon:4530"
/clone="7LEAF--03-L04"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.4%; Score 8.2; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 12;
Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        415 TTTCTGAAAATTT 427
              ||| | ||| |||
Db         13 TTTTTTAAATTTT 1
```

RESULT 13
CF300659/c
LOCUS CF300659 13 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--05-D14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza sativa cDNA clone 7LEAF--05-D14, mRNA sequence.
ACCESSION CF300659
VERSION CF300659.1 GI:33672420
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 13)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .13
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--05-D14"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.4%; Score 7.8; DB 1; Length 13;
Best Local Similarity 81.8%; Pred. No. 14;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1108 TTCTACATTTT 1118
              || || |||||
Db         12 TTTTAAATTTT 2
```

RESULT 14
BQ587288
LOCUS BQ587288 12 bp mRNA linear EST 06-DEC-2002
DEFINITION E012340w-024-010-G19-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone 024-010-G19 5-PRIME, mRNA sequence.
ACCESSION BQ587288
VERSION BQ587288.1 GI:26116870
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 12)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M., Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H. and Radelof,U.
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698
COMMENT Contact: Weisshaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaa@mpiz-koeln.mpg.de
Insert Length: 12 Std Error: 0.00
Plate: 10 row: G column: 19
Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES Location/Qualifiers
source 1. .12
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:185570"
/db_xref="taxon:161934"
/clone="024-010-G19"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-leaf"
/note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI; cDNA library from sugar beet, library provided by KWS Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites SalI-NotI, primer sites and orientation:
SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database:http://gabi.rzpd.de"

Query Match 0.3%; Score 7.2; DB 1; Length 12;
Best Local Similarity 75.0%; Pred. No. 17;
Matches 9; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1803 TTTTCTCTCTCA 1814
              |||| ||| ||
Db          1 TTTTTTCTTCCA 12
```

RESULT 15
BQ587706
LOCUS BQ587706 12 bp mRNA linear EST 06-DEC-2002
DEFINITION E012340-024-010-G19-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone 024-010-G19 5-PRIME, mRNA sequence.
ACCESSION BQ587706
VERSION BQ587706.1 GI:26117288
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
REFERENCE 1 (bases 1 to 12)
AUTHORS Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,

```
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 12   Std Error: 0.00
            Plate: 10  row: G  column: 19
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:185160"
                     /db_xref="taxon:161934"
                     /clone="024-010-G19"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung; Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match             0.3%;  Score 7.2;  DB 1;  Length 12;
  Best Local Similarity   75.0%;  Pred. No. 17;
  Matches    9;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1803 TTTTCTCTCTCA 1814
              |||| ||| ||
Db          1 TTTTTTCTTCCA 12


RESULT 16
BQ587101
LOCUS       BQ587101                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012350-024-011-K22-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone
            024-011-K22 5-PRIME, mRNA sequence.
ACCESSION   BQ587101
VERSION     BQ587101.1  GI:26116683
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13   Std Error: 0.00
            Plate: 11  row: K  column: 22
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:185760"
                     /db_xref="taxon:161934"
                     /clone="024-011-K22"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7; Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung; Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match             0.3%;  Score 7.2;  DB 1;  Length 13;
  Best Local Similarity   75.0%;  Pred. No. 15;
  Matches    9;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2026 TGTTACTTCAAT 2037
              | || |||| ||
Db          2 TCTTTCTTCCAT 13


Search completed: April  8, 2004, 15:27:30
Job time : 0.001 secs
```

OM nucleic - nucleic search, using sw model

Run on: April 8, 2004, 15:19:50 ; Search time 3 Seconds
(without alignments)
2.835 Million cell updates/sec

Title: us-10-002-491-3
Perfect score: 2218
Sequence: 1 acgagactctctcctcctcc.....aaaaaaaaaaaaaaaaaaa 2218

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 118 seqs, 1917 residues

Total number of hits satisfying chosen parameters: 236

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 125 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	23.6	1.1	29	1	AR096037	ACCESSION:AR096037
	2	23.6	1.1	29	1	AR217415	ACCESSION:AR217415
	3	19	0.9	23	1	AR139022	ACCESSION:AR139022
c	4	16.8	0.8	21	1	AX770644	ACCESSION:AX770644
	5	14.4	0.6	16	1	AX255622	ACCESSION:AX255622
	6	14.4	0.6	16	1	AX255665	ACCESSION:AX255665
	7	14.4	0.6	16	1	AX804490	ACCESSION:AX804490
c	8	14.4	0.6	17	1	AR046169	ACCESSION:AR046169
c	9	14.4	0.6	17	1	AR046171	ACCESSION:AR046171
	10	14.4	0.6	17	1	E04342	ACCESSION:E04342
c	11	14.4	0.6	17	1	I53221	ACCESSION:I53221
c	12	14.4	0.6	17	1	I53223	ACCESSION:I53223
	13	14.4	0.6	17	1	AR188875	ACCESSION:AR188875
	14	14.4	0.6	17	1	AR324728	ACCESSION:AR324728
	15	14.4	0.6	17	1	AR329508	ACCESSION:AR329508
	16	14.4	0.6	17	1	AX475416	ACCESSION:AX475416
	17	14.4	0.6	17	1	AX475417	ACCESSION:AX475417
c	18	14.4	0.6	17	1	AX672442	ACCESSION:AX672442
	19	14.4	0.6	17	1	AX723944	ACCESSION:AX723944
c	20	14.4	0.6	17	1	AX730352	ACCESSION:AX730352
c	21	14.4	0.6	17	1	AX733378	ACCESSION:AX733378
c	22	14.4	0.6	17	1	AX737466	ACCESSION:AX737466
c	23	14.4	0.6	17	1	AX761145	ACCESSION:AX761145
	24	14.4	0.6	17	1	BD201129	ACCESSION:BD201129
	25	14.4	0.6	17	1	BD201130	ACCESSION:BD201130
	26	14.4	0.6	17	1	BD201674	ACCESSION:BD201674
	27	14	0.6	17	1	AX731670	ACCESSION:AX731670
c	28	13.8	0.6	17	1	AR046173	ACCESSION:AR046173
	29	13.8	0.6	17	1	AR046239	ACCESSION:AR046239
	30	13.8	0.6	17	1	AR046241	ACCESSION:AR046241
	31	13.8	0.6	17	1	BD257498	ACCESSION:BD257498
c	32	13.8	0.6	17	1	I53225	ACCESSION:I53225
	33	13.8	0.6	17	1	I53291	ACCESSION:I53291
	34	13.8	0.6	17	1	I53293	ACCESSION:I53293
	35	13.8	0.6	17	1	AR186750	ACCESSION:AR186750
	36	13.8	0.6	17	1	AR187077	ACCESSION:AR187077
c	37	13.8	0.6	17	1	AR187218	ACCESSION:AR187218
c	38	13.8	0.6	17	1	AR258893	ACCESSION:AR258893
	39	13.8	0.6	17	1	AR323381	ACCESSION:AR323381
	40	13.8	0.6	17	1	AR323687	ACCESSION:AR323687
c	41	13.8	0.6	17	1	AR323828	ACCESSION:AR323828
	42	13.8	0.6	17	1	AR327770	ACCESSION:AR327770
	43	13.8	0.6	17	1	AR329509	ACCESSION:AR329509
c	44	13.8	0.6	17	1	AR401952	ACCESSION:AR401952
	45	13.8	0.6	17	1	AX216849	ACCESSION:AX216849
c	46	13.8	0.6	17	1	AX217049	ACCESSION:AX217049
c	47	13.8	0.6	17	1	AX227475	ACCESSION:AX227475
c	48	13.8	0.6	17	1	AX382377	ACCESSION:AX382377
	49	13.8	0.6	17	1	AX422007	ACCESSION:AX422007
c	50	13.8	0.6	17	1	AX422138	ACCESSION:AX422138
	51	13.8	0.6	17	1	AX422613	ACCESSION:AX422613
c	52	13.8	0.6	17	1	AX724979	ACCESSION:AX724979
	53	13.8	0.6	17	1	AX728845	ACCESSION:AX728845
	54	13.8	0.6	17	1	AX732535	ACCESSION:AX732535
c	55	13.8	0.6	17	1	AX732917	ACCESSION:AX732917
	56	13.8	0.6	17	1	AX733541	ACCESSION:AX733541
c	57	13.8	0.6	17	1	AX736911	ACCESSION:AX736911
	58	13.8	0.6	17	1	AX757371	ACCESSION:AX757371
	59	13.8	0.6	17	1	AX757539	ACCESSION:AX757539
c	60	13.8	0.6	17	1	BD067452	ACCESSION:BD067452
	61	13.8	0.6	17	1	BD187337	ACCESSION:BD187337
c	62	13.8	0.6	17	1	BD200615	ACCESSION:BD200615
c	63	13.8	0.6	17	1	BD201502	ACCESSION:BD201502
c	64	13.4	0.6	15	1	A88288	ACCESSION:A88288
c	65	13.4	0.6	15	1	A90255	ACCESSION:A90255
c	66	13.4	0.6	15	1	I35238	ACCESSION:I35238
c	67	13.4	0.6	15	1	BD065801	ACCESSION:BD065801
c	68	13.4	0.6	15	1	BD104846	ACCESSION:BD104846
	69	13	0.6	14	1	A45189	ACCESSION:A45189
c	70	13	0.6	14	1	A88289	ACCESSION:A88289
c	71	13	0.6	14	1	A88290	ACCESSION:A88290
	72	13	0.6	14	1	A88950	ACCESSION:A88950
c	73	13	0.6	14	1	A90256	ACCESSION:A90256
c	74	13	0.6	14	1	A90257	ACCESSION:A90257
	75	13	0.6	14	1	AR202832	ACCESSION:AR202832
c	76	13	0.6	14	1	BD065802	ACCESSION:BD065802
c	77	13	0.6	14	1	BD065803	ACCESSION:BD065803
	78	13	0.6	14	1	BD066463	ACCESSION:BD066463
	79	13	0.6	15	1	AR033698	ACCESSION:AR033698
	80	13	0.6	15	1	AR113520	ACCESSION:AR113520
	81	13	0.6	15	1	AR133937	ACCESSION:AR133937
	82	13	0.6	15	1	I57927	ACCESSION:I57927
	83	13	0.6	15	1	BD207431	ACCESSION:BD207431
	84	12.8	0.6	16	1	BD233115	ACCESSION:BD233115
	85	12.8	0.6	16	1	AR234367	ACCESSION:AR234367
c	86	12.8	0.6	16	1	AR258885	ACCESSION:AR258885
	87	12.8	0.6	16	1	AX007669	ACCESSION:AX007669
c	88	12.8	0.6	16	1	AX382369	ACCESSION:AX382369
c	89	12.4	0.6	14	1	A88287	ACCESSION:A88287
c	90	12.4	0.6	14	1	A90254	ACCESSION:A90254
	91	12.4	0.6	14	1	AR029996	ACCESSION:AR029996
	92	12.4	0.6	14	1	AR030008	ACCESSION:AR030008
c	93	12.4	0.6	14	1	BD065800	ACCESSION:BD065800
	94	12.4	0.6	15	1	A07231	ACCESSION:A07231
c	95	12.4	0.6	15	1	A07233	ACCESSION:A07233
	96	12.4	0.6	15	1	AR041376	ACCESSION:AR041376
c	97	12.4	0.6	15	1	AR041405	ACCESSION:AR041405
c	98	12.4	0.6	15	1	AR041406	ACCESSION:AR041406
c	99	12.4	0.6	15	1	AR041929	ACCESSION:AR041929
c	100	12.4	0.6	15	1	AR041930	ACCESSION:AR041930
	101	12.4	0.6	15	1	AR045279	ACCESSION:AR045279
c	102	12.4	0.6	15	1	AR056019	ACCESSION:AR056019
c	103	12.4	0.6	15	1	AR074211	ACCESSION:AR074211
c	104	12.4	0.6	15	1	AR113777	ACCESSION:AR113777
c	105	12.4	0.6	15	1	AR132205	ACCESSION:AR132205
c	106	12.4	0.6	15	1	AR132206	ACCESSION:AR132206

c 107	12.4	0.6	15	1	AR132207	ACCESSION:AR132207
c 108	12.4	0.6	15	1	BD246789	ACCESSION:BD246789
c 109	12.4	0.6	15	1	I20453	ACCESSION:I20453
110	12.4	0.6	15	1	I52331	ACCESSION:I52331
c 111	12.4	0.6	15	1	AR209754	ACCESSION:AR209754
c 112	12.4	0.6	15	1	AX032573	ACCESSION:AX032573
c 113	12.4	0.6	15	1	AX633116	ACCESSION:AX633116
114	12.4	0.6	15	1	AX636811	ACCESSION:AX636811
c 115	12.4	0.6	15	1	AX636868	ACCESSION:AX636868
c 116	12.4	0.6	15	1	AX636870	ACCESSION:AX636870
c 117	12.4	0.6	15	1	AX637407	ACCESSION:AX637407
c 118	12.4	0.6	15	1	AX637409	ACCESSION:AX637409
c 119	10.6	0.5	17	1	AX757371	ACCESSION:AX757371
c 120	10.6	0.5	29	1	AR096037	ACCESSION:AR096037
c 121	10.6	0.5	29	1	AR217415	ACCESSION:AR217415
c 122	10.4	0.5	17	1	BD257498	ACCESSION:BD257498
123	10.4	0.5	21	1	AX770644	ACCESSION:AX770644
124	10.2	0.5	15	1	I35238	ACCESSION:I35238
c 125	10.2	0.5	15	1	AR133937	ACCESSION:AR133937

ALIGNMENTS

```
RESULT 1
AR096037
LOCUS       AR096037                  29 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 3 from patent US 6005086.
ACCESSION   AR096037
VERSION     AR096037.1  GI:10024472
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Evans,R.M., Forman,B.M. and Weinberger,C.A.
  TITLE     Farnesoid activated receptor polypeptides, and nucleic acid
            encoding the same
  JOURNAL   Patent: US 6005086-A 3 21-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 0.5;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 2
AR217415
LOCUS       AR217415                  29 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 3 from patent US 6416957.
ACCESSION   AR217415
VERSION     AR217415.1  GI:23317106
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Evans,R.M., Forman,B.M. and Weinberger,C.A.
  TITLE     Method for modulating process mediated by farnesoid activated
            receptors
  JOURNAL   Patent: US 6416957-A 3 09-JUL-2002;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 0.5;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 3
AR139022
LOCUS       AR139022                  23 bp    DNA     linear   PAT 16-JUN-2001
DEFINITION  Sequence 4 from patent US 6200802.
ACCESSION   AR139022
VERSION     AR139022.1  GI:14481367
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Greene,M.E. and Blumberg,B.
  TITLE     Human peroxisome proliferator activated receptor gamma:
            compositions and methods
  JOURNAL   Patent: US 6200802-A 4 13-MAR-2001;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.9%;  Score 19;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 3.7;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        783 TGTGAGGGGTGTAAAGGTTTCTT 805
              ||:||:|| ||:||:|| ||:||
Db          1 TGYGARGGNTGYAARGGNTTYTT 23


RESULT 4
AX770644/c
LOCUS       AX770644                  21 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 3 from Patent WO03033736.
ACCESSION   AX770644
VERSION     AX770644.1  GI:32437947
KEYWORDS    .
SOURCE      Oryza sp.
  ORGANISM  Oryza sp.
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
  AUTHORS   Sardesai,N., Kumar,A., Nair,S. and Mohan,M.
  TITLE     Fine mapping and application of dna markers linked to a gall midge
            resistance gene for marker-aided selection in rice
  JOURNAL   Patent: WO 03033736-A 3 24-APR-2003;
            International Centre for Genetic Engineering and Biotechnology (IN)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:52841"

  Query Match             0.8%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 9.8;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1396 TGGAAGAAAGAATTCGAAAT 1415
              | |||||||||||| |||||
Db         21 TTGAAGAAAGAATTAGAAAT 2


RESULT 5
AX255622
```

```
LOCUS       AX255622                16 bp    RNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 43 from Patent WO0170982.
ACCESSION   AX255622
VERSION     AX255622.1  GI:16074678
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 43 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1358 TTTCAATAAGAAACTT 1373
              || |||||||||||||
Db          1 TTACAATAAGAAACTT 16


RESULT 6
AX255665
LOCUS       AX255665                16 bp    DNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 86 from Patent WO0170982.
ACCESSION   AX255665
VERSION     AX255665.1  GI:16074721
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 86 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1358 TTTCAATAAGAAACTT 1373
              || |||||||||||||
Db          1 TTACAATAAGAAACTT 16


RESULT 7
AX804490
LOCUS       AX804490                16 bp    DNA     linear   PAT 25-NOV-2003
DEFINITION  Sequence 658 from Patent WO03060160.
ACCESSION   AX804490
VERSION     AX804490.1  GI:38521631
KEYWORDS    .
SOURCE      Oreochromis niloticus (Nile tilapia)
  ORGANISM  Oreochromis niloticus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
            Labroidei; Cichlidae; Oreochromis.
REFERENCE   1
  AUTHORS   Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
  TITLE     Verification of food origin based on nucleic acid pattern
            recognition
  JOURNAL   Patent: WO 03060160-A 658 24-JUL-2003;
            Genomar ASA (NO)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Oreochromis niloticus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:8128"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        849 GGGGGCAACTGTGTGA 864
              || |||||||||||||
Db          1 GGCGGCAACTGTGTGA 16


RESULT 8
AR046169/c
LOCUS       AR046169                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 962 from patent US 5817796.
ACCESSION   AR046169
VERSION     AR046169.1  GI:5967634
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 962 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              |||||||||||.||||
Db         17 TTTTTATAAAACTATT 2


RESULT 9
AR046171/c
LOCUS       AR046171                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 964 from patent US 5817796.
ACCESSION   AR046171
VERSION     AR046171.1  GI:5967636
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 964 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
```

```
                    ||||||||||| ||||
Db          16 TTTTTATAAAACTATT 1


RESULT 10
E04342
LOCUS       E04342                    17 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  Linker.
ACCESSION   E04342
VERSION     E04342.1  GI:2172545
KEYWORDS    JP 1993041992-A/5.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Shiroza,A.
  TITLE     NEW VECTOR
  JOURNAL   Patent: JP 1993041992-A 5 23-FEB-1993;
            OJI KOONSUTAAC KK, OJI PAPER CO LTD
COMMENT     OS   Artificial gene
            OC   Artificial sequence; Genes.
            PN   JP 1993041992-A/5
            PD   23-FEB-1993
            PF   24-OCT-1991 JP 1991277708
            PR   24-OCT-1990 JP 90P   284408
            PI   SHIROZA AKINORI
            PC   C12N15/70,C12N15/74;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: No.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1293 GAAGACCAGATTGCTT 1308
                ||||| ||||||||||
Db          2 GAAGATCAGATTGCTT 17


RESULT 11
I53221/c
LOCUS       I53221                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 962 from patent US 5646042.
ACCESSION   I53221
VERSION     I53221.1  GI:2474424
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 962 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
                ||||||||||| ||||
Db         17 TTTTTATAAAACTATT 2


RESULT 12
I53223/c
LOCUS       I53223                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 964 from patent US 5646042.
ACCESSION   I53223
VERSION     I53223.1  GI:2474426
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 964 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
                ||||||||||| ||||
Db         16 TTTTTATAAAACTATT 1


RESULT 13
AR188875
LOCUS       AR188875                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 4363 from patent US 6346398.
ACCESSION   AR188875
VERSION     AR188875.1  GI:20234840
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 4363 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
                ||||||| |||||||||
Db          2 AGATTCTCCAGCCTGA 17


RESULT 14
AR324728
LOCUS       AR324728                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2130 from patent US 6566127.
ACCESSION   AR324728
VERSION     AR324728.1  GI:33710536
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2130 20-MAY-2003;
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              |||||| |||||||||
Db          2 AGATTCTCCAGCCTGA 17


RESULT 15
AR329508
LOCUS       AR329508                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6910 from patent US 6566127.
ACCESSION   AR329508
VERSION     AR329508.1  GI:33715316
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6910 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              |||||| |||||||||
Db          1 AGATTCTCCAGCCTGA 16


RESULT 16
AX475416
LOCUS       AX475416                 17 bp    DNA     linear   PAT 13-AUG-2002
DEFINITION  Sequence 637 from Patent WO0224750.
ACCESSION   AX475416
VERSION     AX475416.1  GI:22214701
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 637 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        767 CTATAATGCACTGACC 782
              ||| ||||||||||||
Db          2 CTACAATGCACTGACC 17


RESULT 17
AX475417
LOCUS       AX475417                 17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 638 from Patent WO0224750.
ACCESSION   AX475417
VERSION     AX475417.1  GI:22214702
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 638 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        767 CTATAATGCACTGACC 782
              ||| ||||||||||||
Db          1 CTACAATGCACTGACC 16


RESULT 18
AX672442/c
LOCUS       AX672442                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 887 from Patent WO03004526.
ACCESSION   AX672442
VERSION     AX672442.1  GI:29330790
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 887 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1220 AATGGCAACCAATCAT 1235
              |||||||||||||| ||
Db         17 AATGGCAACCAATGAT 2


RESULT 19
AX723944
LOCUS       AX723944                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1631 from Patent WO03025176.
ACCESSION   AX723944
VERSION     AX723944.1  GI:30503287
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
```

```
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1631 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        726 GAGCTGTGTGTTGTTT 741
              || |||||||||||||
Db          1 GATCTGTGTGTTGTTT 16


RESULT 20
AX730352/c
LOCUS       AX730352                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1986 from Patent WO03025175.
ACCESSION   AX730352
VERSION     AX730352.1  GI:30509695
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 1986 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        655 CTGAGGTAGCAGAGAT 670
              ||| ||||||||||||
Db         17 CTGTGGTAGCAGAGAT 2


RESULT 21
AX733378/c
LOCUS       AX733378                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5012 from Patent WO03025175.
ACCESSION   AX733378
VERSION     AX733378.1  GI:30512721
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5012 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        815 CATTACCAAAAACGCT 830
              |||||||||||||| |
Db         17 CATTACCAAAAACGAT 2


RESULT 22
AX737466/c
LOCUS       AX737466                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3056 from Patent WO03025177.
ACCESSION   AX737466
VERSION     AX737466.1  GI:30516754
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3056 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1220 AATGGCAACCAATCAT 1235
              |||||||||||||| ||
Db         17 AATGGCAACCAATGAT 2


RESULT 23
AX761145/c
LOCUS       AX761145                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4466 from Patent WO03040369.
ACCESSION   AX761145
VERSION     AX761145.1  GI:32255761
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4466 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 25;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1342 TTCGTTCAGCTGAGAT 1357
              || |||||||||||||
Db         17 TTTGTTCAGCTGAGAT 2
```

RESULT 24
BD201129
LOCUS BD201129 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD201129
VERSION BD201129.1 GI:33010899
KEYWORDS JP 2002509721-A/4155.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 4155 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/4155
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1. .17
FT /organism='Homo sapiens (human)'.
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 25;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        798 GGTTTCTTCAGGAGAA 813
              |||||||||| |||||
Db          2 GGTTTCTTCAAGAGAA 17
```

RESULT 25
BD201130
LOCUS BD201130 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD201130
VERSION BD201130.1 GI:33010900
KEYWORDS JP 2002509721-A/4156.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 4156 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/4156
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1. .17
FT /organism='Homo sapiens (human)'.
FEATURES Location/Qualifiers
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 25;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        798 GGTTTCTTCAGGAGAA 813
              |||||||||| |||||
Db          1 GGTTTCTTCAAGAGAA 16
```

RESULT 26
BD201674
LOCUS BD201674 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD201674
VERSION BD201674.1 GI:33011444
KEYWORDS JP 2002509721-A/4700.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 4700 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Homo sapiens (human)
PN JP 2002509721-A/4700
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response

```
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              ||||||||||||| ||
Db          2 TTTTTATAAAAGTGTT 17


RESULT 27
AX731670
LOCUS       AX731670                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3304 from Patent WO03025175.
ACCESSION   AX731670
VERSION     AX731670.1  GI:30511013
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3304 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 30;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        975 CTGAGAAAAAATGT 988
              ||||||||||||||
Db          4 CTGAGAAAAAATGT 17


RESULT 28
AR046173/c
LOCUS       AR046173                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 966 from patent US 5817796.
ACCESSION   AR046173
VERSION     AR046173.1  GI:5967638
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 966 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTAT 1468
              | |||||||||||| |||
Db         17 ATTTTTTATAAAACTAT 1


RESULT 29
AR046239
LOCUS       AR046239                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1032 from patent US 5817796.
ACCESSION   AR046239
VERSION     AR046239.1  GI:5967704
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 1032 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 ACCAGGATTTCAGACTT 1284
              || || ||||||||||
Db          1 ACTAGTATTTCAGACTT 17


RESULT 30
AR046241
LOCUS       AR046241                 17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1034 from patent US 5817796.
ACCESSION   AR046241
VERSION     AR046241.1  GI:5967706
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 1034 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1269 CCAGGATTTCAGACTTT 1285
              | || ||||||||||||
Db          1 CTAGTATTTCAGACTTT 17


RESULT 31
BD257498
LOCUS       BD257498                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD257498
VERSION     BD257498.1  GI:33067268
KEYWORDS    JP 2002541795-A/5291.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
```

```
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 5291 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/5291
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key              Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        795 AAAGGTTTCTTCAGGAG 811
              ||| |||||||||| |||
Db          1 AAAAGTTTCTTCAAGAG 17


RESULT 32
I53225/c
LOCUS       I53225                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 966 from patent US 5646042.
ACCESSION   I53225
VERSION     I53225.1  GI:2474428
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 966 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTAT 1468
              | |||||||||| |||
Db         17 ATTTTTTATAAAACTAT 1


RESULT 33
I53291
LOCUS       I53291                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 1032 from patent US 5646042.
ACCESSION   I53291
VERSION     I53291.1  GI:2474494
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 1032 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 ACCAGGATTTCAGACTT 1284
              || || ||||||||||||
Db          1 ACTAGTATTTCAGACTT 17


RESULT 34
I53293
LOCUS       I53293                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 1034 from patent US 5646042.
ACCESSION   I53293
VERSION     I53293.1  GI:2474496
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 1034 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1269 CCAGGATTTCAGACTTT 1285
              | || ||||||||||||
Db          1 CTAGTATTTCAGACTTT 17


RESULT 35
AR186750
LOCUS       AR186750                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2238 from patent US 6346398.
ACCESSION   AR186750
VERSION     AR186750.1  GI:20232715
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2238 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1101 CAGACTCTTCTACATTT 1117
```

```
              | ||| ||||||||||||
Db          1 CTGACCCTTCTACATTT 17


RESULT 36
AR187077
LOCUS       AR187077                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2565 from patent US 6346398.
ACCESSION   AR187077
VERSION     AR187077.1  GI:20233042
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2565 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1159 TAACAAATAAAATTTTA 1175
              ||||||||||||  |||
Db          1 TAACAAATAAAACCTTA 17


RESULT 37
AR187218/c
LOCUS       AR187218                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2706 from patent US 6346398.
ACCESSION   AR187218
VERSION     AR187218.1  GI:20233183
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2706 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1450 TTAGTTTTTATAAAAGT 1466
              || |||| |||||||||
Db         17 TTGGTTTGTATAAAAGT 1


RESULT 38
AR258893/c
LOCUS       AR258893                  17 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 111 from patent US 6489307.
ACCESSION   AR258893
VERSION     AR258893.1  GI:27309333
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to .beta.1-adrenoceptor-specific
            mRNA and methods of use
  JOURNAL   Patent: US 6489307-A 111 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGCG 701
              ||| | ||||||||||||
Db         17 AGCTCGGCATGGGCGCG 1


RESULT 39
AR323381
LOCUS       AR323381                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 783 from patent US 6566127.
ACCESSION   AR323381
VERSION     AR323381.1  GI:33709189
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 783 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1101 CAGACTCTTCTACATTT 1117
              | ||| ||||||||||||
Db          1 CTGACCCTTCTACATTT 17


RESULT 40
AR323687
LOCUS       AR323687                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 1089 from patent US 6566127.
ACCESSION   AR323687
VERSION     AR323687.1  GI:33709495
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 1089 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1159 TAACAAATAAAATTTTA 1175
              ||||||||||||  |||
```

```
Db          1 TAACAAATAAAACCTTA 17


RESULT 41
AR323828/c
LOCUS       AR323828                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 1230 from patent US 6566127.
ACCESSION   AR323828
VERSION     AR323828.1  GI:33709636
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 1230 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1450 TTAGTTTTTATAAAAGT 1466
              || |||| |||||||||
Db         17 TTGGTTTGTATAAAAGT 1


RESULT 42
AR327770
LOCUS       AR327770                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5172 from patent US 6566127.
ACCESSION   AR327770
VERSION     AR327770.1  GI:33713578
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5172 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1103 GACTCTTCTACATTTTA 1119
              ||| |||||||||| |
Db          1 GACCCTTCTACATTTGA 17


RESULT 43
AR329509
LOCUS       AR329509                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6911 from patent US 6566127.
ACCESSION   AR329509
VERSION     AR329509.1  GI:33715317
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6911 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1613 GATTCACCAGCCTGAAA 1629
              ||||| |||||||||| |
Db          1 GATTCTCCAGCCTGACA 17


RESULT 44
AR401952/c
LOCUS       AR401952                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 292 from patent US 6623962.
ACCESSION   AR401952
VERSION     AR401952.1  GI:40149402
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 292 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
              ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 45
AX216849
LOCUS       AX216849                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2291 from Patent WO0159103.
ACCESSION   AX216849
VERSION     AX216849.1  GI:15526910
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2291 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        606 ATATATGAACTCAGGCG 622
              ||| | ||||||||||||
Db          1 ATAAAGGAACTCAGGCG 17
```

```
RESULT 46
AX217049/c
LOCUS       AX217049                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2491 from Patent WO0159103.
ACCESSION   AX217049
VERSION     AX217049.1  GI:15527110
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2491 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        567 TTCTACCCCCAGCAGCC 583
              || |||| |||||||||
Db         17 TTTTACCTCCAGCAGCC 1
```

```
RESULT 47
AX227475/c
LOCUS       AX227475                  17 bp    RNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 847 from Patent WO0157206.
ACCESSION   AX227475
VERSION     AX227475.1  GI:15556616
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fattaey,A.R., Jarvis,T., Mcswiggen,J., Booher,R.N. and Holman,P.S.
  TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (chk
            1) enzyme
  JOURNAL   Patent: WO 0157206-A 847 09-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        800 TTTCTTCAGGAGAAGCA 816
              ||||||||  |||||||
Db         17 TTTCTTCACTAGAAGCA 1
```

```
RESULT 48
AX382377/c
LOCUS       AX382377                  17 bp    DNA     linear   PAT 18-MAR-2002
DEFINITION  Sequence 111 from Patent WO0204623.
ACCESSION   AX382377
VERSION     AX382377.1  GI:19577150
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to _g(b) 1? adrenoceptor-specific
            mrna and methods of use
  JOURNAL   Patent: WO 0204623-A 111 17-JAN-2002;
            University of Florida (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="SYNTHETIC OLIGONUCLEOTIDE"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGCG 701
              ||| | ||||||||||||
Db         17 AGCTCGGCATGGGCGCG 1
```

```
RESULT 49
AX422007
LOCUS       AX422007                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 343 from Patent WO0188124.
ACCESSION   AX422007
VERSION     AX422007.1  GI:21525389
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 343 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1248 GTAGAATTCACAAAAAA 1264
              |||||||||| ||| ||
Db          1 GTAGAATTCAGAAACAA 17
```

```
RESULT 50
AX422138/c
LOCUS       AX422138                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 474 from Patent WO0188124.
ACCESSION   AX422138
VERSION     AX422138.1  GI:21525520
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 474 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1357 TTTTCAATAAGAAACTT 1373
              ||||||  ||||  |||||
Db         17 TTTTCATTAAGCAACTT 1


RESULT 51
AX422613
LOCUS       AX422613                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 949 from Patent WO0188124.
ACCESSION   AX422613
VERSION     AX422613.1  GI:21525995
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 949 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1479 AAAATGACTCAAGAGGA 1495
              |||  ||  ||||||||||
Db          1 AAAGTGCCTCAAGAGGA 17


RESULT 52
AX724979/c
LOCUS       AX724979                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2666 from Patent WO03025176.
ACCESSION   AX724979
VERSION     AX724979.1  GI:30504322
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2666 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1274 ATTTCAGACTTTGGACC 1290
              ||  ||||||||||||  |
Db         17 ATGTCAGACTTTGGATC 1


RESULT 53
AX728845
LOCUS       AX728845                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 479 from Patent WO03025175.
ACCESSION   AX728845
VERSION     AX728845.1  GI:30508188
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 479 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        713 GATCAAAGGGGATGAGC 729
              |||||||| |||||  |
Db          1 GATCAAAGGTGATGACC 17


RESULT 54
AX732535
LOCUS       AX732535                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4169 from Patent WO03025175.
ACCESSION   AX732535
VERSION     AX732535.1  GI:30511878
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4169 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        668 GATGCCTGTAACAAAGA 684
              ||| ||||||||| |||
Db          1 GATCCCTGTAACACAGA 17


RESULT 55
AX732917/c
LOCUS       AX732917                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4551 from Patent WO03025175.
ACCESSION   AX732917
VERSION     AX732917.1  GI:30512260
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4551 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1082 TGAACTCACCCCAGATC 1098
              || |||||| |||||||
Db         17 TGCACTCACACCAGATC 1


RESULT 56
AX733541
LOCUS       AX733541                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5175 from Patent WO03025175.
ACCESSION   AX733541
VERSION     AX733541.1  GI:30512884
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5175 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        713 GATCAAAGGGGATGAGC 729
              |||||| | ||||||||
Db          1 GATCAAGGAGGATGAGC 17


RESULT 57
AX736911/c
LOCUS       AX736911                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2501 from Patent WO03025177.
ACCESSION   AX736911
VERSION     AX736911.1  GI:30516199
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2501 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1082 TGAACTCACCCCAGATC 1098
              || |||||| |||||||
Db         17 TGCACTCACACCAGATC 1


RESULT 58
AX757371
LOCUS       AX757371                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 692 from Patent WO03040369.
ACCESSION   AX757371
VERSION     AX757371.1  GI:32251987
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 692 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1125 GATTCATATAACAAACA 1141
              ||| ||| |||||||||
Db          1 GATCCATTTAACAAACA 17


RESULT 59
AX757539
LOCUS       AX757539                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 860 from Patent WO03040369.
ACCESSION   AX757539
VERSION     AX757539.1  GI:32252155
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 860 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1095 GATCAACAGACTCTTCT 1111
              ||||||||| ||| |||
Db          1 GATCAACAGCCTCCTCT 17


RESULT 60
BD067452/c
LOCUS       BD067452                  17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067452
VERSION     BD067452.1  GI:22613055
KEYWORDS    JP 2001511003-A/292.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 292 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/292
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
              ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 61
BD187337
LOCUS       BD187337                  17 bp    DNA     linear   PAT 17-JUN-2003
DEFINITION  Monoclonal antibody against catalytic domain of MT4-MMP.
ACCESSION   BD187337
VERSION     BD187337.1  GI:31879626
KEYWORDS    WO 02101046-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Miki,I., Ota,S., Shitara,K. and Furuya,A.
  TITLE     Monoclonal antibody against catalytic domain of MT4-MMP
  JOURNAL   Patent: WO 02101046-A 4 19-DEC-2002;
            KYOWA HAKKO KOGYO CO LTD,ICHIRO MIKI,SO OTA,KENYA SHITARA, AKIKO
            FURUYA
COMMENT     OS   Artificial Sequence
            PN   WO 02101046-A/4
            PD   19-DEC-2002
            PF   11-JUN-2002 WO 2002JP005788
            PR   11-JUN-2001 JP 01P   176256
            PI   ICHIRO MIKI,SO OTA,KENYA SHITARA,AKIKO FURUYA PC
            C12N15/12,C12N15/08,C07K16/40,C12N5/20,A61K39/395,A61P29/00, PC
            A61P35/00,
            PC   A61P43/00,G01N33/53
            CC   Description of Artificial Sequence:synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        859 GTGTGATGGATATGTAC 875
              ||||||||||||| | |
Db          1 GTGTGATGGATATCTGC 17


RESULT 62
BD200615/c
LOCUS       BD200615                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD200615
VERSION     BD200615.1  GI:33010385
KEYWORDS    JP 2002509721-A/3641.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 3641 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/3641
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
```

```
                concerning molecule
          CC   participating in vasculogenic response
          FH   Key             Location/Qualifiers
          FT   source          1. .17
          FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1147 TGCCTCAGGAAATAACA 1163
              || ||||||| ||||||
Db         17 TGACTCAGGACATAACA 1


RESULT 63
BD201502/c
LOCUS       BD201502                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201502
VERSION     BD201502.1  GI:33011272
KEYWORDS    JP 2002509721-A/4528.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4528 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4528
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 33;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1423 TCTCTGATGAATATATA 1439
              |||||| ||||| ||||
Db         17 TCTCTGTTGAATGTATA 1


RESULT 64
A88288/c
```

```
LOCUS       A88288                   15 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 436 from Patent WO9833904.
ACCESSION   A88288
VERSION     A88288.1  GI:6736858
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 436 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match              0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTTA 1459
              | ||||||||||||||
Db         15 TCTGTTTAGTTTTTA 1


RESULT 65
A90255/c
LOCUS       A90255                   15 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 436 from Patent EP0856579.
ACCESSION   A90255
VERSION     A90255.1  GI:6738769
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 436 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match              0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTTA 1459
              | ||||||||||||||
Db         15 TCTGTTTAGTTTTTA 1


RESULT 66
I35238/c
LOCUS       I35238                   15 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 206 from patent US 5599706.
ACCESSION   I35238
VERSION     I35238.1  GI:2088206
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
  TITLE     Ribozymes targeted to apo(a) mRNA
  JOURNAL   Patent: US 5599706-A 206 04-FEB-1997;
FEATURES             Location/Qualifiers
```

```
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        801 TTCTTCAGGAGAAGC 815
              ||||||||  ||||||
Db         15 TTCTTCAGAAGAAGC 1


RESULT 67
BD065801/c
LOCUS       BD065801                 15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065801
VERSION     BD065801.1  GI:22611404
KEYWORDS    JP 2001511000-A/436.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 436 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/436
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match              0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTTA 1459
              | ||||||||||||||
Db         15 TCTGTTTAGTTTTTA 1


RESULT 68
BD104846/c
LOCUS       BD104846                 15 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104846
VERSION     BD104846.1  GI:22650420
KEYWORDS    WO 0192572-A/950.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 950 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/950
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
            MATSUMURA,
            PI   SHOGO MORIYA,MICHIO NISHIDA
            PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            CC   Description of Artificial Sequence:capture
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match              0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1640 CTTTGCCTGTCTCCT 1654
              |||| ||||||||||
Db         15 CTTTCCCTGTCTCCT 1


RESULT 69
A45189
LOCUS       A45189                   14 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 66 from Patent WO9517507.
ACCESSION   A45189
VERSION     A45189.1  GI:2299684
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W., Schlingensiepen,K., Schlingensiepen,R. and
            Schlingensiepen,G.
  TITLE     ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF
            DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
  JOURNAL   Patent: WO 9517507-A 66 29-JUN-1995;
            BIOGNOSTIK GES (DE)
COMMENT     Other publication AU 1313095 950710.
FEATURES              Location/Qualifiers
     source           1. .14
                      /organism="unidentified"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32644"

  Query Match              0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity  100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1632 CCTCAACACTTTG 1644
              |||||||||||||
Db          2 CCTCAACACTTTG 14


RESULT 70
A88289/c
LOCUS       A88289                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 437 from Patent WO9833904.
ACCESSION   A88289
VERSION     A88289.1  GI:6736859
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
```

```
  JOURNAL   Patent: WO 9833904-A 437 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         13 TGTTTAGTTTTTA 1


RESULT 71
A88290/c
LOCUS       A88290                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 438 from Patent WO9833904.
ACCESSION   A88290
VERSION     A88290.1  GI:6736860
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 438 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         14 TGTTTAGTTTTTA 2


RESULT 72
A88950
LOCUS       A88950                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1098 from Patent WO9833904.
ACCESSION   A88950
VERSION     A88950.1  GI:6737520
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1098 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1632 CCTCAACACTTTG 1644
              |||||||||||||
Db          2 CCTCAACACTTTG 14


RESULT 73
A90256/c
LOCUS       A90256                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 437 from Patent EP0856579.
ACCESSION   A90256
VERSION     A90256.1  GI:6738770
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 437 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         13 TGTTTAGTTTTTA 1


RESULT 74
A90257/c
LOCUS       A90257                   14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 438 from Patent EP0856579.
ACCESSION   A90257
VERSION     A90257.1  GI:6738771
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 438 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         14 TGTTTAGTTTTTA 2


RESULT 75
AR202832
LOCUS       AR202832                 14 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 66 from patent US 6365345.
ACCESSION   AR202832
VERSION     AR202832.1  GI:21499062
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W., Schlingensiepen,K.-H., Schlingensiepen,R. and
            Schlingensiepen,G.-F.
  TITLE     Antisense nucleic acids for the prevention and treatment of
            disorders in which expression of c-erbB plays a role
  JOURNAL   Patent: US 6365345-A 66 02-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1632 CCTCAACACTTTG 1644
              |||||||||||||
Db          2 CCTCAACACTTTG 14


RESULT 76
BD065802/c
LOCUS       BD065802                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065802
VERSION     BD065802.1  GI:22611405
KEYWORDS    JP 2001511000-A/437.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 437 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/437
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         13 TGTTTAGTTTTTA 1


RESULT 77
BD065803/c
LOCUS       BD065803                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065803
VERSION     BD065803.1  GI:22611406
KEYWORDS    JP 2001511000-A/438.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 438 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/438
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         14 TGTTTAGTTTTTA 2


RESULT 78
BD066463
LOCUS       BD066463                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066463
VERSION     BD066463.1  GI:22612066
KEYWORDS    JP 2001511000-A/1098.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1098 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1098
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 40;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1632 CCTCAACACTTTG 1644
              |||||||||||||
Db          2 CCTCAACACTTTG 14


RESULT 79
AR033698
```

```
LOCUS       AR033698                15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 464 from patent US 5869253.
ACCESSION   AR033698
VERSION     AR033698.1  GI:5949303
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 5869253-A 464 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |||||||||||||
Db          2 ATGCCTCAGGAAA 14


RESULT 80
AR113520
LOCUS       AR113520                15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 464 from patent US 6132966.
ACCESSION   AR113520
VERSION     AR113520.1  GI:14093842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 6132966-A 464 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |||||||||||||
Db          2 ATGCCTCAGGAAA 14


RESULT 81
AR133937
LOCUS       AR133937                15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2362 from patent US 6194150.
ACCESSION   AR133937
VERSION     AR133937.1  GI:14122842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 2362 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 CTGGGTTTCTACC 573
              |||||||||||||
Db          1 CTGGGTTTCTACC 13


RESULT 82
I57927
LOCUS       I57927                  15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 464 from patent US 5610054.
ACCESSION   I57927
VERSION     I57927.1  GI:2482991
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Enzymatic RNA molecule targeted against Hepatitis C virus
  JOURNAL   Patent: US 5610054-A 464 11-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |||||||||||||
Db          2 ATGCCTCAGGAAA 14


RESULT 83
BD207431
LOCUS       BD207431                15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD207431
VERSION     BD207431.1  GI:33017201
KEYWORDS    JP 2002512791-A/1021.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 1021 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/1021
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                 virus)'.
```

```
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |||||||||||||
Db          2 ATGCCTCAGGAAA 14


RESULT 84
BD233115
LOCUS       BD233115                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION   BD233115
VERSION     BD233115.1  GI:33042885
KEYWORDS    JP 2002518065-A/211.
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Stuyver,L.
  TITLE     Method of detecting mutation selected by drug in HIV protease gene
  JOURNAL   Patent: JP 2002518065-A 211 25-JUN-2002;
            INNOGENETICS NV
COMMENT     OS   Aids-associated retrovirus
            PN   JP 2002518065-A/211
            PD   25-JUN-2002
            PF   22-JUN-1999 JP 2000556068
            PR   24-JUN-1998 EP   98870143.9
            PI   LIEVEN STUYVER
            PC   C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
            CC   Method of detecting mutation selected by drug in HIV protease
            CC         gene
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Aids-associated retrovirus'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:11966"

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTA 1467
              || |||||| ||||||
Db          1 AGGTTTTATCAAAGTA 16


RESULT 85
AR234367
LOCUS       AR234367                  16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 21 from patent US 6458567.
ACCESSION   AR234367
VERSION     AR234367.1  GI:27277055
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Barber,J.R., Welch,P.J., Tritz,R., Yei,S. and Yu,M.
  TITLE     Hepatitis C Virus ribozymes
  JOURNAL   Patent: US 6458567-A 21 01-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||||| |||||||
Db          1 ATAGGGTCAGCGGTTG 16


RESULT 86
AR258885/c
LOCUS       AR258885                  16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 103 from patent US 6489307.
ACCESSION   AR258885
VERSION     AR258885.1  GI:27309325
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to .beta.1-adrenoceptor-specific
            mRNA and methods of use
  JOURNAL   Patent: US 6489307-A 103 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGC 700
              ||| | ||||||||||
Db         16 AGCTCGGCATGGGCGC 1


RESULT 87
AX007669
LOCUS       AX007669                  16 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 211 from Patent WO9967428.
ACCESSION   AX007669
VERSION     AX007669.1  GI:9995366
KEYWORDS    .
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1
  AUTHORS   Stuyver,L.
  TITLE     Method for detection of drug-selected mutations in the hiv protease
            gene
  JOURNAL   Patent: WO 9967428-A 211 29-DEC-1999;
            INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11966"

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTA 1467
              || |||||| ||||||
Db          1 AGGTTTTATCAAAGTA 16


RESULT 88
```

```
AX382369/c
LOCUS       AX382369                16 bp    DNA     linear   PAT 18-MAR-2002
DEFINITION  Sequence 103 from Patent WO0204623.
ACCESSION   AX382369
VERSION     AX382369.1  GI:19577142
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Phillips,M.I. and Zhang,Y.
  TITLE     Antisense compositions targeted to _g(b) 1? adrenoceptor-specific
            mrna and methods of use
  JOURNAL   Patent: WO 0204623-A 103 17-JAN-2002;
            University of Florida (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="SYNTHETIC OLIGONUCLEOTIDE"

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGC 700
              ||| | ||||||||||
Db         16 AGCTCGGCATGGGCGC 1


RESULT 89
A88287/c
LOCUS       A88287                  14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 435 from Patent WO9833904.
ACCESSION   A88287
VERSION     A88287.1  GI:6736857
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 435 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTT 1458
              | ||||||||||||
Db         14 TCTGTTTAGTTTTT 1


RESULT 90
A90254/c
LOCUS       A90254                  14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 435 from Patent EP0856579.
ACCESSION   A90254
VERSION     A90254.1  GI:6738768
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 435 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTT 1458
              | ||||||||||||
Db         14 TCTGTTTAGTTTTT 1


RESULT 91
AR029996
LOCUS       AR029996                14 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 185 from patent US 5861244.
ACCESSION   AR029996
VERSION     AR029996.1  GI:5943210
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 185 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        536 TTCCTCGTCATCCT 549
              |||||| |||||||
Db          1 TTCCTCTTCATCCT 14


RESULT 92
AR030008
LOCUS       AR030008                14 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 197 from patent US 5861244.
ACCESSION   AR030008
VERSION     AR030008.1  GI:5943222
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 197 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        536 TTCCTCGTCATCCT 549
              |||||| |||||||
Db          1 TTCCTCTTCATCCT 14
```

```
RESULT 93
BD065800/c
LOCUS       BD065800                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065800
VERSION     BD065800.1  GI:22611403
KEYWORDS    JP 2001511000-A/435.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 435 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/435
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .14
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTT 1458
              | ||||||||||||
Db         14 TCTGTTTAGTTTTT 1


RESULT 94
A07231
LOCUS       A07231                    15 bp    DNA     linear   PAT 25-AUG-1993
DEFINITION  Oligonucleotide homologous to the alpha-1 antitrypsin gene.
ACCESSION   A07231
VERSION     A07231.1  GI:413003
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Garman,A.J. and Moore,R.S.
  TITLE     Detection of nucleic acid sequences using fluorescence polarisation
  JOURNAL   Patent: EP 0382433-A 14 16-AUG-1990;
            IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1078 AAACTGAACTCACC 1091
              ||| ||||||||||
Db          2 AAAATGAACTCACC 15


RESULT 95
A07233/c
LOCUS       A07233                    15 bp    DNA     linear   PAT 25-AUG-1993
DEFINITION  Oligonucleotide.
ACCESSION   A07233
VERSION     A07233.1  GI:413005
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Garman,A.J. and Moore,R.S.
  TITLE     Detection of nucleic acid sequences using fluorescence polarisation
  JOURNAL   Patent: EP 0382433-A 16 16-AUG-1990;
            IMPERIAL CHEMICAL INDUSTRIES PLC
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1078 AAACTGAACTCACC 1091
              ||| ||||||||||
Db         14 AAAATGAACTCACC 1


RESULT 96
AR041376
LOCUS       AR041376                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 166 from patent US 5811300.
ACCESSION   AR041376
VERSION     AR041376.1  GI:5961872
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
  TITLE     TNF-.alpha. ribozymes
  JOURNAL   Patent: US 5811300-A 166 22-SEP-1998;
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1522 TCCTGTCTCCAGAT 1535
              |||| |||||||||
Db          2 TCCTCTCTCCAGAT 15


RESULT 97
AR041405/c
LOCUS       AR041405                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 195 from patent US 5811300.
ACCESSION   AR041405
VERSION     AR041405.1  GI:5961901
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
  TITLE     TNF-.alpha. ribozymes
  JOURNAL   Patent: US 5811300-A 195 22-SEP-1998;
FEATURES              Location/Qualifiers
     source           1. .15
```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         15 AAATAATAAATAAA 2
```

RESULT 98
AR041406/c
LOCUS AR041406 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 196 from patent US 5811300.
ACCESSION AR041406
VERSION AR041406.1 GI:5961902
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 196 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         14 AAATAATAAATAAA 1
```

RESULT 99
AR041929/c
LOCUS AR041929 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 719 from patent US 5811300.
ACCESSION AR041929
VERSION AR041929.1 GI:5962425
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 719 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         15 AAATAATAAATAAA 2
```

RESULT 100
AR041930/c
LOCUS AR041930 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 720 from patent US 5811300.
ACCESSION AR041930
VERSION AR041930.1 GI:5962426
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-.alpha. ribozymes
JOURNAL Patent: US 5811300-A 720 22-SEP-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         14 AAATAATAAATAAA 1
```

RESULT 101
AR045279
LOCUS AR045279 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 72 from patent US 5817796.
ACCESSION AR045279
VERSION AR045279.1 GI:5966744
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 72 06-OCT-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1444 CTATGTTTAGTTTT 1457
              |||||||| |||||
Db          1 CTATGTTTTGTTTT 14
```

RESULT 102
AR056019/c
LOCUS AR056019 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 223 from patent US 5837542.
ACCESSION AR056019
VERSION AR056019.1 GI:5981596
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 223 17-NOV-1998;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 55;

```
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              ||||||||||| ||
Db         15 AAATAACAAATGAA 2


RESULT 103
AR074211/c
LOCUS       AR074211                 15 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 19 from patent US 5952490.
ACCESSION   AR074211
VERSION     AR074211.1  GI:10000966
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
            Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,J.R. and
            Imbach,J.Louis.
  TITLE     Oligonucleotides having a conserved G4 core sequence
  JOURNAL   Patent: US 5952490-A 19 14-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 104
AR113777/c
LOCUS       AR113777                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 223 from patent US 6132967.
ACCESSION   AR113777
VERSION     AR113777.1  GI:14094099
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 223 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              ||||||||||| ||
Db         15 AAATAACAAATGAA 2


RESULT 105
AR132205/c
LOCUS       AR132205                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 630 from patent US 6194150.
ACCESSION   AR132205
VERSION     AR132205.1  GI:14121110
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 630 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 106
AR132206/c
LOCUS       AR132206                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 631 from patent US 6194150.
ACCESSION   AR132206
VERSION     AR132206.1  GI:14121111
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 631 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 107
AR132207/c
LOCUS       AR132207                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 632 from patent US 6194150.
ACCESSION   AR132207
VERSION     AR132207.1  GI:14121112
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 632 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 108
BD246789/c
LOCUS       BD246789                  15 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Method for attenuating harmful side-effects related to cell
            transplantation.
ACCESSION   BD246789
VERSION     BD246789.1  GI:33056559
KEYWORDS    JP 2002533358-A/3.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Hurwitz,D.R., Cherington,V., Galanopoulos,T., Levine,P.H. and
            Greenberger,J.S.
  TITLE     Method for attenuating harmful side-effects related to cell
            transplantation
  JOURNAL   Patent: JP 2002533358-A 3 08-OCT-2002;
            ALG CO
COMMENT     OS   Canis familiaris (dog)
            PN   JP 2002533358-A/3
            PD   08-OCT-2002
            PF   28-DEC-1999 JP 2000590482
            PR   31-DEC-1998 US    09/224048
            PI   DAVID R HURWITZ,VAN CHERINGTON,THEOFANIS GALANOPOULOS,PETER H
            PI   LEVINE,
            PI   JOEL S GREENBERGER
            PC   A61K35/12,A61K35/28,A61K35/48,A61K48/00,A61P7/02,A61P7/04, PC
             C12N5/06,
            PC   C12N15/09//(C12N5/06,C12R1:91),C12N15/00,C12N5/00,(C12N5/00,
            PC   C12R1:91)
            CC   Method for attenuating harmful side-effects related CC   to
            cell transplantation
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Canis familiaris (dog)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Canis familiaris"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9615"

  Query Match              0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1286 GGACCATGAAGACC 1299
              || ||||||||||||
Db         15 GGGCCATGAAGACC 2


RESULT 109
I20453/c
LOCUS       I20453                    15 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 32 from patent US 5514577.
ACCESSION   I20453
VERSION     I20453.1  GI:1600808
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G., Crooke,S.T., Mirabelli,C.K., Ecker,D.J., Hanecak,R.C.,
            Anderson,K.P., Brown-Driver,V.L. and Wyatt,J.R.
  TITLE     Oligonucleotide therapies for modulating the effects of herpes
            viruses
  JOURNAL   Patent: US 5514577-A 32 07-MAY-1996;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 110
I52331
LOCUS       I52331                    15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 72 from patent US 5646042.
ACCESSION   I52331
VERSION     I52331.1  GI:2473532
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 72 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1444 CTATGTTTAGTTTT 1457
              |||||||| |||||
Db          1 CTATGTTTTGTTTT 14


RESULT 111
AR209754/c
LOCUS       AR209754                  15 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 5 from patent US 6387366.
ACCESSION   AR209754
VERSION     AR209754.1  GI:21511806
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Hurwitz,D.R., Cherington,V., Galanopoulos,T., Levine,P.H. and
            Greenberger,J.S.
  TITLE     Methods for reducing adverse side effects associated with cellular
            transplantation
  JOURNAL   Patent: US 6387366-A 5 14-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match              0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1286 GGACCATGAAGACC 1299
              || ||||||||||||
Db         15 GGGCCATGAAGACC 2


RESULT 112
AX032573/c
```

```
LOCUS       AX032573                 15 bp    DNA     linear   PAT 20-SEP-2000
DEFINITION  Sequence 19 from Patent EP1016715.
ACCESSION   AX032573
VERSION     AX032573.1  GI:10279511
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Imbach,J.L., Brown-Driver,V.L., Vickers,T.A., Ecker,D.J.,
            Bennett,C.F., Chiang,M.Y., Anderson,K.P., Hanecak,R.C. and
            Wyatt,J.R.
  TITLE     Oligonucleotides having a conserved g4 core sequence
  JOURNAL   Patent: EP 1016715-A 19 05-JUL-2000;
            ISIS PHARMACEUTICALS INC (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 113
AX633116/c
LOCUS       AX633116                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 255 from Patent EP1260586.
ACCESSION   AX633116
VERSION     AX633116.1  GI:28468730
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 255 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              |||||||||||  ||
Db         15 AAATAACAAATGAA 2


RESULT 114
AX636811
LOCUS       AX636811                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3950 from Patent EP1260586.
ACCESSION   AX636811
VERSION     AX636811.1  GI:28472425
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 3950 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1522 TCCTGTCTCCAGAT 1535
              |||| |||||||||
Db          2 TCCTCTCTCCAGAT 15


RESULT 115
AX636868/c
LOCUS       AX636868                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4007 from Patent EP1260586.
ACCESSION   AX636868
VERSION     AX636868.1  GI:28472482
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 4007 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         15 AAATAATAAATAAA 2


RESULT 116
AX636870/c
LOCUS       AX636870                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4009 from Patent EP1260586.
ACCESSION   AX636870
VERSION     AX636870.1  GI:28472484
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
```

```
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 4009 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         14 AAATAATAAATAAA 1


RESULT 117
AX637407/c
LOCUS       AX637407                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4546 from Patent EP1260586.
ACCESSION   AX637407
VERSION     AX637407.1  GI:28473021
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 4546 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         15 AAATAATAAATAAA 2


RESULT 118
AX637409/c
LOCUS       AX637409                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4548 from Patent EP1260586.
ACCESSION   AX637409
VERSION     AX637409.1  GI:28473023
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 4548 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 55;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              |||||| |||||||
Db         14 AAATAATAAATAAA 1


RESULT 119
AX757371/c
LOCUS       AX757371                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 692 from Patent WO03040369.
ACCESSION   AX757371
VERSION     AX757371.1  GI:32251987
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 692 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             0.5%;  Score 10.6;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1957 TGTGTTTTAAAAGGCTC 1973
              ||| | ||||| || ||
Db         17 TGTTTGTTAAATGGATC 1


RESULT 120
AR096037/c
LOCUS       AR096037                  29 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 3 from patent US 6005086.
ACCESSION   AR096037
VERSION     AR096037.1  GI:10024472
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Evans,R.M., Forman,B.M. and Weinberger,C.A.
  TITLE     Farnesoid activated receptor polypeptides, and nucleic acid
            encoding the same
  JOURNAL   Patent: US 6005086-A 3 21-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 121
AR217415/c
LOCUS       AR217415                 29 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 3 from patent US 6416957.
ACCESSION   AR217415
VERSION     AR217415.1  GI:23317106
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 29)
  AUTHORS   Evans,R.M., Forman,B.M. and Weinberger,C.A.
  TITLE     Method for modulating process mediated by farnesoid activated
            receptors
  JOURNAL   Patent: US 6416957-A 3 09-JUL-2002;
FEATURES             Location/Qualifiers
     source          1. .29
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 122
BD257498/c
LOCUS       BD257498                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD257498
VERSION     BD257498.1  GI:33067268
KEYWORDS    JP 2002541795-A/5291.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 5291 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/5291
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             0.5%;  Score 10.4;  DB 1;  Length 17;
  Best Local Similarity   91.7%;  Pred. No. 1.3e+02;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1194 GAAGAAAATTTT 1205
              |||||| ||||
Db         12 GAAGAAACTTTT 1


RESULT 123
AX770644
LOCUS       AX770644                 21 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 3 from Patent WO03033736.
ACCESSION   AX770644
VERSION     AX770644.1  GI:32437947
KEYWORDS    .
SOURCE      Oryza sp.
  ORGANISM  Oryza sp.
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
  AUTHORS   Sardesai,N., Kumar,A., Nair,S. and Mohan,M.
  TITLE     Fine mapping and application of dna markers linked to a gall midge
            resistance gene for marker-aided selection in rice
  JOURNAL   Patent: WO 03033736-A 3 24-APR-2003;
            International Centre for Genetic Engineering and Biotechnology (IN)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Oryza sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:52841"

  Query Match             0.5%;  Score 10.4;  DB 1;  Length 21;
  Best Local Similarity   70.0%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1513 CAATTGTTATCCTGTCTCCA 1532
              || || | || || ||| ||
Db          1 CATTTCTAATTCTTTCTTCA 20


RESULT 124
I35238
LOCUS       I35238                   15 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 206 from patent US 5599706.
ACCESSION   I35238
VERSION     I35238.1  GI:2088206
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., McSwiggen,J., Newton,R.S. and Ramharack,R.
  TITLE     Ribozymes targeted to apo(a) mRNA
  JOURNAL   Patent: US 5599706-A 206 04-FEB-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        799 GTTTCTTCAGGAGAA 813
              | |||||| | ||||
Db          1 GCTTCTTCTGAAGAA 15
```

```
RESULT 125
AR133937/c
LOCUS       AR133937                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2362 from patent US 6194150.
ACCESSION   AR133937
VERSION     AR133937.1  GI:14122842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 2362 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        645 CAGGGAGAAACTGAG 659
              |||| ||||||  ||
Db         15 CAGGTAGAAACCCAG 1


Search completed: April  8, 2004, 15:19:54
Job time : 4 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 8, 2004, 15:24:46 ; Search time 2 Seconds
(without alignments)
2.899 Million cell updates/sec

Title: us-10-002-491-3
Perfect score: 2218
Sequence: 1 acgagactctctcctcctcc.....aaaaaaaaaaaaaaaaaaa 2218

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 79 seqs, 1307 residues

Total number of hits satisfying chosen parameters: 158

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rnidb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	23.6	1.1	29	1	US-08-372-183-3	Sequence 3, Appli
	2	23.6	1.1	29	1	US-09-469-721-3	Sequence 3, Appli
	3	23.6	1.1	29	1	US-09-696-443-3	Sequence 3, Appli
	4	23.6	1.1	29	1	PCT-US95-17023-3	Sequence 3, Appli
	5	19	0.9	23	1	US-08-134-557D-4	Sequence 4, Appli
	6	15.4	0.7	17	1	US-09-866-108A-9953	Sequence 9953, Ap
c	7	14.4	0.6	17	1	US-08-373-124A-962	Sequence 962, App
c	8	14.4	0.6	17	1	US-08-373-124A-964	Sequence 964, App
c	9	14.4	0.6	17	1	US-08-435-628-962	Sequence 962, App
c	10	14.4	0.6	17	1	US-08-435-628-964	Sequence 964, App
	11	14.4	0.6	17	1	US-08-584-040-4363	Sequence 4363, Ap
	12	14.4	0.6	17	1	US-09-371-772B-2130	Sequence 2130, Ap
	13	14.4	0.6	17	1	US-09-371-772B-6910	Sequence 6910, Ap
	14	14.4	0.6	17	1	US-09-866-108A-9952	Sequence 9952, Ap
	15	14.4	0.6	17	1	US-09-866-108A-9954	Sequence 9954, Ap
c	16	13.8	0.6	17	1	US-08-373-124A-966	Sequence 966, App
	17	13.8	0.6	17	1	US-08-373-124A-1032	Sequence 1032, Ap
	18	13.8	0.6	17	1	US-08-373-124A-1034	Sequence 1034, Ap
c	19	13.8	0.6	17	1	US-08-435-628-966	Sequence 966, App
	20	13.8	0.6	17	1	US-08-435-628-1032	Sequence 1032, Ap
	21	13.8	0.6	17	1	US-08-435-628-1034	Sequence 1034, Ap
c	22	13.8	0.6	17	1	US-08-985-162-292	Sequence 292, App
	23	13.8	0.6	17	1	US-08-584-040-2238	Sequence 2238, Ap
	24	13.8	0.6	17	1	US-08-584-040-2565	Sequence 2565, Ap
c	25	13.8	0.6	17	1	US-08-584-040-2706	Sequence 2706, Ap
c	26	13.8	0.6	17	1	US-09-614-034-111	Sequence 111, App
	27	13.8	0.6	17	1	US-09-371-772B-783	Sequence 783, App
	28	13.8	0.6	17	1	US-09-371-772B-1089	Sequence 1089, Ap
c	29	13.8	0.6	17	1	US-09-371-772B-1230	Sequence 1230, Ap
	30	13.8	0.6	17	1	US-09-371-772B-5172	Sequence 5172, Ap
	31	13.8	0.6	17	1	US-09-371-772B-6911	Sequence 6911, Ap
c	32	13.8	0.6	17	1	US-09-401-063-292	Sequence 292, App
c	33	13.8	0.6	17	1	US-09-866-108A-2258	Sequence 2258, Ap
	34	13.8	0.6	17	1	US-09-866-108A-9955	Sequence 9955, Ap
	35	13.8	0.6	17	1	US-09-866-108A-9956	Sequence 9956, Ap
c	36	13.4	0.6	15	1	US-08-311-760A-206	Sequence 206, App
c	37	13.4	0.6	15	1	US-08-774-310-206	Sequence 206, App
	38	13	0.6	14	1	US-08-666-341A-66	Sequence 66, Appl
	39	13	0.6	15	1	US-08-182-968A-464	Sequence 464, App
	40	13	0.6	15	1	US-08-774-306A-464	Sequence 464, App
	41	13	0.6	15	1	US-08-585-684B-2362	Sequence 2362, Ap
	42	13	0.6	15	1	US-09-064-156A-464	Sequence 464, App
	43	13	0.6	15	1	US-09-038-073-2362	Sequence 2362, Ap
	44	12.8	0.6	16	1	US-08-954-210-21	Sequence 21, Appl
	45	12.8	0.6	16	1	US-09-431-419A-21	Sequence 21, Appl
c	46	12.8	0.6	16	1	US-09-614-034-103	Sequence 103, App
	47	12.4	0.6	14	1	US-08-173-489C-185	Sequence 185, App
	48	12.4	0.6	14	1	US-08-173-489C-197	Sequence 197, App
c	49	12.4	0.6	15	1	US-08-031-147A-32	Sequence 32, Appl
	50	12.4	0.6	15	1	US-08-373-124A-72	Sequence 72, Appl
	51	12.4	0.6	15	1	US-08-363-240A-60	Sequence 60, Appl
	52	12.4	0.6	15	1	US-08-311-486C-166	Sequence 166, App
c	53	12.4	0.6	15	1	US-08-311-486C-195	Sequence 195, App
c	54	12.4	0.6	15	1	US-08-311-486C-196	Sequence 196, App
c	55	12.4	0.6	15	1	US-08-311-486C-719	Sequence 719, App
c	56	12.4	0.6	15	1	US-08-311-486C-720	Sequence 720, App
	57	12.4	0.6	15	1	US-08-435-628-72	Sequence 72, Appl
c	58	12.4	0.6	15	1	US-08-292-620A-223	Sequence 223, App
c	59	12.4	0.6	15	1	US-08-585-684B-630	Sequence 630, App
c	60	12.4	0.6	15	1	US-08-585-684B-631	Sequence 631, App
c	61	12.4	0.6	15	1	US-08-585-684B-632	Sequence 632, App
c	62	12.4	0.6	15	1	US-08-403-888A-19	Sequence 19, Appl
c	63	12.4	0.6	15	1	US-09-071-845-223	Sequence 223, App
c	64	12.4	0.6	15	1	US-09-038-073-630	Sequence 630, App
c	65	12.4	0.6	15	1	US-09-038-073-631	Sequence 631, App
c	66	12.4	0.6	15	1	US-09-038-073-632	Sequence 632, App
c	67	12.4	0.6	15	1	US-09-224-048A-5	Sequence 5, Appli
c	68	12.4	0.6	15	1	PCT-US94-02471-32	Sequence 32, Appl
c	69	12	0.5	13	1	US-08-441-887A-134	Sequence 134, App
	70	12	0.5	15	1	US-08-182-968A-428	Sequence 428, App
	71	12	0.5	15	1	US-08-074-879-7	Sequence 7, Appli
	72	12	0.5	15	1	US-08-468-057A-7	Sequence 7, Appli
	73	12	0.5	15	1	US-08-963-933-13	Sequence 13, Appl
	74	12	0.5	15	1	US-08-774-306A-428	Sequence 428, App
	75	12	0.5	15	1	US-09-064-156A-428	Sequence 428, App
	76	12	0.5	15	1	US-09-081-646-116	Sequence 116, App
	77	12	0.5	15	1	US-09-081-646-822	Sequence 822, App
c	78	12	0.5	15	1	US-08-705-477E-43	Sequence 43, Appl
	79	12	0.5	15	1	US-08-705-477E-48	Sequence 48, Appl
c	80	11.2	0.5	17	1	US-09-866-108A-9953	Sequence 9953, Ap
c	81	11.2	0.5	17	1	US-09-866-108A-9952	Sequence 9952, Ap
c	82	10.8	0.5	17	1	US-09-866-108A-9954	Sequence 9954, Ap
c	83	10.8	0.5	17	1	US-09-866-108A-9955	Sequence 9955, Ap
c	84	10.6	0.5	29	1	US-08-372-183-3	Sequence 3, Appli
c	85	10.6	0.5	29	1	US-09-469-721-3	Sequence 3, Appli
c	86	10.6	0.5	29	1	US-09-696-443-3	Sequence 3, Appli
c	87	10.6	0.5	29	1	PCT-US95-17023-3	Sequence 3, Appli
	88	10.2	0.5	15	1	US-08-311-760A-206	Sequence 206, App
	89	10.2	0.5	15	1	US-08-774-310-206	Sequence 206, App
c	90	10.2	0.5	15	1	US-08-585-684B-2362	Sequence 2362, Ap
c	91	10.2	0.5	15	1	US-09-038-073-2362	Sequence 2362, Ap
	92	10.2	0.5	15	1	US-08-311-486C-195	Sequence 195, App
	93	10.2	0.5	15	1	US-08-311-486C-719	Sequence 719, App
	94	10.2	0.5	15	1	US-08-292-620A-223	Sequence 223, App
	95	10.2	0.5	15	1	US-09-071-845-223	Sequence 223, App
c	96	10.2	0.5	15	1	US-08-963-933-13	Sequence 13, Appl
c	97	10	0.5	15	1	US-08-311-486C-166	Sequence 166, App
	98	10	0.5	17	1	US-08-373-124A-962	Sequence 962, App
	99	10	0.5	17	1	US-08-373-124A-964	Sequence 964, App
	100	10	0.5	17	1	US-08-435-628-962	Sequence 962, App

ALIGNMENTS

RESULT 1

```
US-08-372-183-3
; Sequence 3, Application US/08372183
; Patent No. 6005086
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/372,183
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
US-08-372-183-3

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 1.4;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 2
US-09-469-721-3
; Sequence 3, Application US/09469721
; Patent No. 6184353
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/469,721
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/372,183
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
US-09-469-721-3

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 1.4;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 3
US-09-696-443-3
; Sequence 3, Application US/09696443
; Patent No. 6416957
;   GENERAL INFORMATION:
;        APPLICANT: Evans, Ronald M.
;                   Forman, Barry M.
;                   Weinberger, Cary A.
;        TITLE OF INVENTION: METHOD FOR MODULATING PROCESSES MEDIATED
;                            BY FARNESOID ACTIVATED RECEPTORS
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
;             STREET: 444 South Flower Street, Suite 2000
;             CITY: Los Angeles
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 90071
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/696,443
;             FILING DATE: 24-Oct-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/372,183
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Reiter, Stephen E.
;             REGISTRATION NUMBER: 31,192
;             REFERENCE/DOCKET NUMBER: P41 9844
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 619-546-4737
;             TELEFAX: 619-546-9392
;   INFORMATION FOR SEQ ID NO: 3:
```

```
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 29 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: Other nucleic acid;
;             DESCRIPTION: Oligonucleotide
;        SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-696-443-3

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 1.4;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 4
PCT-US95-17023-3
; Sequence 3, Application PC/TUS9517023
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/17023
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
PCT-US95-17023-3

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 1.4;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              ||||||||||| || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 5
US-08-134-557D-4
; Sequence 4, Application US/08134557D
; Patent No. 6200802
;  GENERAL INFORMATION:
;    APPLICANT:  Greene, Marianne E.
;    APPLICANT:  Blumberg, Bruce
;    TITLE OF INVENTION:  Human Peroxisome Proliferator Activated
;    TITLE OF INVENTION:  Receptor Gamma:  Compositions and Methods
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rockey, Milnamow & Katz, Ltd.
;      STREET:  2 Prudential Plaza, Suite 4700 180 N. Stetson
;      CITY:  Chicago
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/134,557D
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Katz, Martin L.
;      REGISTRATION NUMBER:  25,011
;      REFERENCE/DOCKET NUMBER:  ARCH:098
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-616-5400
;      TELEFAX:  312-616-5460
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-134-557D-4

  Query Match             0.9%;  Score 19;  DB 1;  Length 23;
  Best Local Similarity   69.6%;  Pred. No. 5.8;
  Matches   16;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        783 TGTGAGGGGTGTAAAGGTTTCTT 805
              ||:||:|| ||:||:|| ||:||
Db          1 TGYGARGGNTGYAARGGNTTYTT 23


RESULT 6
US-09-866-108A-9953
; Sequence 9953, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9953
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108A-9953

  Query Match             0.7%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 12;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1072 GGGAGAAAACTGAACTC 1088
              ||||||||||||| |||
Db          1 GGGAGAAAACTGAGCTC 17


RESULT 7
US-08-373-124A-962/c
; Sequence 962, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  962:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-962

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              |||||||||| ||||
Db         17 TTTTTATAAAACTATT 2


RESULT 8
US-08-373-124A-964/c
; Sequence 964, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  964:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-964

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
                ||||||||||| ||||
Db         16 TTTTTATAAAACTATT 1


RESULT 9
US-08-435-628-962/c
; Sequence 962, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  962:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-962

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
                ||||||||||| ||||
Db         17 TTTTTATAAAACTATT 2


RESULT 10
US-08-435-628-964/c
; Sequence 964, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  964:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-964

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 19;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
                ||||||||||| ||||
Db         16 TTTTTATAAAACTATT 1
```

```
RESULT 11
US-08-584-040-4363
; Sequence 4363, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4363:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4363

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 19;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              ||||::| ||||||:||
Db          2 AGAUUCUCCAGCCUGA 17


RESULT 12
US-09-371-772B-2130
; Sequence 2130, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2130
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2130

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 19;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              ||||::| ||||||:||
Db          2 AGAUUCUCCAGCCUGA 17


RESULT 13
US-09-371-772B-6910
; Sequence 6910, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6910
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6910

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 19;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              ||||::| ||||||:||
Db          1 AGAUUCUCCAGCCUGA 16


RESULT 14
US-09-866-108A-9952
; Sequence 9952, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9952

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1072 GGGAGAAAACTGAACT 1087
              ||||||||||||| ||
Db          2 GGGAGAAAACTGAGCT 17
```

RESULT 15
US-09-866-108A-9954
; Sequence 9954, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9954
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9954

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1073 GGAGAAAACTGAACTC 1088
              ||||||||||||| |||
Db          1 GGAGAAAACTGAGCTC 16
```

RESULT 16
US-08-373-124A-966/c
; Sequence 966, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 966:

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-966

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTAT 1468
              | |||||||||||  |||
Db         17 ATTTTTTATAAAACTAT 1


RESULT 17
US-08-373-124A-1032
; Sequence 1032, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1032:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-1032

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 25;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 ACCAGGATTTCAGACTT 1284
              || ||  |:::|||||::
Db          1 ACUAGUAUUUCAGACUU 17


RESULT 18
US-08-373-124A-1034
; Sequence 1034, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1034:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-1034

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 25;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1269 CCAGGATTTCAGACTTT 1285
              | ||  |:::|||||:::
Db          1 CUAGUAUUUCAGACUUU 17


RESULT 19
US-08-435-628-966/c
```

```
; Sequence 966, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  966:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-966

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTAT 1468
              | ||||||||||| |||
Db         17 ATTTTTTATAAAACTAT 1


RESULT 20
US-08-435-628-1032
; Sequence 1032, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1032:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-1032

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 25;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1268 ACCAGGATTTCAGACTT 1284
              || || |:::|||||::
Db          1 ACUAGUAUUUCAGACUU 17


RESULT 21
US-08-435-628-1034
; Sequence 1034, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1034:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-1034

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 25;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1269 CCAGGATTTCAGACTTT 1285
              | ||  |:::|||||:::
Db          1 CUAGUAUUUCAGACUUU 17


RESULT 22
US-08-985-162-292/c
; Sequence 292, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  292:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-292

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
              ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 23
US-08-584-040-2238
; Sequence 2238, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2238:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2238

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 25;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1101 CAGACTCTTCTACATTT 1117
              | ||| |::|:|||::: 
Db          1 CUGACCCUUCUACAUUU 17


RESULT 24
US-08-584-040-2565
; Sequence 2565, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2565:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2565

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 25;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1159 TAACAAATAAAATTTTA 1175
              :||||||:||||  ::|
Db          1 UAACAAAUAAAACCUUA 17


RESULT 25
US-08-584-040-2706/c
; Sequence 2706, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2706:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2706

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1450 TTAGTTTTTATAAAAGT 1466
              || |||| |||||||||
```

```
Db         17 TTGGTTTGTATAAAAGT 1


RESULT 26
US-09-614-034-111/c
; Sequence 111, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/09/614,034
;  CURRENT FILING DATE:  2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 111
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-111

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGCG 701
              ||| | ||||||||||||
Db         17 AGCTCGGCATGGGCGCG 1


RESULT 27
US-09-371-772B-783
; Sequence 783, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 783
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-783

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 25;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1101 CAGACTCTTCTACATTT 1117
              | ||| |::|:|||:::
Db          1 CUGACCCUUCUACAUUU 17


RESULT 28
US-09-371-772B-1089
; Sequence 1089, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1089
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1089

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 25;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1159 TAACAAATAAAATTTTA 1175
              :||||||:||||  ::|
Db          1 UAACAAAUAAAACCUUA 17


RESULT 29
US-09-371-772B-1230/c
; Sequence 1230, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1230
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1230

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1450 TTAGTTTTTATAAAAGT 1466
              || |||| |||||||||
Db         17 TTGGTTTGTATAAAAGT 1
```

```
RESULT 30
US-09-371-772B-5172
; Sequence 5172, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5172
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5172

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 25;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1103 GACTCTTCTACATTTTA 1119
                |||  |::|:|||::: |
Db          1 GACCCUUCUACAUUUGA 17


RESULT 31
US-09-371-772B-6911
; Sequence 6911, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6911
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6911

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 25;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1613 GATTCACCAGCCTGAAA 1629
                ||::| ||||||:|| |
Db          1 GAUUCUCCAGCCUGACA 17


RESULT 32
US-09-401-063-292/c
; Sequence 292, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  292:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-292

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
                ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 33
US-09-866-108A-2258/c
; Sequence 2258, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
```

```
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2258
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2258

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1017 GAAGACAGTGAAGGTCG 1033
              || |||||||||||| |
Db         17 GAGGACAGTGAAGGTGG 1


RESULT 34
US-09-866-108A-9955
; Sequence 9955, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9955
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9955

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1074 GAGAAAACTGAACTCAC 1090
              |||||||||||| ||| |
Db          1 GAGAAAACTGAGCTCTC 17


RESULT 35
US-09-866-108A-9956
; Sequence 9956, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9956
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9956

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 25;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1075 AGAAAACTGAACTCACC 1091
              ||||||||||  ||| ||
Db          1 AGAAAACTGAGCTCTCC 17


RESULT 36
US-08-311-760A-206/c
; Sequence 206, Application US/08311760A
; Patent No. 5599706
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,760A
;      FILING DATE:  September 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/155
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  206:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-760A-206

  Query Match             0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 21;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        801 TTCTTCAGGAGAAGC 815
              ||||||||  ||||||
Db         15 TTCTTCAGAAGAAGC 1


RESULT 37
US-08-774-310-206/c
; Sequence 206, Application US/08774310
; Patent No. 5877022
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,310
;      FILING DATE:  December 23, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/311,760
;      FILING DATE:  September 23, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/229
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  206:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-310-206

  Query Match             0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 21;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        801 TTCTTCAGGAGAAGC 815
              ||||||||  ||||||
Db         15 TTCTTCAGAAGAAGC 1


RESULT 38
US-08-666-341A-66
; Sequence 66, Application US/08666341A
; Patent No. 6365345
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Antisense nucleic Acids for the
;    TITLE OF INVENTION:  prevention and treatment of disorders in which expression
;    TITLE OF INVENTION:  of c-erbB plays a role
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman and Stern, PLLC
;      STREET:  400 Seventh street, N.W.
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disc
;      COMPUTER:  IBM PC compatible
```

```
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/666,341A
;      FILING DATE:  15-AUG-1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93120710.4
;  INFORMATION FOR SEQ ID NO:  66:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
US-08-666-341A-66

  Query Match             0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1632 CCTCAACACTTTG 1644
              |||||||||||||
Db          2 CCTCAACACTTTG 14


RESULT 39
US-08-182-968A-464
; Sequence 464, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  464:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-464

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 25;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 40
US-08-774-306A-464
; Sequence 464, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  464:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-464

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 25;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 41
US-08-585-684B-2362
; Sequence 2362, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
```

```
;     APPLICANT:  McSwiggen, James
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;     TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;     TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;     NUMBER OF SEQUENCES:  2751
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/585,684B
;       FILING DATE:  January 16, 1996
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/000,951
;       FILING DATE:  July 7, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/078
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2362:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-585-684B-2362

  Query Match              0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 25;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 CTGGGTTTCTACC 573
              |:|||:::|:|||
Db          1 CUGGGUUUCUACC 13


RESULT 42
US-09-064-156A-464
; Sequence 464, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;     APPLICANT:  Draper, Kenneth G.
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR
;     TITLE OF INVENTION:  INHIBITING HEPATITIS C
;     TITLE OF INVENTION:  VIRUS REPLICATION
;     NUMBER OF SEQUENCES:  498
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/064,156A
;       FILING DATE:  April 21, 1998
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/774,306
;       FILING DATE:  December 26, 1996
;       APPLICATION NUMBER:  08/182,968
;       FILING DATE:  January 13, 1994
;       APPLICATION NUMBER:  07/882,888
;       FILING DATE:  May 14, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  234/083
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  464:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-064-156A-464

  Query Match              0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 25;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 43
US-09-038-073-2362
; Sequence 2362, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Daniel T.
;     APPLICANT:  Jarvis, Thale
;     APPLICANT:  McSwiggen, James
;     TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;     TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;     TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;     NUMBER OF SEQUENCES:  2751
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/038,073
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/585,684
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/078
;     TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2362:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-038-073-2362

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 25;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 CTGGGTTTCTACC 573
              |:|||:::|:|||
Db          1 CUGGGUUUCUACC 13


RESULT 44
US-08-954-210-21
; Sequence 21, Application US/08954210
; Patent No. 6043077
;  GENERAL INFORMATION:
;     APPLICANT:  Barber, Jack R.
;     APPLICANT:  Welch, Peter J.
;     APPLICANT:  Tritz, Richard
;     APPLICANT:  Yei, Soonpin
;     APPLICANT:  Yu, Mang
;     TITLE OF INVENTION:  HEPATITIS C VIRUS RIBOZYMES
;     NUMBER OF SEQUENCES:  73
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  SEED and BERRY LLP
;       STREET:  6300 Columbia Center, 701 Fifth Avenue
;       CITY:  Seattle
;       STATE:  Washington
;       COUNTRY:  USA
;       ZIP:  98104-7092
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/954,210
;       FILING DATE:  20-OCT-1997
;       CLASSIFICATION:  514
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  McMasters, David D.
;       REGISTRATION NUMBER:  33,963
;       REFERENCE/DOCKET NUMBER:  480124.403C1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (206) 622-4900
;       TELEFAX:  (206) 682-6031
;   INFORMATION FOR SEQ ID NO:  21:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-954-210-21

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 33;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||:| ||||::|
Db          1 AUAGGGUCAGCGGUUG 16


RESULT 45
US-09-431-419A-21
; Sequence 21, Application US/09431419A
; Patent No. 6458567
; GENERAL INFORMATION:
;  APPLICANT: Barber, Jack R.
;  APPLICANT:  Welch, Peter J.
;  APPLICANT:  Tritz, Richard
;  APPLICANT:  Yei, Soonpin
;  APPLICANT:  Yu, Mang
;  TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES
;  FILE REFERENCE: 480124.403C3
;  CURRENT APPLICATION NUMBER: US/09/431,419A
;  CURRENT FILING DATE:  1999-11-01
;  NUMBER OF SEQ ID NOS: 73
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 21
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Hepatitis C Virus
US-09-431-419A-21

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 33;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||:| ||||::|
Db          1 AUAGGGUCAGCGGUUG 16


RESULT 46
US-09-614-034-103/c
; Sequence 103, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/09/614,034
;  CURRENT FILING DATE:  2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 103
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-103

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGC 700
              ||| | ||||||||||
Db         16 AGCTCGGCATGGGCGC 1


RESULT 47
US-08-173-489C-185
; Sequence 185, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;     APPLICANT:  WANG, C. -G.
;     APPLICANT:  HEPBURN, A. G.
;     TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
```

```
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  185:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus adw2 isolate,
;      DESCRIPTION:  nucleotides 1810 to 1823
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;      INDIVIDUAL ISOLATE:  adw2
;    PUBLICATION INFORMATION:
;      AUTHORS:  Valenzuela, P,  Quiroga, M,  Zaldivar, J,
;      AUTHORS:  Gray, P,  Ruter, W J.
;      TITLE:  The nucleotide sequence of
;      TITLE:  the Hepatitis B viral genome and the
;      TITLE:  identification of the major viral genes
;      JOURNAL:  In "Animal Virus Genetics", Fields, B N,
;      JOURNAL:  Jaenisch, R,  Fox C F eds
;      VOLUME:
;      PAGES:  57-70
;      DATE:  1980
;      RELEVANT RESIDUES IN SEQ ID NO:  185 :FROM 1 TO 14
US-08-173-489C-185

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 27;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        536 TTCCTCGTCATCCT 549
              |||||| |||||||
Db          1 TTCCTCTTCATCCT 14


RESULT 48
US-08-173-489C-197
; Sequence 197, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  197:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus adr isolate,
;      DESCRIPTION:  nucleotides 274 to 287
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;      INDIVIDUAL ISOLATE:  adr
;    PUBLICATION INFORMATION:
;      AUTHORS:  Fujiyama, A,  Miyanohara, A,  No. 5861244aki, C,
;      AUTHORS:  Toneyama, T,, Ohromo, N,  Matsubara, K.
;      TITLE:  Cloning and structural
;      TITLE:  analysis of Hepatitis B virus DNAs subtype adr
;      JOURNAL:  Nucleic Acids Research
;      VOLUME:  11
;      PAGES:  4601-4610
;      DATE:  1983
;      RELEVANT RESIDUES IN SEQ ID NO:  197 :FROM 1 TO 14
US-08-173-489C-197

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 27;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        536 TTCCTCGTCATCCT 549
              |||||| |||||||
Db          1 TTCCTCTTCATCCT 14


RESULT 49
US-08-031-147A-32/c
; Sequence 32, Application US/08031147A
; Patent No. 5514577
;  GENERAL INFORMATION:
;    APPLICANT:  Draper et al.
;    TITLE OF INVENTION:  Oligonucleotide Therapies for
;    TITLE OF INVENTION:  Modulating the Effects of Herpesviruses
;    NUMBER OF SEQUENCES:  57
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5514577ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/031,147A
;      FILING DATE:  March 12, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  485,297
;      FILING DATE:  February 26, 1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  852,132
;      FILING DATE:  April 28, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  954,185
;      FILING DATE:  September 29, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISIS-0469
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
US-08-031-147A-32

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 50
US-08-373-124A-72
; Sequence 72, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  72:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-72

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   28.6%;  Pred. No. 33;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1444 CTATGTTTAGTTTT 1457
              |:|:|::: |::::
Db          1 CUAUGUUUUGUUUU 14


RESULT 51
US-08-363-240A-60
; Sequence 60, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
```

```
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  210/096
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  60:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-363-240A-60

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 33;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1092 CCAGATCAACAGAC 1105
              |||||:|||||  ||
Db          2 CCAGAUCAACACAC 15


RESULT 52
US-08-311-486C-166
; Sequence 166, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  166:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-166

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   57.1%;  Pred. No. 33;
  Matches    8;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1522 TCCTGTCTCCAGAT 1535
              :||: :|:|||||:
Db          2 UCCUCUCUCCAGAU 15


RESULT 53
US-08-311-486C-195/c
; Sequence 195, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  195:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

US-08-311-486C-195

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAAA 1169
|||||| |||||||
Db 15 AAATAATAAATAAA 2

RESULT 54
US-08-311-486C-196/c
; Sequence 196, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-'
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below: two
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 196:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-486C-196

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAAA 1169
|||||| |||||||
Db 14 AAATAATAAATAAA 1

RESULT 55
US-08-311-486C-719/c
; Sequence 719, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-'
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below: two
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 719:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-486C-719

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAAA 1169
|||||| |||||||
Db 15 AAATAATAAATAAA 2

RESULT 56
US-08-311-486C-720/c
; Sequence 720, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:

```
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  720:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-720

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              ||||||| |||||||
Db         14 AAATAATAAATAAA 1


RESULT 57
US-08-435-628-72
; Sequence 72, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  72:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-72

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   28.6%;  Pred. No. 33;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1444 CTATGTTTAGTTTT 1457
              |:|:|::: |::::
Db          1 CUAUGUUUUGUUUU 14


RESULT 58
US-08-292-620A-223/c
; Sequence 223, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
```

```
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  223:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-223

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAAA 1169
              ||||||||||| ||
Db         15 AAATAACAAATGAA 2


RESULT 59
US-08-585-684B-630/c
; Sequence 630, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  630:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-630

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       545 ATCCTATTATTCCA 558
             ||||||||| ||||
Db        15 ATCCTATTAGTCCA 2


RESULT 60
US-08-585-684B-631/c
; Sequence 631, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  631:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-631

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 61
US-08-585-684B-632/c
; Sequence 632, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-632

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 62
US-08-403-888A-19/c
; Sequence 19, Application US/08403888A
; Patent No. 5952490
;  GENERAL INFORMATION:
;    APPLICANT:  Hanecak et al.
;    TITLE OF INVENTION:  Oligonucleotides Having A Conserved G4 Core
;    TITLE OF INVENTION:  Sequence
;    NUMBER OF SEQUENCES:  146
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5952490ris LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/403,888A
;      FILING DATE:  12-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/954,185
;      FILING DATE:  29-SEP-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul K. Legaard
;      REGISTRATION NUMBER:  38,534
;      REFERENCE/DOCKET NUMBER:  ISIS-1229
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-403-888A-19

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 63
US-09-071-845-223/c
; Sequence 223, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 223:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-223

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAAA 1169
||||||||||| ||
Db 15 AAATAACAAATGAA 2

RESULT 64
US-09-038-073-630/c
; Sequence 630, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 630:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-630

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 545 ATCCTATTATTCCA 558
||||||||| ||||
Db 15 ATCCTATTAGTCCA 2

RESULT 65
US-09-038-073-631/c
; Sequence 631, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 631:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```
;      TOPOLOGY:  linear
US-09-038-073-631

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 66
US-09-038-073-632/c
; Sequence 632, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-632

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 67
US-09-224-048A-5/c
; Sequence 5, Application US/09224048A
; Patent No. 6387366
; GENERAL INFORMATION:
;  APPLICANT: Hurwitz, David R.
;  APPLICANT:  Cherington, Van
;  APPLICANT:  Galanopoulos, Theofanis
;  APPLICANT:  Levine, Peter H.
;  APPLICANT:  Greenberger, Joel S.
;  TITLE OF INVENTION: METHOD FOR REDUCING ADVERSE SIDE EFFECTS ASSOCIATED
;  TITLE OF INVENTION:  WITH BONE MARROW CELL TRANSPLANTATION
;  FILE REFERENCE: 07787/007001
;  CURRENT APPLICATION NUMBER: US/09/224,048A
;  CURRENT FILING DATE:  1998-12-31
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Canis familiaris
US-09-224-048A-5

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1286 GGACCATGAAGACC 1299
              || ||||||||||
Db         15 GGGCCATGAAGACC 2


RESULT 68
PCT-US94-02471-32/c
; Sequence 32, Application PC/TUS9402471
;  GENERAL INFORMATION:
;    APPLICANT:  Draper et al.
;    TITLE OF INVENTION:  Oligonucleotide Therapies for
;    TITLE OF INVENTION:  Modulating the Effects of Herpesviruses
;    NUMBER OF SEQUENCES:  57
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & Norris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/02471
;      FILING DATE:  Herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  485,297
;      FILING DATE:  February 26, 1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  852,132
;      FILING DATE:  April 28, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  954,185
;      FILING DATE:  September 29, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISIS-0469
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
PCT-US94-02471-32

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        686 GCCCCGCATGGGCG 699
              ||||||||| ||||
Db         14 GCCCCGCATCGGCG 1


RESULT 69
US-08-441-887A-134/c
; Sequence 134, Application US/08441887A
; Patent No. 5837832
;  GENERAL INFORMATION:
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua X.
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes on
;    TITLE OF INVENTION:  Biological Chips
;    NUMBER OF SEQUENCES:  360
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/441,887A
;      FILING DATE:  16-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/082,937
;      FILING DATE:  25-JUN-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joseph O.
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004160US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-326-2400
;      TELEFAX:  650-326-2422
;  INFORMATION FOR SEQ ID NO:  134:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (probe)
US-08-441-887A-134

  Query Match             0.5%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        544 CATCCTATTATT 555
              ||||||||||||
Db         13 CATCCTATTATT 2


RESULT 70
US-08-182-968A-428
; Sequence 428, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  428:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-428

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 39;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          1 GUACUCUCCUGG 12


RESULT 71
US-08-074-879-7
; Sequence 7, Application US/08074879
; Patent No. 5656423
;  GENERAL INFORMATION:
;    APPLICANT:  Orth, Gerard
;    APPLICANT:  Volpers, Christoph
;    APPLICANT:  Streek, Rolf
;    TITLE OF INVENTION:  DNA Sequences Derived from the Genome of
;    TITLE OF INVENTION:  the Papillomavirus HPV39, Their Use in In Vitro Diagnosis
;    TITLE OF INVENTION:  and for the Production of an Immunogenic Composition
;    NUMBER OF SEQUENCES:  11
```

```
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;       ADDRESSEE:  Dunner
;       STREET:  1300 I Street, N.W.
;       CITY:  Washington
;       STATE:  DC
;       COUNTRY:  USA
;       ZIP:  20005-3315
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/074,879
;       FILING DATE:  16-JUN-1993
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  WO 92/1136
;       FILING DATE:  09-JUL-1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Potter, Jane E.R.
;       REGISTRATION NUMBER:  33,332
;       REFERENCE/DOCKET NUMBER:  02356.0066-00000
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  202-408-4000
;       TELEFAX:  202-408-4400
;   INFORMATION FOR SEQ ID NO:  7:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-074-879-7

  Query Match              0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1109 TCTACATTTTAT 1120
              ||||||||||||
Db          1 TCTACATTTTAT 12


RESULT 72
US-08-468-057A-7
; Sequence 7, Application US/08468057A
; Patent No. 5665535
;  GENERAL INFORMATION:
;    APPLICANT:  Orth, Gerard
;    APPLICANT:  Volpers, Christoph
;    APPLICANT:  Streek, Rolf
;    TITLE OF INVENTION:  DNA Sequences Derived from the Genome of
;    TITLE OF INVENTION:  the Papillomavirus HPV39, Their Use in In Vitro Diagnosis
;    TITLE OF INVENTION:  and for the Production of an Immunogenic Composition
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner
;      STREET:  1300 I Street, N.W.
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20005-3315
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/468,057A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/074,879
;      FILING DATE:  16-JUN-1993
;      APPLICATION NUMBER:  WO 92/1136
;      FILING DATE:  09-JUL-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Potter, Jane E.R.
;      REGISTRATION NUMBER:  33,332
;      REFERENCE/DOCKET NUMBER:  02356.0066-00000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-408-4000
;      TELEFAX:  202-408-4400
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-468-057A-7

  Query Match              0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1109 TCTACATTTTAT 1120
              ||||||||||||
Db          1 TCTACATTTTAT 12


RESULT 73
US-08-963-933-13
; Sequence 13, Application US/08963933
; Patent No. 5837469
;  GENERAL INFORMATION:
;    APPLICANT:  Harris, James M.
;    TITLE OF INVENTION:  Assay for Chlamydia Trachomatis by
;    TITLE OF INVENTION:  Amplification and Detection of Chlamydia Trachomatis
;    TITLE OF INVENTION:  Nucleic Acid
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick - Becton, Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/963,933
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highet, David W.
;      REGISTRATION NUMBER:  30,265
;      REFERENCE/DOCKET NUMBER:  P-3897
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (201) 847-5317
;      TELEFAX:  (201) 848-9228
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-963-933-13
```

```
  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        739 TTTGTGGAGACA 750
              ||||||||||||
Db          4 TTTGTGGAGACA 15


RESULT 74
US-08-774-306A-428
; Sequence 428, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  428:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-428

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 39;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          1 GUACUCUCCUGG 12


RESULT 75
US-09-064-156A-428
; Sequence 428, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/064,156A
;      FILING DATE:  April 21, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/774,306
;      FILING DATE:  December 26, 1996
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  234/083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  428:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-064-156A-428

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 39;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          1 GUACUCUCCUGG 12


RESULT 76
US-09-081-646-116
; Sequence 116, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 116
;   LENGTH: 15
;   TYPE: DNA
```

; ORGANISM: Homo sapiens
US-09-081-646-116

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1015 ATGAAGACAGTG 1026
||||||||||||
Db 2 ATGAAGACAGTG 13

RESULT 77
US-09-081-646-822
; Sequence 822, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 822
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-822

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1015 ATGAAGACAGTG 1026
||||||||||||
Db 2 ATGAAGACAGTG 13

RESULT 78
US-08-705-477E-43/c
; Sequence 43, Application US/08705477E
; Patent No. 6569432
; GENERAL INFORMATION:
; APPLICANT: Israeli, Ron S
; APPLICANT: Heston, Warren D.W.
; APPLICANT: Fair, William R.
; APPLICANT: Overfelli, Ouathek
; APPLICANT: Pinto, John
; TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 1769/41426-G
; CURRENT APPLICATION NUMBER: US/08/705,477E
; CURRENT FILING DATE: 1996-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-705-477E-43

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1583 ACTTCTTGATGT 1594
||||||||||||

Db 12 ACTTCTTGATGT 1

RESULT 79
US-08-705-477E-48
; Sequence 48, Application US/08705477E
; Patent No. 6569432
; GENERAL INFORMATION:
; APPLICANT: Israeli, Ron S
; APPLICANT: Heston, Warren D.W.
; APPLICANT: Fair, William R.
; APPLICANT: Overfelli, Ouathek
; APPLICANT: Pinto, John
; TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 1769/41426-G
; CURRENT APPLICATION NUMBER: US/08/705,477E
; CURRENT FILING DATE: 1996-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-705-477E-48

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1600 AAAAGTTGTGTA 1611
||||||||||||
Db 2 AAAAGTTGTGTA 13

RESULT 80
US-09-866-108A-9953/c
; Sequence 9953, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine

```
; Patent No. 6686188
; SEQ ID NO 9953
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9953

  Query Match             0.5%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 69;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTCTC 1811
              ||||| ||||||| |
Db         16 AGCTCAGTTTTCTCCC 1


RESULT 81
US-09-866-108A-9952/c
; Sequence 9952, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9952
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9952

  Query Match             0.5%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 69;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTCTC 1811
              ||||| ||||||| |
Db         17 AGCTCAGTTTTCTCCC 2


RESULT 82
US-09-866-108A-9954/c
; Sequence 9954, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9954
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9954

  Query Match             0.5%;  Score 10.8;  DB 1;  Length 17;
  Best Local Similarity   85.7%;  Pred. No. 78;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTC 1809
              ||||| |||||||
Db         15 AGCTCAGTTTTCTC 2


RESULT 83
US-09-866-108A-9955/c
; Sequence 9955, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
```

```
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9955
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-9955

  Query Match           0.5%;  Score 10.8;  DB 1;  Length 17;
  Best Local Similarity   85.7%;  Pred. No. 78;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTC 1809
              ||||| |||||||
Db         14 AGCTCAGTTTTCTC 1


RESULT 84
US-08-372-183-3/c
; Sequence 3, Application US/08372183
; Patent No. 6005086
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/372,183
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
US-08-372-183-3

  Query Match           0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 90;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 85
US-09-469-721-3/c
; Sequence 3, Application US/09469721
; Patent No. 6184353
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/469,721
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/372,183
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
US-09-469-721-3

  Query Match           0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 90;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 86
US-09-696-443-3/c
```

```
; Sequence 3, Application US/09696443
; Patent No. 6416957
;  GENERAL INFORMATION:
;       APPLICANT: Evans, Ronald M.
;                  Forman, Barry M.
;                  Weinberger, Cary A.
;       TITLE OF INVENTION: METHOD FOR MODULATING PROCESSES MEDIATED
;                           BY FARNESOID ACTIVATED RECEPTORS
;       NUMBER OF SEQUENCES: 7
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
;            STREET: 444 South Flower Street, Suite 2000
;            CITY: Los Angeles
;            STATE: CA
;            COUNTRY: USA
;            ZIP: 90071
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/696,443
;            FILING DATE: 24-Oct-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/372,183
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Reiter, Stephen E.
;            REGISTRATION NUMBER: 31,192
;            REFERENCE/DOCKET NUMBER: P41 9844
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 619-546-4737
;            TELEFAX: 619-546-9392
;   INFORMATION FOR SEQ ID NO: 3:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 29 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: Other nucleic acid;
;            DESCRIPTION: Oligonucleotide
;       SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-696-443-3

  Query Match             0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 90;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 87
PCT-US95-17023-3/c
; Sequence 3, Application PC/TUS9517023
;  GENERAL INFORMATION:
;    APPLICANT:  Evans, Ronald M.
;    APPLICANT:  Forman, Barry M.
;    APPLICANT:  Weinberger, Cary A.
;    TITLE OF INVENTION:  METHOD FOR MODULATING PROCESSES MEDIATED
;    TITLE OF INVENTION:  BY FARNESOID ACTIVATED RECEPTORS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pretty, Schroeder, Brueggemann & Clark
;      STREET:  444 South Flower Street, Suite 2000
;      CITY:  Los Angeles
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/17023
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Reiter, Stephen E.
;      REGISTRATION NUMBER:  31,192
;      REFERENCE/DOCKET NUMBER:  P41 9844
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-546-4737
;      TELEFAX:  619-546-9392
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  29 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Oligonucleotide
PCT-US95-17023-3

  Query Match             0.5%;  Score 10.6;  DB 1;  Length 29;
  Best Local Similarity   59.3%;  Pred. No. 90;
  Matches   16;  Conservative    1;  Mismatches   10;  Indels    0;  Gaps    0;

Qy       1292 TGAAGACCAGATTGCTTTGCTGAAAGG 1318
              ||||||  :  ||||    || | |||
Db         28 TGAAGAARMCYTTGCAGCCCTCACAGG 2


RESULT 88
US-08-311-760A-206
; Sequence 206, Application US/08311760A
; Patent No. 5599706
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,760A
;      FILING DATE:  September 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/155
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  206:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-760A-206

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 76;
  Matches    8;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        799 GTTTCTTCAGGAGAA 813
              | ::|::| | ||||
Db          1 GCUUCUUCUGAAGAA 15


RESULT 89
US-08-774-310-206
; Sequence 206, Application US/08774310
; Patent No. 5877022
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,310
;      FILING DATE:  December 23, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/311,760
;      FILING DATE:  September 23, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/229
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  206:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-310-206

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   53.3%;  Pred. No. 76;
  Matches    8;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        799 GTTTCTTCAGGAGAA 813
              | ::|::| | ||||
Db          1 GCUUCUUCUGAAGAA 15


RESULT 90
US-08-585-684B-2362/c
; Sequence 2362, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2362:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2362

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 76;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        645 CAGGGAGAAACTGAG 659
              |||| ||||||  ||
Db         15 CAGGTAGAAACCCAG 1


RESULT 91
US-09-038-073-2362/c
; Sequence 2362, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
```

```
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2362:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2362

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 76;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        645 CAGGGAGAAACTGAG 659
              |||| ||||||  ||
Db         15 CAGGTAGAAACCCAG 1


RESULT 92
US-08-311-486C-195
; Sequence 195, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  195:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-195

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   13.3%;  Pred. No. 76;
  Matches    2;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        424 ATTTATTTGGTGTTT 438
              |:::|:::  : :::
Db          1 AUUUAUUUAUUAUUU 15


RESULT 93
US-08-311-486C-719
; Sequence 719, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
```

```
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  719:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-719

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   13.3%;  Pred. No. 76;
  Matches    2;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        424 ATTTATTTGGTGTTT 438
              |:::|:::  : :::
Db          1 AUUUAUUUAUUAUUU 15


RESULT 94
US-08-292-620A-223
; Sequence 223, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  223:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-223

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   20.0%;  Pred. No. 76;
  Matches    3;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        424 ATTTATTTGGTGTTT 438
              |:: |:::| : :::
Db          1 AUUCAUUUGUUAUUU 15


RESULT 95
US-09-071-845-223
; Sequence 223, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
```

```
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  223:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-223

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   20.0%;  Pred. No. 76;
  Matches    3;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        424 ATTTATTTGGTGTTT 438
              |:: |:::| : :::
Db          1 AUUCAUUUGUUAUUU 15


RESULT 96
US-08-963-933-13/c
; Sequence 13, Application US/08963933
; Patent No. 5837469
;  GENERAL INFORMATION:
;    APPLICANT:  Harris, James M.
;    TITLE OF INVENTION:  Assay for Chlamydia Trachomatis by
;    TITLE OF INVENTION:  Amplification and Detection of Chlamydia Trachomatis
;    TITLE OF INVENTION:  Nucleic Acid
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick - Becton, Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/963,933
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highet, David W.
;      REGISTRATION NUMBER:  30,265
;      REFERENCE/DOCKET NUMBER:  P-3897
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (201) 847-5317
;      TELEFAX:  (201) 848-9228
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-963-933-13

  Query Match             0.5%;  Score 10.2;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 76;
  Matches   12;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1525 TGTCTCCAGATAGAC 1539
              |||||||| | || |
Db         15 TGTCTCCACAAAGCC 1


RESULT 97
US-08-311-486C-166/c
; Sequence 166, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  166:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-166

  Query Match             0.5%;  Score 10;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 82;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         92 ATCTGGAGAG 101
              ||||||||||
Db         15 ATCTGGAGAG 6


RESULT 98
US-08-373-124A-962
; Sequence 962, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
```

```
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  962:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-962

  Query Match             0.5%;  Score 10;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 99;
  Matches    5;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1455 TTTTATAAAA 1464
              ::::|:||||
Db          7 UUUUAUAAAA 16


RESULT 99
US-08-373-124A-964
; Sequence 964, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  964:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-964

  Query Match             0.5%;  Score 10;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 99;
  Matches    5;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1455 TTTTATAAAA 1464
              ::::|:||||
Db          6 UUUUAUAAAA 15


RESULT 100
US-08-435-628-962
; Sequence 962, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
```

; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 962:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-962

Query Match 0.5%; Score 10; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 99;
Matches 5; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1455 TTTTATAAAA 1464
              :::::|:||||
Db          7 UUUUAUAAAA 16
```

Search completed: April 8, 2004, 15:24:49
Job time : 3 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 8, 2004, 15:26:52 ; Search time 2 Seconds
(without alignments)
3.815 Million cell updates/sec

Title: us-10-002-491-3
Perfect score: 2218
Sequence: 1 acgagactctctcctcctcc.....aaaaaaaaaaaaaaaaaaa 2218

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 92 seqs, 1720 residues

Total number of hits satisfying chosen parameters: 184

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	27	1.2	27	1	US-10-002-491-4	Sequence 4, Appli
	2	27	1.2	27	1	US-10-002-491-6	Sequence 6, Appli
	3	23.6	1.1	29	1	US-10-155-379-3	Sequence 3, Appli
c	4	23	1.0	23	1	US-10-002-491-5	Sequence 5, Appli
c	5	20	0.9	20	1	US-10-002-491-12	Sequence 12, Appl
c	6	20	0.9	20	1	US-10-002-491-13	Sequence 13, Appl
c	7	20	0.9	20	1	US-10-002-491-14	Sequence 14, Appl
c	8	20	0.9	20	1	US-10-002-491-15	Sequence 15, Appl
c	9	20	0.9	20	1	US-10-002-491-16	Sequence 16, Appl
c	10	20	0.9	20	1	US-10-002-491-17	Sequence 17, Appl
c	11	20	0.9	20	1	US-10-002-491-18	Sequence 18, Appl
c	12	20	0.9	20	1	US-10-002-491-19	Sequence 19, Appl
c	13	20	0.9	20	1	US-10-002-491-20	Sequence 20, Appl
c	14	20	0.9	20	1	US-10-002-491-21	Sequence 21, Appl
c	15	20	0.9	20	1	US-10-002-491-22	Sequence 22, Appl
c	16	20	0.9	20	1	US-10-002-491-23	Sequence 23, Appl
c	17	20	0.9	20	1	US-10-002-491-39	Sequence 39, Appl
c	18	20	0.9	20	1	US-10-002-491-40	Sequence 40, Appl
c	19	20	0.9	20	1	US-10-002-491-41	Sequence 41, Appl
c	20	20	0.9	20	1	US-10-002-491-42	Sequence 42, Appl
c	21	20	0.9	20	1	US-10-002-491-43	Sequence 43, Appl
c	22	20	0.9	20	1	US-10-002-491-44	Sequence 44, Appl
c	23	20	0.9	20	1	US-10-002-491-45	Sequence 45, Appl
c	24	20	0.9	20	1	US-10-002-491-46	Sequence 46, Appl
c	25	20	0.9	20	1	US-10-002-491-47	Sequence 47, Appl
c	26	20	0.9	20	1	US-10-002-491-48	Sequence 48, Appl
c	27	20	0.9	20	1	US-10-002-491-49	Sequence 49, Appl
c	28	20	0.9	20	1	US-10-002-491-50	Sequence 50, Appl
c	29	20	0.9	20	1	US-10-002-491-51	Sequence 51, Appl
c	30	20	0.9	20	1	US-10-002-491-52	Sequence 52, Appl
c	31	20	0.9	20	1	US-10-002-491-53	Sequence 53, Appl
c	32	20	0.9	20	1	US-10-002-491-54	Sequence 54, Appl
c	33	20	0.9	20	1	US-10-002-491-55	Sequence 55, Appl
c	34	20	0.9	20	1	US-10-002-491-56	Sequence 56, Appl
c	35	20	0.9	20	1	US-10-002-491-57	Sequence 57, Appl
c	36	20	0.9	20	1	US-10-002-491-58	Sequence 58, Appl
c	37	20	0.9	20	1	US-10-002-491-59	Sequence 59, Appl
c	38	20	0.9	20	1	US-10-002-491-60	Sequence 60, Appl
c	39	20	0.9	20	1	US-10-002-491-61	Sequence 61, Appl
c	40	20	0.9	20	1	US-10-002-491-62	Sequence 62, Appl
c	41	20	0.9	20	1	US-10-002-491-63	Sequence 63, Appl
c	42	20	0.9	20	1	US-10-002-491-64	Sequence 64, Appl
c	43	20	0.9	20	1	US-10-002-491-65	Sequence 65, Appl
c	44	20	0.9	20	1	US-10-002-491-66	Sequence 66, Appl
c	45	20	0.9	20	1	US-10-002-491-67	Sequence 67, Appl
c	46	20	0.9	20	1	US-10-002-491-68	Sequence 68, Appl
c	47	20	0.9	20	1	US-10-002-491-69	Sequence 69, Appl
c	48	20	0.9	20	1	US-10-002-491-70	Sequence 70, Appl
c	49	20	0.9	20	1	US-10-002-491-71	Sequence 71, Appl
c	50	20	0.9	20	1	US-10-002-491-72	Sequence 72, Appl
c	51	20	0.9	20	1	US-10-002-491-73	Sequence 73, Appl
c	52	20	0.9	20	1	US-10-002-491-74	Sequence 74, Appl
	53	16.4	0.7	19	1	US-09-851-501-31	Sequence 31, Appl
	54	16.4	0.7	19	1	US-10-142-722-31	Sequence 31, Appl
	55	16.4	0.7	19	1	US-10-300-683-31	Sequence 31, Appl
c	56	16.4	0.7	20	1	US-10-376-566-62	Sequence 62, Appl
	57	15.4	0.7	17	1	US-09-866-108-9953	Sequence 9953, Ap
	58	14.4	0.6	17	1	US-09-866-108-9952	Sequence 9952, Ap
	59	14.4	0.6	17	1	US-09-866-108-9954	Sequence 9954, Ap
c	60	13.8	0.6	17	1	US-09-866-108-2258	Sequence 2258, Ap
	61	13.8	0.6	17	1	US-09-866-108-9955	Sequence 9955, Ap
	62	13.8	0.6	17	1	US-09-866-108-9956	Sequence 9956, Ap
	63	13.8	0.6	17	1	US-09-864-785-2915	Sequence 2915, Ap
c	64	13.8	0.6	17	1	US-09-730-289B-1076	Sequence 1076, Ap
c	65	13.8	0.6	17	1	US-09-730-289B-1077	Sequence 1077, Ap
	66	13.8	0.6	17	1	US-09-780-533A-2291	Sequence 2291, Ap
c	67	13.8	0.6	17	1	US-09-780-533A-2491	Sequence 2491, Ap
c	68	13.8	0.6	17	1	US-09-848-754A-292	Sequence 292, App
c	69	13.8	0.6	17	1	US-09-848-754A-1414	Sequence 1414, Ap
c	70	13.8	0.6	17	1	US-09-776-474-847	Sequence 847, App
	71	13.8	0.6	17	1	US-10-156-306-2834	Sequence 2834, Ap
c	72	13.8	0.6	17	1	US-10-339-793-195	Sequence 195, App
c	73	13.8	0.6	17	1	US-10-230-006-801	Sequence 801, App
c	74	13.8	0.6	17	1	US-10-308-503-111	Sequence 111, App
c	75	13.4	0.6	15	1	US-10-297-068-950	Sequence 950, App
	76	13	0.6	15	1	US-09-504-231A-486	Sequence 486, App
	77	13	0.6	15	1	US-09-274-553D-486	Sequence 486, App
	78	13	0.6	15	1	US-10-440-850-972	Sequence 972, App
c	79	12.8	0.6	16	1	US-10-308-503-103	Sequence 103, App
	80	12.4	0.6	15	1	US-10-001-835-27	Sequence 27, Appl
	81	12.4	0.6	15	1	US-10-010-802-194	Sequence 194, App
c	82	12.4	0.6	15	1	US-10-287-919-2642	Sequence 2642, Ap
c	83	12.4	0.6	15	1	US-10-274-095-3	Sequence 3, Appli
c	84	12.4	0.6	15	1	US-10-440-850-319	Sequence 319, App
	85	12.2	0.6	20	1	US-10-002-491-44	Sequence 44, Appl
	86	12	0.5	15	1	US-09-504-231A-450	Sequence 450, App
	87	12	0.5	15	1	US-09-504-231A-1190	Sequence 1190, Ap
	88	12	0.5	15	1	US-09-274-553D-450	Sequence 450, App
	89	12	0.5	15	1	US-09-274-553D-1190	Sequence 1190, Ap
c	90	12	0.5	15	1	US-10-197-019-28	Sequence 28, Appl
c	91	12	0.5	15	1	US-10-197-019-48	Sequence 48, Appl
c	92	12	0.5	15	1	US-10-443-694-43	Sequence 43, Appl
	93	12	0.5	15	1	US-10-443-694-48	Sequence 48, Appl
	94	12	0.5	20	1	US-10-002-491-19	Sequence 19, Appl
	95	11.6	0.5	20	1	US-10-002-491-15	Sequence 15, Appl
	96	11.6	0.5	20	1	US-10-002-491-16	Sequence 16, Appl
c	97	11.6	0.5	27	1	US-10-002-491-4	Sequence 4, Appli
c	98	11.2	0.5	17	1	US-09-866-108-9953	Sequence 9953, Ap
c	99	11.2	0.5	17	1	US-09-866-108-9952	Sequence 9952, Ap
	100	11	0.5	20	1	US-10-002-491-49	Sequence 49, Appl

ALIGNMENTS

RESULT 1

```
US-10-002-491-4
; Sequence 4, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 4
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-002-491-4

  Query Match             1.2%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        956 TCAGTGTAAATCTAAGCGACTGAGAAA 982
              ||||||||||||||||||||||||||||
Db          1 TCAGTGTAAATCTAAGCGACTGAGAAA 27


RESULT 2
US-10-002-491-6
; Sequence 6, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 6
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Probe
US-10-002-491-6

  Query Match             1.2%;  Score 27;  DB 1;  Length 27;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   27;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        991 AGCAGCATGCAGATCAGACCGTGAATG 1017
              ||||||||||||||||||||||||||||
Db          1 AGCAGCATGCAGATCAGACCGTGAATG 27


RESULT 3
US-10-155-379-3
; Sequence 3, Application US/10155379
; Publication No. US20030022290A1
;   GENERAL INFORMATION:
;        APPLICANT: Evans, Ronald M.
;                   Forman, Barry M.
;                   Weinberger, Cary A.
;        TITLE OF INVENTION: METHOD FOR MODULATING PROCESSES MEDIATED
;                            BY FARNESOID ACTIVATED RECEPTORS
;        NUMBER OF SEQUENCES: 7
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
;             STREET: 444 South Flower Street, Suite 2000
;             CITY: Los Angeles
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 90071
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/155,379
;             FILING DATE: 24-May-2002
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/372,183
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Reiter, Stephen E.
;             REGISTRATION NUMBER: 31,192
;             REFERENCE/DOCKET NUMBER: P41 9844
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 619-546-4737
;             TELEFAX: 619-546-9392
;   INFORMATION FOR SEQ ID NO: 3:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 29 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: Other nucleic acid;
;             DESCRIPTION: Oligonucleotide
;        SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-10-155-379-3

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 4.5;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              |||||||||||  ||  ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 4
US-10-002-491-5/c
; Sequence 5, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 5
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-002-491-5

  Query Match             1.0%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 3;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1019 AGACAGTGAAGGTCGTGACTTGC 1041
              |||||||||||||||||||||||
Db         23 AGACAGTGAAGGTCGTGACTTGC 1


RESULT 5
US-10-002-491-12/c
; Sequence 12, Application US/10002491
```

; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-12

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 549 TATTATTCCAACCTGGGTTT 568
||||||||||||||||||||
Db 20 TATTATTCCAACCTGGGTTT 1

RESULT 6
US-10-002-491-13/c
; Sequence 13, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-13

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 717 AAAGGGGATGAGCTGTGTGT 736
||||||||||||||||||||
Db 20 AAAGGGGATGAGCTGTGTGT 1

RESULT 7
US-10-002-491-14/c
; Sequence 14, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-14

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 861 GTGATGGATATGTACATGCG 880
||||||||||||||||||||
Db 20 GTGATGGATATGTACATGCG 1

RESULT 8
US-10-002-491-15/c
; Sequence 15, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-15

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 917 AGAGATGGGAATGTTGGCTG 936
||||||||||||||||||||
Db 20 AGAGATGGGAATGTTGGCTG 1

RESULT 9
US-10-002-491-16/c
; Sequence 16, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-16

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 946 TAACTGAAATTCAGTGTAAA 965
||||||||||||||||||||
Db 20 TAACTGAAATTCAGTGTAAA 1

RESULT 10
US-10-002-491-17/c
; Sequence 17, Application US/10002491
; Publication No. US20030109467A1

; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-17

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 981 AAAAATGTGAAGCAGCATGC 1000
||||||||||||||||||||
Db 20 AAAAATGTGAAGCAGCATGC 1

RESULT 11
US-10-002-491-18/c
; Sequence 18, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-18

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1067 ATGCAGGGAGAAAACTGAAC 1086
||||||||||||||||||||
Db 20 ATGCAGGGAGAAAACTGAAC 1

RESULT 12
US-10-002-491-19/c
; Sequence 19, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-19

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1191 GCAGAAGAAAATTTTCTCAT 1210
||||||||||||||||||||
Db 20 GCAGAAGAAAATTTTCTCAT 1

RESULT 13
US-10-002-491-20/c
; Sequence 20, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-20

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1293 GAAGACCAGATTGCTTTGCT 1312
||||||||||||||||||||
Db 20 GAAGACCAGATTGCTTTGCT 1

RESULT 14
US-10-002-491-21/c
; Sequence 21, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-21

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1354 AGATTTTCAATAAGAAACTT 1373
||||||||||||||||||||
Db 20 AGATTTTCAATAAGAAACTT 1

RESULT 15
US-10-002-491-22/c
; Sequence 22, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-22

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1542 TACATAAAGGATAGAGAGGC 1561
||||||||||||||||||||
Db 20 TACATAAAGGATAGAGAGGC 1

RESULT 16
US-10-002-491-23/c
; Sequence 23, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-23

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1688 TCACCACGCTGAGATGCTGA 1707
||||||||||||||||||||
Db 20 TCACCACGCTGAGATGCTGA 1

RESULT 17
US-10-002-491-39/c
; Sequence 39, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-39

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 534 ATTTCCTCGTCATCCTATTA 553
||||||||||||||||||||
Db 20 ATTTCCTCGTCATCCTATTA 1

RESULT 18
US-10-002-491-40/c
; Sequence 40, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-40

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 553 ATTCCAACCTGGGTTTCTAC 572
||||||||||||||||||||
Db 20 ATTCCAACCTGGGTTTCTAC 1

RESULT 19
US-10-002-491-41/c
; Sequence 41, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-41

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 587 AGAGTGGTACTCTCCTGGAA 606
||||||||||||||||||||
Db 20 AGAGTGGTACTCTCCTGGAA 1

RESULT 20
US-10-002-491-42/c
; Sequence 42, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-42

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 596 CTCTCCTGGAATATATGAAC 615
||||||||||||||||||||
Db 20 CTCTCCTGGAATATATGAAC 1

RESULT 21
US-10-002-491-43/c
; Sequence 43, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-43

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 609 TATGAACTCAGGCGTATGCC 628
||||||||||||||||||||
Db 20 TATGAACTCAGGCGTATGCC 1

RESULT 22
US-10-002-491-44/c
; Sequence 44, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-44

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 645 CAGGGAGAAACTGAGGTAGC 664
||||||||||||||||||||
Db 20 CAGGGAGAAACTGAGGTAGC 1

RESULT 23
US-10-002-491-45/c
; Sequence 45, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-45

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 699 GCGTCAGCAGGGAGGATCAA 718
||||||||||||||||||||
Db 20 GCGTCAGCAGGGAGGATCAA 1

RESULT 24
US-10-002-491-46/c
; Sequence 46, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-46

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 726 GAGCTGTGTGTTGTTTGTGG 745
||||||||||||||||||||
Db 20 GAGCTGTGTGTTGTTTGTGG 1

RESULT 25
US-10-002-491-47/c
; Sequence 47, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt

; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-47

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 734 TGTTGTTTGTGGAGACAGAG 753
||||||||||||||||||||
Db 20 TGTTGTTTGTGGAGACAGAG 1

RESULT 26
US-10-002-491-48/c
; Sequence 48, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-48

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 745 GAGACAGAGCCTCTGGATAC 764
||||||||||||||||||||
Db 20 GAGACAGAGCCTCTGGATAC 1

RESULT 27
US-10-002-491-49/c
; Sequence 49, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-49

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 751 GAGCCTCTGGATACCACTAT 770
||||||||||||||||||||
Db 20 GAGCCTCTGGATACCACTAT 1

RESULT 28
US-10-002-491-50/c
; Sequence 50, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-50

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 757 CTGGATACCACTATAATGCA 776
||||||||||||||||||||
Db 20 CTGGATACCACTATAATGCA 1

RESULT 29
US-10-002-491-51/c
; Sequence 51, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-51

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 931 TGGCTGAATGCTTGTTAACT 950
||||||||||||||||||||
Db 20 TGGCTGAATGCTTGTTAACT 1

RESULT 30
US-10-002-491-52/c
; Sequence 52, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION

; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-52

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1033 GTGACTTGCGACAAGTGACC 1052
||||||||||||||||||||
Db 20 GTGACTTGCGACAAGTGACC 1

RESULT 31
US-10-002-491-53/c
; Sequence 53, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-53

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1039 TGCGACAAGTGACCTCGACA 1058
||||||||||||||||||||
Db 20 TGCGACAAGTGACCTCGACA 1

RESULT 32
US-10-002-491-54/c
; Sequence 54, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-54

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1065 TCATGCAGGGAGAAAACTGA 1084
||||||||||||||||||||
Db 20 TCATGCAGGGAGAAAACTGA 1

RESULT 33
US-10-002-491-55/c
; Sequence 55, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-55

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1134 AACAAACAGAGGATGCCTCA 1153
||||||||||||||||||||
Db 20 AACAAACAGAGGATGCCTCA 1

RESULT 34
US-10-002-491-56/c
; Sequence 56, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-56

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1143 AGGATGCCTCAGGAAATAAC 1162
||||||||||||||||||||
Db 20 AGGATGCCTCAGGAAATAAC 1

RESULT 35
US-10-002-491-57/c
; Sequence 57, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239

; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-57

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1178 AGAAGAATTCAGTGCAGAAG 1197
||||||||||||||||||||
Db 20 AGAAGAATTCAGTGCAGAAG 1

RESULT 36
US-10-002-491-58/c
; Sequence 58, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-58

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1213 TGACGGAAATGGCAACCAAT 1232
||||||||||||||||||||
Db 20 TGACGGAAATGGCAACCAAT 1

RESULT 37
US-10-002-491-59/c
; Sequence 59, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-59

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1264 AGCTACCAGGATTTCAGACT 1283
||||||||||||||||||||
Db 20 AGCTACCAGGATTTCAGACT 1

RESULT 38
US-10-002-491-60/c
; Sequence 60, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-60

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1332 GCTATGTTCCTTCGTTCAGC 1351
||||||||||||||||||||
Db 20 GCTATGTTCCTTCGTTCAGC 1

RESULT 39
US-10-002-491-61/c
; Sequence 61, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-61

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1342 TTCGTTCAGCTGAGATTTTC 1361
||||||||||||||||||||
Db 20 TTCGTTCAGCTGAGATTTTC 1

RESULT 40
US-10-002-491-62/c
; Sequence 62, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491

```
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-62

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1364 TAAGAAACTTCCGTCTGGGC 1383
             ||||||||||||||||||||
Db         20 TAAGAAACTTCCGTCTGGGC 1


RESULT 41
US-10-002-491-63/c
; Sequence 63, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-63

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1390 ACCTATTGGAAGAAAGAATT 1409
             ||||||||||||||||||||
Db         20 ACCTATTGGAAGAAAGAATT 1


RESULT 42
US-10-002-491-64/c
; Sequence 64, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-64

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1411 GAAATAGTGGTATCTCTGAT 1430
             ||||||||||||||||||||
Db         20 GAAATAGTGGTATCTCTGAT 1


RESULT 43
US-10-002-491-65/c
; Sequence 65, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-65

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1429 ATGAATATATAACACCTATG 1448
             ||||||||||||||||||||
Db         20 ATGAATATATAACACCTATG 1


RESULT 44
US-10-002-491-66/c
; Sequence 66, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-66

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1493 GGAGTATGCTCTGCTTACAG 1512
             ||||||||||||||||||||
Db         20 GGAGTATGCTCTGCTTACAG 1


RESULT 45
US-10-002-491-67/c
; Sequence 67, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
```

```
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-67

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1525 TGTCTCCAGATAGACAATAC 1544
              ||||||||||||||||||||
Db         20 TGTCTCCAGATAGACAATAC 1


RESULT 46
US-10-002-491-68/c
; Sequence 68, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-68

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1567 AGAAGCTTCAGGAGCCACTT 1586
              ||||||||||||||||||||
Db         20 AGAAGCTTCAGGAGCCACTT 1


RESULT 47
US-10-002-491-69/c
; Sequence 69, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-69

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1608 TGTAAGATTCACCAGCCTGA 1627
              ||||||||||||||||||||
Db         20 TGTAAGATTCACCAGCCTGA 1


RESULT 48
US-10-002-491-70/c
; Sequence 70, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-70

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1623 CCTGAAAATCCTCAACACTT 1642
              ||||||||||||||||||||
Db         20 CCTGAAAATCCTCAACACTT 1


RESULT 49
US-10-002-491-71/c
; Sequence 71, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 71
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-71

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 6.4;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1630 ATCCTCAACACTTTGCCTGT 1649
              ||||||||||||||||||||
Db         20 ATCCTCAACACTTTGCCTGT 1


RESULT 50
US-10-002-491-72/c
; Sequence 72, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
```

; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-72

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1654 TGGGTCGCCTGACTGAATTA 1673
||||||||||||||||||||
Db 20 TGGGTCGCCTGACTGAATTA 1

RESULT 51
US-10-002-491-73/c
; Sequence 73, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-73

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1672 TACGGACATTCAATCATCAC 1691
||||||||||||||||||||
Db 20 TACGGACATTCAATCATCAC 1

RESULT 52
US-10-002-491-74/c
; Sequence 74, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-74

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6.4;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1692 CACGCTGAGATGCTGATGTC 1711
||||||||||||||||||||
Db 20 CACGCTGAGATGCTGATGTC 1

RESULT 53
US-09-851-501-31
; Sequence 31, Application US/09851501
; Patent No. US20020119442A1
; GENERAL INFORMATION:
; APPLICANT: DUNLOP, Charles, L.M.
; APPLICANT: WEISEL, James, M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY GENETIC TRAITS
; FILE REFERENCE: CHARDUN.001CP1
; CURRENT APPLICATION NUMBER: US/09/851,501
; CURRENT FILING DATE: 2001-05-08
; PRIOR APPLICATION NUMBER: PCT/US00/30493
; PRIOR FILING DATE: 2000-11-03
; PRIOR APPLICATION NUMBER: 60/165,301
; PRIOR FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-09-851-501-31

Query Match 0.7%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 784 GTGAGGGGTGTAAAGGTT 801
||||||||||||||| ||||
Db 2 GTGAGGGGTGTAATGGTT 19

RESULT 54
US-10-142-722-31
; Sequence 31, Application US/10142722
; Publication No. US20030039996A1
; GENERAL INFORMATION:
; APPLICANT: DUNLOP, Charles, L.M.
; APPLICANT: WEISEL, James, M.
; TITLE OF INVENTION: APPROACHES TO IDENTIFY GENETIC TRAITS
; FILE REFERENCE: CHARDUN.001C1
; CURRENT APPLICATION NUMBER: US/10/142,722
; CURRENT FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: PCT/US00/30493
; PRIOR FILING DATE: 2000-11-03
; PRIOR APPLICATION NUMBER: 60/165,301
; PRIOR FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-142-722-31

Query Match 0.7%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 784 GTGAGGGGTGTAAAGGTT 801
||||||||||||||| ||||
Db 2 GTGAGGGGTGTAATGGTT 19

RESULT 55
US-10-300-683-31
; Sequence 31, Application US/10300683

```
; Publication No. US20030235834A1
; GENERAL INFORMATION:
;  APPLICANT: Dunlop, Charles L.M.
;  APPLICANT:  Weisel, James M.
;  TITLE OF INVENTION: APPROACHES TO IDENTIFY CYSTIC FIBROSIS
;  FILE REFERENCE: CHARDUN.010A
;  CURRENT APPLICATION NUMBER: US/10/300,683
;  CURRENT FILING DATE:  2002-11-19
;  PRIOR APPLICATION NUMBER: 60/333,531
;  PRIOR FILING DATE: 2001-11-19
;  NUMBER OF SEQ ID NOS: 554
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Diagnostic Oligonucleotide
US-10-300-683-31

  Query Match             0.7%;  Score 16.4;  DB 1;  Length 19;
  Best Local Similarity   94.4%;  Pred. No. 21;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        784 GTGAGGGGTGTAAAGGTT 801
              ||||||||||||||| ||||
Db          2 GTGAGGGGTGTAATGGTT 19


RESULT 56
US-10-376-566-62/c
; Sequence 62, Application US/10376566
; Publication No. US20030158144A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  APPLICANT:  Mark P. Roach
;  APPLICANT:  Erich Koller
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ESTROGEN RECEPTOR BETA EXPRESSION
;  FILE REFERENCE: RTS-0347
;  CURRENT APPLICATION NUMBER: US/10/376,566
;  CURRENT FILING DATE:  2003-02-27
;  PRIOR APPLICATION NUMBER: US/10/005,058
;  PRIOR FILING DATE: 2001-12-07
;  NUMBER OF SEQ ID NOS: 96
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-376-566-62

  Query Match             0.7%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 24;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1171 TTTTAAAAGAAGAATTCA 1188
              |||||||||||||| |||||
Db         19 TTTTAAAAGAAGCATTCA 2


RESULT 57
US-09-866-108-9953
; Sequence 9953, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9953
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9953

  Query Match             0.7%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 23;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1072 GGGAGAAAACTGAACTC 1088
              ||||||||||||| |||
Db          1 GGGAGAAAACTGAGCTC 17


RESULT 58
US-09-866-108-9952
; Sequence 9952, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9952
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9952

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 32;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1072 GGGAGAAAACTGAACT 1087
              ||||||||||||| ||
Db          2 GGGAGAAAACTGAGCT 17


RESULT 59
US-09-866-108-9954
; Sequence 9954, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9954
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9954

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 32;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1073 GGAGAAAACTGAACTC 1088
              ||||||||||||| |||
Db          1 GGAGAAAACTGAGCTC 16


RESULT 60
US-09-866-108-2258/c
; Sequence 2258, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2258
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2258

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1017 GAAGACAGTGAAGGTCG 1033
|| |||||||||||| |
Db 17 GAGGACAGTGAAGGTGG 1

RESULT 61
US-09-866-108-9955
; Sequence 9955, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9955
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9955

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1074 GAGAAAACTGAACTCAC 1090
|||||||||| ||| |
Db 1 GAGAAAACTGAGCTCTC 17

RESULT 62
US-09-866-108-9956
; Sequence 9956, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9956
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9956

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1075 AGAAAACTGAACTCACC 1091
|||||||||| ||| ||
Db 1 AGAAAACTGAGCTCTCC 17

```
RESULT 63
US-09-864-785-2915
; Sequence 2915, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2915
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-2915

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 39;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        803 CTTCAGGAGAAGCATTA 819
              |:: || |||||||::|
Db          1 CUUAAGCAGAAGCAUUA 17


RESULT 64
US-09-730-289B-1076/c
; Sequence 1076, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1076
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-1076

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1516 TTGTTATCCTGTCTCCA 1532
              ||||| |||||||| ||
Db         17 TTGTTTTCCTGTCTGCA 1


RESULT 65
US-09-730-289B-1077/c
; Sequence 1077, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1077
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-1077

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1515 ATTGTTATCCTGTCTCC 1531
              ||||| |||||||| |
Db         17 ATTGTTTTCCTGTCTGC 1


RESULT 66
US-09-780-533A-2291
; Sequence 2291, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2291
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2291

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 39;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        606 ATATATGAACTCAGGCG 622
              |:| | ||||:||||||
Db          1 AUAAAGGAACUCAGGCG 17


RESULT 67
US-09-780-533A-2491/c
; Sequence 2491, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2491
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2491

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        567 TTCTACCCCCAGCAGCC 583
              || |||| |||||||||
Db         17 TTTTACCTCCAGCAGCC 1


RESULT 68
US-09-848-754A-292/c
; Sequence 292, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 292
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-292

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
              ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 69
US-09-848-754A-1414/c
; Sequence 1414, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1414

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        719 AGGGGATGAGCTGTGTG 735
              |||| |||||||| |||
Db         17 AGGGCATGAGCTGCGTG 1


RESULT 70
US-09-776-474-847/c
; Sequence 847, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Booher, Robert
;  APPLICANT:  Holman, Patricia
;  APPLICANT:  Fattaey, Ali
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
;  TITLE OF INVENTION:  Enzyme
;  FILE REFERENCE: MBHB00-955-A (400/008)
;  CURRENT APPLICATION NUMBER: US/09/776,474
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,983
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 2992
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 847
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-776-474-847

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 39;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        800 TTTCTTCAGGAGAAGCA 816
              |||||||| |||||||
Db         17 TTTCTTCACTAGAAGCA 1


RESULT 71
US-10-156-306-2834
; Sequence 2834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2834
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-2834

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 39;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1273 GATTTCAGACTTTGGAC 1289
              ||::  ||||:::||||
Db          1 GAUUGGAGACUUUGGAC 17


RESULT 72
US-10-339-793-195/c
; Sequence 195, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Shang, Jin
;  APPLICANT:  Bowen, Benjamin
```

; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 195
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-793-195

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1082 TGAACTCACCCCAGATC 1098
|| |||||| |||||||
Db 17 TGCACTCACACCAGATC 1

RESULT 73
US-10-230-006-801/c
; Sequence 801, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-801

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1469 TGGGGAACTGAAAATGA 1485
||| || ||||||||||
Db 17 TGGAGATCTGAAAATGA 1

RESULT 74
US-10-308-503-111/c
; Sequence 111, Application US/10308503
; Publication No. US20030191080A1
; GENERAL INFORMATION:
; APPLICANT: PHILLIPS, M. IAN
; APPLICANT: ZHANG, YUAN
; TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
; TITLE OF INVENTION: METHODS OF USE
; FILE REFERENCE: 4300.013900
; CURRENT APPLICATION NUMBER: US/10/308,503
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/614,034
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 09/152,717
; PRIOR FILING DATE: 1998-09-14
; PRIOR APPLICATION NUMBER: PCT/US99/21007
; PRIOR FILING DATE: 1999-09-14
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 111
; LENGTH: 17
; TYPE: DNA
; ORGANISM: UNKNOWN
; FEATURE:
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-10-308-503-111

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 685 AGCCCCGCATGGGCGCG 701
||| | ||||||||||
Db 17 AGCTCGGCATGGGCGCG 1

RESULT 75
US-10-297-068-950/c
; Sequence 950, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140P1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 950
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-950

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1640 CTTTGCCTGTCTCCT 1654
|||| ||||||||||
Db 15 CTTTCCCTGTCTCCT 1

RESULT 76
US-09-504-231A-486
; Sequence 486, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: rpi 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18

```
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3242
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 486
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-504-231A-486

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 39;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 77
US-09-274-553D-486
; Sequence 486, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/274,553D
;  CURRENT FILING DATE:  1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3148
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 486
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-274-553D-486

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 39;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 78
US-10-440-850-972
; Sequence 972, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 972
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-440-850-972

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 39;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 CTGGGTTTCTACC 573
              |:|||:::|:|||
Db          1 CUGGGUUUCUACC 13


RESULT 79
US-10-308-503-103/c
; Sequence 103, Application US/10308503
; Publication No. US20030191080A1
; GENERAL INFORMATION:
;  APPLICANT: PHILLIPS, M. IAN
;  APPLICANT:  ZHANG, YUAN
;  TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mR
;  TITLE OF INVENTION:  METHODS OF USE
;  FILE REFERENCE: 4300.013900
;  CURRENT APPLICATION NUMBER: US/10/308,503
;  CURRENT FILING DATE:  2003-12-03
;  PRIOR APPLICATION NUMBER: US/09/614,034
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 09/152,717
;  PRIOR FILING DATE: 1998-09-14
;  PRIOR APPLICATION NUMBER: PCT/US99/21007
;  PRIOR FILING DATE: 1999-09-14
;  NUMBER OF SEQ ID NOS: 204
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 103
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: UNKNOWN
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-10-308-503-103

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 48;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGC 700
              ||| | ||||||||||
Db         16 AGCTCGGCATGGGCGC 1


RESULT 80
US-10-001-835-27
; Sequence 27, Application US/10001835
; Publication No. US20020160387A1
; GENERAL INFORMATION:
;  APPLICANT: Salceda, Susana
;  APPLICANT:  Macina, Roberto
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Cafferkey, Robert
```

; APPLICANT: Sun, Yongming
; APPLICANT: Liu, Chenghua
; TITLE OF INVENTION: Compositions and Methods Relating to Ovary Specific Genes and Prc
; FILE REFERENCE: DEX-0277
; CURRENT APPLICATION NUMBER: US/10/001,835
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 60/249,997
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 228
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-001-835-27

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 47;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAAA 1169
|||||| |||||||
Db 2 AAATAATAAATAAA 15

RESULT 81
US-10-010-802-194
; Sequence 194, Application US/10010802
; Publication No. US20030078220A1
; GENERAL INFORMATION:
; APPLICANT: Genaissance Pharmaceuticals
; APPLICANT: Chew, Anne
; APPLICANT: Denton, R. Rex
; APPLICANT: Duda, Amy
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stephens, J. Claiborne
; APPLICANT: Windemuth, Andreas
; TITLE OF INVENTION: Drug Target Isogenes: Polymorphisms in the Interleukin
; TITLE OF INVENTION: 4 Receptor Alpha Gene
; FILE REFERENCE: MWH-0002US2 IL4R alpha
; CURRENT APPLICATION NUMBER: US/10/010,802
; CURRENT FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: PCT/US00/19094
; PRIOR FILING DATE: 2000-07-13
; NUMBER OF SEQ ID NOS: 413
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 194
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-010-802-194

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 47;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 TGTGGAGACAGAGC 754
|||||||||||| ||
Db 2 TGTGGAGACAGGGC 15

RESULT 82
US-10-287-919-2642/c
; Sequence 2642, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 2642
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (1606834)...(1606848)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 3369
US-10-287-919-2642

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 47;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1161 ACAAATAAAATTTT 1174
| ||||||||||||
Db 14 AGAAATAAAATTTT 1

RESULT 83
US-10-274-095-3/c
; Sequence 3, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; TITLE OF INVENTION: Levels
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: fragment
US-10-274-095-3

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 47;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 621 CGTATGCCAGCTGA 634
|||||||| |||||
Db 15 CGTATGCCTGCTGA 2

RESULT 84
US-10-440-850-319/c
; Sequence 319, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11

```
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 319
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-440-850-319

  Query Match             0.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 47;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        545 ATCCTATTATTCCA 558
              ||||||||| ||||
Db         15 ATCCTATTAGTCCA 2


RESULT 85
US-10-002-491-44
; Sequence 44, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonuclectide
US-10-002-491-44

  Query Match             0.6%;  Score 12.2;  DB 1;  Length 20;
  Best Local Similarity   82.4%;  Pred. No. 88;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         23 ACCTCATTGTCTCCCCG 39
              |||||| | |||||| |
Db          4 ACCTCAGTTTCTCCCTG 20


RESULT 86
US-09-504-231A-450
; Sequence 450, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/504,231A
;  CURRENT FILING DATE:  2000-02-15
;  PRIOR APPLICATION NUMBER: 09/274,553
;  PRIOR FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3242
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 450
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-504-231A-450

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          1 GUACUCUCCUGG 12


RESULT 87
US-09-504-231A-1190
; Sequence 1190, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/504,231A
;  CURRENT FILING DATE:  2000-02-15
;  PRIOR APPLICATION NUMBER: 09/274,553
;  PRIOR FILING DATE: 1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3242
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1190
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-504-231A-1190

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          3 GUACUCUCCUGG 14


RESULT 88
US-09-274-553D-450
; Sequence 450, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/274,553D
;  CURRENT FILING DATE:  1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
```

```
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3148
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 450
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-274-553D-450

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          1 GUACUCUCCUGG 12


RESULT 89
US-09-274-553D-1190
; Sequence 1190, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
;  APPLICANT: Blatt, Lawrence
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Roberts, Beth
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Macejak, Dennis
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
;  TITLE OF INVENTION:  HEPATITIS C VIRUS INFECTION
;  FILE REFERENCE: rpi 247/282
;  CURRENT APPLICATION NUMBER: US/09/274,553D
;  CURRENT FILING DATE:  1999-03-23
;  PRIOR APPLICATION NUMBER: 09/257,608
;  PRIOR FILING DATE: 1999-02-24
;  PRIOR APPLICATION NUMBER: 60/100,842
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/083,217
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 3148
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1190
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid Target
US-09-274-553D-1190

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   66.7%;  Pred. No. 54;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        593 GTACTCTCCTGG 604
              |:||:|:||:||
Db          3 GUACUCUCCUGG 14


RESULT 90
US-10-197-019-28/c
; Sequence 28, Application US/10197019
; Publication No. US20030207284A1
; GENERAL INFORMATION:
;  APPLICANT: Chew, Anne
;  APPLICANT:  Denton, R. Rex
;  APPLICANT:  Gilson, Christopher Raleigh
;  APPLICANT:  Nandabalan, Krishnan
;  APPLICANT:  Parks, Katie E.
;  TITLE OF INVENTION: HAPLOTYPES OF THE UCP2 GENE
;  FILE REFERENCE: MWH-0042US
;  CURRENT APPLICATION NUMBER: US/10/197,019
;  CURRENT FILING DATE:  2002-07-16
;  PRIOR APPLICATION NUMBER: PCT/US01/02485
;  PRIOR FILING DATE: 2001-01-25
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-197-019-28

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 54;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        745 GAGACAGAGCCTCT 758
              |:|||||| ||||
Db         15 GRGACAGAGACTCT 2


RESULT 91
US-10-197-019-48/c
; Sequence 48, Application US/10197019
; Publication No. US20030207284A1
; GENERAL INFORMATION:
;  APPLICANT: Chew, Anne
;  APPLICANT:  Denton, R. Rex
;  APPLICANT:  Gilson, Christopher Raleigh
;  APPLICANT:  Nandabalan, Krishnan
;  APPLICANT:  Parks, Katie E.
;  TITLE OF INVENTION: HAPLOTYPES OF THE UCP2 GENE
;  FILE REFERENCE: MWH-0042US
;  CURRENT APPLICATION NUMBER: US/10/197,019
;  CURRENT FILING DATE:  2002-07-16
;  PRIOR APPLICATION NUMBER: PCT/US01/02485
;  PRIOR FILING DATE: 2001-01-25
;  NUMBER OF SEQ ID NOS: 116
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-197-019-48

  Query Match             0.5%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   85.7%;  Pred. No. 54;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        974 ACTGAGAAAAAATG 987
              :|||||||||||  |
Db         14 MCTGAGAAAAAAGG 1


RESULT 92
US-10-443-694-43/c
; Sequence 43, Application US/10443694
; Publication No. US20040001846A1
; GENERAL INFORMATION:
;  APPLICANT: Israeli, Ron S
;  APPLICANT:  Heston, Warren D.W.
;  APPLICANT:  Fair, William R
;  APPLICANT:  Overfelli, Ouathek
;  APPLICANT:  Pinto, John
;  TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
;  FILE REFERENCE: 1769/41426-GB
;  CURRENT APPLICATION NUMBER: US/10/443,694
;  CURRENT FILING DATE:  2003-05-21
;  PRIOR APPLICATION NUMBER: US 08/705,477
;  PRIOR FILING DATE: 1996-08-29
```

; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-443-694-43

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1583 ACTTCTTGATGT 1594
||||||||||||
Db 12 ACTTCTTGATGT 1

RESULT 93
US-10-443-694-48
; Sequence 48, Application US/10443694
; Publication No. US20040001846A1
; GENERAL INFORMATION:
; APPLICANT: Israeli, Ron S
; APPLICANT: Heston, Warren D.W.
; APPLICANT: Fair, William R
; APPLICANT: Overfelli, Ouathek
; APPLICANT: Pinto, John
; TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
; FILE REFERENCE: 1769/41426-GB
; CURRENT APPLICATION NUMBER: US/10/443,694
; CURRENT FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: US 08/705,477
; PRIOR FILING DATE: 1996-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-443-694-48

Query Match 0.5%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1600 AAAAGTTGTGTA 1611
||||||||||||
Db 2 AAAAGTTGTGTA 13

RESULT 94
US-10-002-491-19
; Sequence 19, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-19

Query Match 0.5%; Score 12; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1196 AGAAAATTTTCT 1207
||||||||||||
Db 4 AGAAAATTTTCT 15

RESULT 95
US-10-002-491-15
; Sequence 15, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-15

Query Match 0.5%; Score 11.6; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 374 CATTGAACATTCCCATTT 391
|| |||||||||| |
Db 1 CAGCCAACATTCCCATCT 18

RESULT 96
US-10-002-491-16
; Sequence 16, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239
; CURRENT APPLICATION NUMBER: US/10/002,491
; CURRENT FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-16

Query Match 0.5%; Score 11.6; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 943 TGTTAACTGAAATTCAGT 960
| | |||||| ||||||
Db 1 TTTACACTGAATTTCAGT 18

RESULT 97
US-10-002-491-4/c
; Sequence 4, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
; FILE REFERENCE: RTS-0239

```
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 4
;   LENGTH: 27
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-002-491-4

  Query Match             0.5%;  Score 11.6;  DB 1;  Length 27;
  Best Local Similarity   65.4%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    9;  Indels    0;  Gaps    0;

Qy        240 TCTCTTAGTTTCCTGGATTTCTTCTG 265
              | ||| |||  | | |||||   |||
Db         27 TTTCTCAGTCGCTTAGATTTACACTG 2


RESULT 98
US-09-866-108-9953/c
; Sequence 9953, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9953
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9953

  Query Match             0.5%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 89;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTCTC 1811
              |||||  ||||||| |
Db         16 AGCTCAGTTTTCTCCC 1


RESULT 99
US-09-866-108-9952/c
; Sequence 9952, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9952
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-9952

  Query Match             0.5%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 89;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1796 AGCTCCTTTTTCTCTC 1811
              |||||  ||||||| |
Db         17 AGCTCAGTTTTCTCCC 2
```

```
RESULT 100
US-10-002-491-49
; Sequence 49, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 49
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-49

  Query Match             0.5%;  Score 11;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1414 ATAGTGGTATC 1424
             ||||||||||| |
Db          1 ATAGTGGTATC 11


Search completed: April  8, 2004, 15:26:55
Job time : 3 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 8, 2004, 15:22:23 ; Search time 5 Seconds
(without alignments)
2.991 Million cell updates/sec

Title: us-10-002-491-3
Perfect score: 2218
Sequence: 1 acgagactctctcctcctcc.....aaaaaaaaaaaaaaaaaaa 2218

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 203 seqs, 3371 residues

Total number of hits satisfying chosen parameters: 406

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 210 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	27	1.2	27	1	AAL61322	Human farnesoid X
	2	27	1.2	27	1	AAL61320	Human farnesoid X
	3	24.8	1.1	28	1	ACF58014	Mouse npFXRa RNA e
	4	23.6	1.1	29	1	AAT32963	Degenerate probe b
c	5	23	1.0	23	1	AAL61321	Human farnesoid X
c	6	20	0.9	20	1	AAL61331	Human FXR antisens
c	7	20	0.9	20	1	AAL61336	Human FXR antisens
c	8	20	0.9	20	1	AAL61338	Human FXR antisens
c	9	20	0.9	20	1	AAL61357	Human FXR antisens
c	10	20	0.9	20	1	AAL61387	Human FXR antisens
c	11	20	0.9	20	1	AAL61389	Human FXR antisens
c	12	20	0.9	20	1	AAL61361	Human FXR antisens
c	13	20	0.9	20	1	AAL61384	Human FXR antisens
c	14	20	0.9	20	1	AAL61337	Human FXR antisens
c	15	20	0.9	20	1	AAL61372	Human FXR antisens
c	16	20	0.9	20	1	AAL61378	Human FXR antisens
c	17	20	0.9	20	1	AAL61376	Human FXR antisens
c	18	20	0.9	20	1	AAL61382	Human FXR antisens
c	19	20	0.9	20	1	AAL61388	Human FXR antisens
c	20	20	0.9	20	1	AAL61365	Human FXR antisens
c	21	20	0.9	20	1	AAL61328	Human FXR antisens
c	22	20	0.9	20	1	AAL61335	Human FXR antisens
c	23	20	0.9	20	1	AAL61358	Human FXR antisens
c	24	20	0.9	20	1	AAL61367	Human FXR antisens
c	25	20	0.9	20	1	AAL61371	Human FXR antisens
c	26	20	0.9	20	1	AAL61379	Human FXR antisens
c	27	20	0.9	20	1	AAL61359	Human FXR antisens
c	28	20	0.9	20	1	AAL61370	Human FXR antisens
c	29	20	0.9	20	1	AAL61375	Human FXR antisens
c	30	20	0.9	20	1	AAL61385	Human FXR antisens
c	31	20	0.9	20	1	AAL61386	Human FXR antisens
c	32	20	0.9	20	1	AAL61332	Human FXR antisens
c	33	20	0.9	20	1	AAL61355	Human FXR antisens
c	34	20	0.9	20	1	AAL61364	Human FXR antisens
c	35	20	0.9	20	1	AAL61360	Human FXR antisens
c	36	20	0.9	20	1	AAL61366	Human FXR antisens
c	37	20	0.9	20	1	AAL61374	Human FXR antisens
c	38	20	0.9	20	1	AAL61333	Human FXR antisens
c	39	20	0.9	20	1	AAL61334	Human FXR antisens
c	40	20	0.9	20	1	AAL61362	Human FXR antisens
c	41	20	0.9	20	1	AAL61363	Human FXR antisens
c	42	20	0.9	20	1	AAL61383	Human FXR antisens
c	43	20	0.9	20	1	AAL61390	Human FXR antisens
c	44	20	0.9	20	1	AAL61329	Human FXR antisens
c	45	20	0.9	20	1	AAL61330	Human FXR antisens
c	46	20	0.9	20	1	AAL61356	Human FXR antisens
c	47	20	0.9	20	1	AAL61377	Human FXR antisens
c	48	20	0.9	20	1	AAL61380	Human FXR antisens
c	49	20	0.9	20	1	AAL61339	Human FXR antisens
c	50	20	0.9	20	1	AAL61368	Human FXR antisens
c	51	20	0.9	20	1	AAL61369	Human FXR antisens
c	52	20	0.9	20	1	AAL61373	Human FXR antisens
c	53	20	0.9	20	1	AAL61381	Human FXR antisens
c	54	19.4	0.9	24	1	ABL40671	Human Fe-S protein
	55	19	0.9	23	1	AAF55665	Probe for human pe
	56	16.8	0.8	20	1	ABZ98123	Human MCP4 oligonu
	57	16.8	0.8	20	1	ABZ98075	Human MCP4 oligonu
c	58	16.8	0.8	21	1	ACC70407	PCR primer used to
	59	16.4	0.7	19	1	AAF89442	Human genetic mark
	60	16.4	0.7	19	1	AAD50206	Human glucocerebro
c	61	16.4	0.7	20	1	ABT44411	Chimeric antisense
	62	15.4	0.7	17	1	ABN09961	Human GDMLP-1 17-m
c	63	15.4	0.7	18	1	ADC24242	Human NOV1b revers
	64	15	0.7	18	1	AAV66781	CAPS marker PCR pr
	65	14.6	0.7	24	1	ABL40671	Human Fe-S protein
	66	14.4	0.6	16	1	AAS56770	BR2 protein ribozy
	67	14.4	0.6	16	1	AAS56813	Target validation
	68	14.4	0.6	16	1	ADD20023	Oreochromis niloti
	69	14.4	0.6	17	1	AAQ38874	DNA primer for con
c	70	14.4	0.6	17	1	AAT81501	Human c-myb hammer
c	71	14.4	0.6	17	1	AAT81502	Human c-myb hammer
	72	14.4	0.6	17	1	AAX71613	Human KDR VEGF rec
	73	14.4	0.6	17	1	AAA21474	Integrin alpha 6 s
	74	14.4	0.6	17	1	AAA20929	Integrin alpha 6 s
	75	14.4	0.6	17	1	AAA20930	Integrin alpha 6 s
	76	14.4	0.6	17	1	ABN09962	Human GDMLP-1 17-m
	77	14.4	0.6	17	1	ABN09960	Human GDMLP-1 17-m
	78	14.4	0.6	17	1	ABQ63861	Human KTOM1a porti
	79	14.4	0.6	17	1	ABQ63862	Human KTOM1a porti
c	80	14.4	0.6	17	1	ACC52120	Human tumour suppr
c	81	14.4	0.6	17	1	ABT36349	Tumour suppression
c	82	14.4	0.6	17	1	ABT39375	Tumour suppression
	83	14.4	0.6	17	1	ACC64384	Murine oligonucleo
c	84	14.4	0.6	17	1	ADB44143	Tumour suppression
c	85	14.4	0.6	18	1	ABX77487	Human lrba gene 3'
	86	14	0.6	17	1	ABT37667	Tumour suppression
	87	13.8	0.6	17	1	AAT81545	Human c-myb hammer
	88	13.8	0.6	17	1	AAT81546	Human c-myb hammer
c	89	13.8	0.6	17	1	AAT81503	Human c-myb hammer
c	90	13.8	0.6	17	1	AAX69956	Human flt1 VEGF re
	91	13.8	0.6	17	1	AAX69815	Human flt1 VEGF re
	92	13.8	0.6	17	1	AAX69488	Human flt1 VEGF re
c	93	13.8	0.6	17	1	AAV97512	Human EGF-R target
c	94	13.8	0.6	17	1	AAA20415	Integrin alpha 6 s
c	95	13.8	0.6	17	1	AAA21302	Integrin alpha 6 s
c	96	13.8	0.6	17	1	AAV91254	Human C-raf target
c	97	13.8	0.6	17	1	AAA80154	Hepatitis B virus
	98	13.8	0.6	17	1	AAF05300	Hammerhead ribozym
c	99	13.8	0.6	17	1	AAH95461	Human Chk1 ribozym
	100	13.8	0.6	17	1	ABK02291	Human NOGO DNAzyme
c	101	13.8	0.6	17	1	ABK02491	Human NOGO Amberzy
c	102	13.8	0.6	17	1	ABK40655	Human beta1-adreno
	103	13.8	0.6	17	1	ABN09964	Human GDMLP-1 17-m
	104	13.8	0.6	17	1	ABN09963	Human GDMLP-1 17-m
c	105	13.8	0.6	17	1	ABN02266	Human GDMLP-1 17-m
	106	13.8	0.6	17	1	ABK18302	Human ERG hammerhe

	107	13.8	0.6	17	1	ABK17696 Human ERG hammerhe
c	108	13.8	0.6	17	1	ABK17827 Human ERG hammerhe
c	109	13.8	0.6	17	1	ABT38914 Tumour suppression
	110	13.8	0.6	17	1	ABT39538 Tumour suppression
	111	13.8	0.6	17	1	ABT38532 Tumour suppression
	112	13.8	0.6	17	1	ABT34842 Tumour suppression
	113	13.8	0.6	17	1	ACA09096 NFKB sub-unit modu
	114	13.8	0.6	17	1	ABZ20919 MT4-MMP catalytic
c	115	13.8	0.6	17	1	ACC65419 Murine oligonucleo
	116	13.8	0.6	17	1	ADB40369 Tumour suppression
	117	13.8	0.6	17	1	ADB40537 Tumour suppression
c	118	13.8	0.6	17	1	ADE30808 Cholesterol homeos
c	119	13.4	0.6	15	1	AAT37715 Apo(a) mRNA (nt. p
c	120	13.4	0.6	15	1	AAV48847 ErbB-2 gene antise
c	121	13.4	0.6	15	1	AAF47996 IGFBP3 oligonucleo
c	122	13.4	0.6	15	1	ABL31461 Human HLA genotypi
c	123	13.4	0.6	16	1	AAI64950 Human Cream1 prote
	124	13	0.6	13	1	AAV10983 Human ribozyme tar
c	125	13	0.6	13	1	ABC82063 Oligonucleotide SE
	126	13	0.6	13	1	ABF77671 Oligonucleotide SE
c	127	13	0.6	13	1	ABF42907 Oligonucleotide SE
	128	13	0.6	13	1	ABF60108 Oligonucleotide SE
	129	13	0.6	13	1	ABF90851 Oligonucleotide SE
c	130	13	0.6	13	1	ABC01400 Oligonucleotide SE
c	131	13	0.6	13	1	ABH40300 Oligonucleotide SE
	132	13	0.6	13	1	ABC18409 Oligonucleotide SE
	133	13	0.6	13	1	ABC82062 Oligonucleotide SE
	134	13	0.6	13	1	ABC08004 Oligonucleotide SE
c	135	13	0.6	13	1	ABC37607 Oligonucleotide SE
	136	13	0.6	13	1	ABC64450 Oligonucleotide SE
	137	13	0.6	13	1	ABC39964 Oligonucleotide SE
c	138	13	0.6	13	1	ABC79783 Oligonucleotide SE
c	139	13	0.6	13	1	ABC39965 Oligonucleotide SE
c	140	13	0.6	13	1	ABF20975 Oligonucleotide SE
c	141	13	0.6	13	1	ABF53585 Oligonucleotide SE
	142	13	0.6	13	1	ABF94684 Oligonucleotide SE
c	143	13	0.6	13	1	ABF77670 Oligonucleotide SE
c	144	13	0.6	13	1	ABF60109 Oligonucleotide SE
c	145	13	0.6	13	1	ABC18408 Oligonucleotide SE
	146	13	0.6	13	1	ABC79782 Oligonucleotide SE
c	147	13	0.6	13	1	ABC07509 Oligonucleotide SE
	148	13	0.6	13	1	ABF20974 Oligonucleotide SE
	149	13	0.6	13	1	ABF42906 Oligonucleotide SE
c	150	13	0.6	13	1	ABF88708 Oligonucleotide SE
	151	13	0.6	13	1	ABF86380 Oligonucleotide SE
	152	13	0.6	13	1	ABC01401 Oligonucleotide SE
c	153	13	0.6	13	1	ABC64451 Oligonucleotide SE
c	154	13	0.6	13	1	ABF86381 Oligonucleotide SE
	155	13	0.6	13	1	ABC07508 Oligonucleotide SE
c	156	13	0.6	13	1	ABF51767 Oligonucleotide SE
c	157	13	0.6	13	1	ABF90850 Oligonucleotide SE
c	158	13	0.6	13	1	ABC08005 Oligonucleotide SE
	159	13	0.6	13	1	ABF51766 Oligonucleotide SE
	160	13	0.6	13	1	ABH40301 Oligonucleotide SE
	161	13	0.6	13	1	ABC37606 Oligonucleotide SE
	162	13	0.6	13	1	ABF88709 Oligonucleotide SE
c	163	13	0.6	13	1	ABF94685 Oligonucleotide SE
	164	13	0.6	13	1	ABF53584 Oligonucleotide SE
	165	13	0.6	14	1	AAQ92723 c-erbB-2 antisense
c	166	13	0.6	14	1	AAV48848 ErbB-2 gene antise
c	167	13	0.6	14	1	AAV48849 ErbB-2 gene antise
	168	13	0.6	15	1	AAX66868 Mouse CD40 hammerh
	169	13	0.6	15	1	AAZ62853 Substrate for HH r
	170	13	0.6	15	1	ABN80545 Human P450(cytochr
c	171	13	0.6	15	1	ABL45821 Human EDG6 gene al
	172	13	0.6	15	1	ABX00704 Hepatitis C virus
	173	12.8	0.6	16	1	AAT90604 Hepatitis C virus
	174	12.8	0.6	16	1	AAZ97721 HIV-1 protease gen
	175	12.8	0.6	16	1	AAA13421 Hepatitis C virus
c	176	12.8	0.6	16	1	ABK40647 Human beta1-adreno
	177	12.8	0.6	16	1	ABX74340 Hepatitis C recogn
c	178	12.8	0.6	28	1	ACF58014 Mouse npFXRa RNA e
	179	12.6	0.6	13	1	ABC04480 Oligonucleotide SE
	180	12.6	0.6	13	1	ABC39927 Oligonucleotide SE
	181	12.6	0.6	13	1	ABC16033 Oligonucleotide SE
c	182	12.6	0.6	13	1	ABF51058 Oligonucleotide SE
c	183	12.6	0.6	13	1	ABH59876 Oligonucleotide SE
c	184	12.6	0.6	13	1	ABC39926 Oligonucleotide SE
	185	12.6	0.6	13	1	ABH31369 Oligonucleotide SE
c	186	12.6	0.6	13	1	ABF89184 Oligonucleotide SE
	187	12.6	0.6	13	1	ABF51059 Oligonucleotide SE
	188	12.6	0.6	13	1	ABH28233 Oligonucleotide SE
	189	12.6	0.6	13	1	ABF62626 Oligonucleotide SE
	190	12.6	0.6	13	1	ABH57534 Oligonucleotide SE
c	191	12.6	0.6	13	1	ABH57535 Oligonucleotide SE
	192	12.6	0.6	13	1	ABH59877 Oligonucleotide SE
c	193	12.6	0.6	13	1	ABF11960 Oligonucleotide SE
c	194	12.6	0.6	13	1	ABH28232 Oligonucleotide SE
c	195	12.6	0.6	13	1	ABF62627 Oligonucleotide SE
c	196	12.6	0.6	13	1	ABH41465 Oligonucleotide SE
c	197	12.6	0.6	13	1	ABC71778 Oligonucleotide SE
	198	12.6	0.6	13	1	ABH41464 Oligonucleotide SE
c	199	12.6	0.6	13	1	ABH31368 Oligonucleotide SE
	200	12.6	0.6	13	1	ABF11961 Oligonucleotide SE
	201	12.6	0.6	13	1	ABC71779 Oligonucleotide SE
c	202	12.6	0.6	13	1	ABC16032 Oligonucleotide SE
c	203	12.6	0.6	13	1	ABC04481 Oligonucleotide SE
	204	12.6	0.6	13	1	ABF89185 Oligonucleotide SE
	205	12.6	0.6	15	1	AAS98725 Colony stimulating
	206	12.2	0.6	20	1	AAL61360 Human FXR antisens
	207	12	0.5	20	1	AAL61335 Human FXR antisens
	208	11.6	0.5	20	1	AAL61331 Human FXR antisens
	209	11.6	0.5	20	1	AAL61332 Human FXR antisens
c	210	11.6	0.5	27	1	AAL61320 Human farnesoid X

ALIGNMENTS

```
RESULT 1
AAL61322
ID   AAL61322 standard; DNA; 27 BP.
XX
AC   AAL61322;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human farnesoid X receptor (FXR) DNA specific PCR probe.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; RIP14; PCR; probe; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "FAM labelled"
FT   modified_base    27
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "TAMRA labelled"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
```

XX
DR WPI; 2003-468767/44.
XX
PT New antisense oligonucleotides for modulating human farnesoid X receptor
PT (FXR) expression, useful for treating conditions associated with FXR in
PT humans, e.g. cardiovascular disease, atherosclerosis or
PT hypercholesterolemia.
XX
PS Example 13; Page 71; 127pp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC inhibiting the expression of human FXR in cells or tissues. It is
CC particularly useful for treating or preventing a disease or condition
CC associated with FXR in a human, e.g. cardiovascular disease,
CC atherosclerosis or hypercholesterolaemia. The antisense compound is
CC useful for diagnostics, therapeutics, prophylaxis, or as research
CC reagents or kits. It is also used in gene therapy. The present sequence
CC is human FXR DNA specific PCR probe. This sequence is used in the
CC exemplification of the invention
XX
SQ Sequence 27 BP; 9 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGCAGCATGCAGATCAGACCGTGAATG 1017
||||||||||||||||||||||||||||
Db 1 AGCAGCATGCAGATCAGACCGTGAATG 27

RESULT 2
AAL61320
ID AAL61320 standard; DNA; 27 BP.
XX
AC AAL61320;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human farnesoid X receptor (FXR) DNA specific forward PCR primer.
XX
KW Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW retinoid X receptor-interacting protein 14; RIP14; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003044167-A2.
XX
PD 30-MAY-2003.
XX
PF 13-NOV-2002; 2002WO-US036691.
XX
PR 15-NOV-2001; 2001US-00002491.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Watt AT;
XX
DR WPI; 2003-468767/44.
XX
PT New antisense oligonucleotides for modulating human farnesoid X receptor
PT (FXR) expression, useful for treating conditions associated with FXR in
PT humans, e.g. cardiovascular disease, atherosclerosis or
PT hypercholesterolemia.
XX
PS Example 13; Page 71; 127pp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC inhibiting the expression of human FXR in cells or tissues. It is
CC particularly useful for treating or preventing a disease or condition
CC associated with FXR in a human, e.g. cardiovascular disease,
CC atherosclerosis or hypercholesterolaemia. The antisense compound is
CC useful for diagnostics, therapeutics, prophylaxis, or as research
CC reagents or kits. It is also used in gene therapy. The present sequence
CC is human FXR DNA specific PCR primer. This sequence is used in the
CC exemplification of the invention
XX
SQ Sequence 27 BP; 11 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 956 TCAGTGTAAATCTAAGCGACTGAGAAA 982
||||||||||||||||||||||||||||
Db 1 TCAGTGTAAATCTAAGCGACTGAGAAA 27

RESULT 3
ACF58014
ID ACF58014 standard; DNA; 28 BP.
XX
AC ACF58014;
XX
DT 15-JAN-2004 (first entry)
XX
DE Mouse npFXRa RNA expression analysing RT-PCR primer.
XX
KW Nuclear receptor; npFXRb; npFXR-beta; cholesterol; triglyceride; RT-PCR;
KW bile acid; lanosterol; fertility control; npFXRa; primer; ss.
XX
OS Mus sp.
XX
PN WO2003087140-A1.
XX
PD 23-OCT-2003.
XX
PF 07-MAR-2003; 2003WO-EP002357.
XX
PR 13-APR-2002; 2002EP-00008454.
XX
PA (LION-) LION BIOSCIENCE AG.
XX
PI Deuschle U, Jackson D, Kober I, Kranz H, Kremoser C, Otte K;
PI Remmel B;
XX
DR WPI; 2003-833703/77.
XX
PT New nucleic acid molecule coding for the non-primate nuclear receptor
PT npFXRb, useful for the analysis of agents that modulate cholesterol, bile
PT acids, and triglyceride synthesis.
XX
PS Example 1; Page 44; 0pp; English.
XX
CC The invention relates to a novel non-primate nuclear receptor npFXRb
CC (npFXR-beta) or its splice variants. Host cells comprising the npFXRb
CC nucleic acids or the npFXRb transgenic animals are useful for identifying
CC agents that are capable of modulating the cellular function of the non-
CC primate nuclear receptor of npFXRb or its splice variants, preferably for
CC the analysis of agents that modulate cholesterol, bile acids, and
CC triglyceride synthesis. The agent is useful for modulating the synthesis
CC of lanosterol or cholesterol from lanosterol or bile acids or
CC triglycerides in non-primate animals, modulating developmental processes
CC in non-primate animals, and/or modulating the wool fat synthesis in sheep
CC or lamas. The agent is preferably useful for the fertility control of non
CC -primate animals, including mice, rats, rabbits, frogs, birds, fish, or
CC non-vertebrates. Sequences ACF58014-15 represent RT-PCR primers for
CC analysis of murine npFXRa RNA expression
XX

```
SQ   Sequence 28 BP; 5 A; 2 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             1.1%;  Score 24.8;  DB 1;  Length 28;
  Best Local Similarity   92.9%;  Pred. No. 0.87;
  Matches   26;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        924 GGAATGTTGGCTGAATGCTTGTTAACTG 951
              || ||||||||||||| ||||||||||
Db          1 GGGATGTTGGCTGAATGTTTGTTAACTG 28


RESULT 4
AAT32963
ID   AAT32963 standard; DNA; 29 BP.
XX
AC   AAT32963;
XX
DT   31-JAN-1997  (first entry)
XX
DE   Degenerate probe based on P-box/DNA recognition helix.
XX
KW   Farnesoid-activated receptor polypeptide; nuclear receptor;
KW   transcription factor; intracellular metabolites; farnesol; regulation;
KW   biosynthesis; lipid; mevalonate; ss.
XX
OS   Synthetic.
XX
PN   WO9621742-A1.
XX
PD   18-JUL-1996.
XX
PF   28-DEC-1995;   95WO-US017023.
XX
PR   13-JAN-1995;   95US-00372183.
XX
PA   (SALK ) SALK INST BIOLOGICAL STUDIES.
XX
PI   Evans RM,  Forman BM,  Weinberger CA;
XX
DR   WPI; 1996-342294/34.
DR   P-PSDB; AAW03449.
XX
PT   Modulating processes mediated by farnesoid-activated receptor - with a
PT   farnesoid cpd., e.g. for regulation of the mevalonate pathway of lipid
PT   synthesis.
XX
PS   Example 1; Page 14; 45pp; English.
XX
CC   The farnesoid-activated receptor polypeptide (AAW03448) is a nuclear
CC   receptor (transcription factor) regulated by intracellular metabolites
CC   such as farnesol and related compounds. Control over farnesoid-activated
CC   receptor polypeptide mediated processes may allow regulation of key
CC   pathways, especially the mevalonate pathway, or lipid biosynthesis. This
CC   degenerate oligonucleotide corresponding to a highly conserved region the
CC   P-box/DNA recognition helix of the nuclear receptor superfamily DNA
CC   binding domain was used to screen a cDNA library from mouse hepatoma Hepa
CC   -1c1c7. Two new orphan receptor sequences were found and one of them used
CC   to screen a cDNA library from regenerating rat liver. A 2.1 kb sequence
CC   encoding the farnesoid receptor polypeptide was isolated
XX
SQ   Sequence 29 BP; 6 A; 6 C; 7 G; 7 T; 0 U; 3 Other;

  Query Match             1.1%;  Score 23.6;  DB 1;  Length 29;
  Best Local Similarity   82.1%;  Pred. No. 1.5;
  Matches   23;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        780 ACCTGTGAGGGGTGTAAAGGTTTCTTCA 807
              |||||||||||  || ||:|::|||||||
Db          1 ACCTGTGAGGGCTGCAARGKYTTCTTCA 28


RESULT 5
AAL61321/c
ID   AAL61321 standard; DNA; 23 BP.
XX
AC   AAL61321;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human farnesoid X receptor (FXR) DNA specific reverse PCR primer.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; RIP14; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 13; Page 71; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is human FXR DNA specific PCR primer. This sequence is used in the
CC   exemplification of the invention
XX
SQ   Sequence 23 BP; 5 A; 8 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             1.0%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 1.7;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1019 AGACAGTGAAGGTCGTGACTTGC 1041
              |||||||||||||||||||||||
Db         23 AGACAGTGAAGGTCGTGACTTGC 1


RESULT 6
AAL61331/c
ID   AAL61331 standard; DNA; 20 BP.
XX
AC   AAL61331;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126474.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
```

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        917 AGAGATGGGAATGTTGGCTG 936
              ||||||||||||||||||||
Db         20 AGAGATGGGAATGTTGGCTG 1


RESULT 7
AAL61336/c
ID   AAL61336 standard; DNA; 20 BP.
XX
AC   AAL61336;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126492.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1293 GAAGACCAGATTGCTTTGCT 1312
              ||||||||||||||||||||
Db         20 GAAGACCAGATTGCTTTGCT 1


RESULT 8
AAL61338/c
ID   AAL61338 standard; DNA; 20 BP.
XX
```

```
AC   AAL61338;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126501.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1542 TACATAAAGGATAGAGAGGC 1561
              ||||||||||||||||||||
Db         20 TACATAAAGGATAGAGAGGC 1
```

```
RESULT 9
AAL61357/c
ID   AAL61357 standard; DNA; 20 BP.
XX
AC   AAL61357;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145304.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        587 AGAGTGGTACTCTCCTGGAA 606
              ||||||||||||||||||||
Db         20 AGAGTGGTACTCTCCTGGAA 1


RESULT 10
AAL61387/c
ID   AAL61387 standard; DNA; 20 BP.
XX
AC   AAL61387;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145334.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1630 ATCCTCAACACTTTGCCTGT 1649
              ||||||||||||||||||||
Db         20 ATCCTCAACACTTTGCCTGT 1


RESULT 11
AAL61389/c
ID   AAL61389 standard; DNA; 20 BP.
XX
AC   AAL61389;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145336.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
```

```
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match              0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1672 TACGGACATTCAATCATCAC 1691
              ||||||||||||||||||||
Db         20 TACGGACATTCAATCATCAC 1


RESULT 12
AAL61361/c
ID   AAL61361 standard; DNA; 20 BP.
XX
AC   AAL61361;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145308.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match              0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        699 GCGTCAGCAGGGAGGATCAA 718
              ||||||||||||||||||||
Db         20 GCGTCAGCAGGGAGGATCAA 1


RESULT 13
AAL61384/c
ID   AAL61384 standard; DNA; 20 BP.
XX
AC   AAL61384;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145331.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
```

```
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1567 AGAAGCTTCAGGAGCCACTT 1586
              ||||||||||||||||||||
Db         20 AGAAGCTTCAGGAGCCACTT 1


RESULT 14
AAL61337/c
ID   AAL61337 standard; DNA; 20 BP.
XX
AC   AAL61337;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126494.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1354 AGATTTTCAATAAGAAACTT 1373
              ||||||||||||||||||||
Db         20 AGATTTTCAATAAGAAACTT 1


RESULT 15
AAL61372/c
ID   AAL61372 standard; DNA; 20 BP.
XX
AC   AAL61372;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145319.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
```

```
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1143 AGGATGCCTCAGGAAATAAC 1162
              ||||||||||||||||||||
Db         20 AGGATGCCTCAGGAAATAAC 1


RESULT 16
AAL61378/c
ID   AAL61378 standard; DNA; 20 BP.
XX
AC   AAL61378;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145325.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1364 TAAGAAACTTCCGTCTGGGC 1383
              ||||||||||||||||||||
Db         20 TAAGAAACTTCCGTCTGGGC 1


RESULT 17
AAL61376/c
ID   AAL61376 standard; DNA; 20 BP.
XX
AC   AAL61376;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145323.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
```

```
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1332 GCTATGTTCCTTCGTTCAGC 1351
              ||||||||||||||||||||
Db         20 GCTATGTTCCTTCGTTCAGC 1


RESULT 18
AAL61382/c
ID   AAL61382 standard; DNA; 20 BP.
XX
AC   AAL61382;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145329.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1493 GGAGTATGCTCTGCTTACAG 1512
              ||||||||||||||||||||
Db         20 GGAGTATGCTCTGCTTACAG 1


RESULT 19
AAL61388/c
ID   AAL61388 standard; DNA; 20 BP.
XX
AC   AAL61388;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145335.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
```

```
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1654 TGGGTCGCCTGACTGAATTA 1673
              ||||||||||||||||||||
Db         20 TGGGTCGCCTGACTGAATTA 1


RESULT 20
AAL61365/c
ID   AAL61365 standard; DNA; 20 BP.
XX
AC   AAL61365;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145312.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP, Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        751 GAGCCTCTGGATACCACTAT 770
              ||||||||||||||||||||
Db         20 GAGCCTCTGGATACCACTAT 1


RESULT 21
AAL61328/c
ID   AAL61328 standard; DNA; 20 BP.
XX
AC   AAL61328;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126457.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
```

```
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 9 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        549 TATTATTCCAACCTGGGTTT 568
              ||||||||||||||||||||
Db         20 TATTATTCCAACCTGGGTTT 1


RESULT 22
AAL61335/c
ID   AAL61335 standard; DNA; 20 BP.
XX
AC   AAL61335;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126487.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1191 GCAGAAGAAAATTTTCTCAT 1210
              ||||||||||||||||||||
Db         20 GCAGAAGAAAATTTTCTCAT 1


RESULT 23
AAL61358/c
```

```
ID   AAL61358 standard; DNA; 20 BP.
XX
AC   AAL61358;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145305.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        596 CTCTCCTGGAATATATGAAC 615
              ||||||||||||||||||||
Db         20 CTCTCCTGGAATATATGAAC 1


RESULT 24
AAL61367/c
ID   AAL61367 standard; DNA; 20 BP.
XX
AC   AAL61367;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145314.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        931 TGGCTGAATGCTTGTTAACT 950
              ||||||||||||||||||||
Db         20 TGGCTGAATGCTTGTTAACT 1


RESULT 25
AAL61371/c
ID   AAL61371 standard; DNA; 20 BP.
XX
AC   AAL61371;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145318.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 2 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1134 AACAAACAGAGGATGCCTCA 1153
              ||||||||||||||||||||
Db         20 AACAAACAGAGGATGCCTCA 1


RESULT 26
AAL61379/c
ID   AAL61379 standard; DNA; 20 BP.
XX
AC   AAL61379;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145326.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
```

```
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1390 ACCTATTGGAAGAAAGAATT 1409
              ||||||||||||||||||||
Db         20 ACCTATTGGAAGAAAGAATT 1


RESULT 27
AAL61359/c
ID   AAL61359 standard; DNA; 20 BP.
XX
AC   AAL61359;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145306.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        609 TATGAACTCAGGCGTATGCC 628
              ||||||||||||||||||||
Db         20 TATGAACTCAGGCGTATGCC 1


RESULT 28
AAL61370/c
ID   AAL61370 standard; DNA; 20 BP.
XX
AC   AAL61370;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145317.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
```

```
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1065 TCATGCAGGGAGAAAACTGA 1084
              ||||||||||||||||||||
Db         20 TCATGCAGGGAGAAAACTGA 1


RESULT 29
AAL61375/c
ID   AAL61375 standard; DNA; 20 BP.
XX
AC   AAL61375;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145322.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1264 AGCTACCAGGATTTCAGACT 1283
              ||||||||||||||||||||
Db         20 AGCTACCAGGATTTCAGACT 1


RESULT 30
AAL61385/c
ID   AAL61385 standard; DNA; 20 BP.
XX
AC   AAL61385;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145332.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
```

```
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1608 TGTAAGATTCACCAGCCTGA 1627
              ||||||||||||||||||||
Db         20 TGTAAGATTCACCAGCCTGA 1


RESULT 31
AAL61386/c
ID   AAL61386 standard; DNA; 20 BP.
XX
AC   AAL61386;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145333.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 1 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1623 CCTGAAAATCCTCAACACTT 1642
              ||||||||||||||||||||
Db         20 CCTGAAAATCCTCAACACTT 1


RESULT 32
AAL61332/c
ID   AAL61332 standard; DNA; 20 BP.
XX
AC   AAL61332;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126476.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
```

```
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        946 TAACTGAAATTCAGTGTAAA 965
              ||||||||||||||||||||
Db         20 TAACTGAAATTCAGTGTAAA 1


RESULT 33
AAL61355/c
ID   AAL61355 standard; DNA; 20 BP.
XX
AC   AAL61355;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145302.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 9 A; 1 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        534 ATTTCCTCGTCATCCTATTA 553
              ||||||||||||||||||||
Db         20 ATTTCCTCGTCATCCTATTA 1


RESULT 34
AAL61364/c
ID   AAL61364 standard; DNA; 20 BP.
XX
AC   AAL61364;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145311.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
```

```
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        745 GAGACAGAGCCTCTGGATAC 764
              ||||||||||||||||||||
Db         20 GAGACAGAGCCTCTGGATAC 1


RESULT 35
AAL61360/c
ID   AAL61360 standard; DNA; 20 BP.
XX
AC   AAL61360;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145307.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        645 CAGGGAGAAACTGAGGTAGC 664
              ||||||||||||||||||||
Db         20 CAGGGAGAAACTGAGGTAGC 1


RESULT 36
AAL61366/c
ID   AAL61366 standard; DNA; 20 BP.
XX
AC   AAL61366;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145313.
XX
```

```
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        757 CTGGATACCACTATAATGCA 776
              ||||||||||||||||||||
Db         20 CTGGATACCACTATAATGCA 1


RESULT 37
AAL61374/c
ID   AAL61374 standard; DNA; 20 BP.
XX
AC   AAL61374;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145321.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1213 TGACGGAAATGGCAACCAAT 1232
              ||||||||||||||||||||
Db         20 TGACGGAAATGGCAACCAAT 1
```

```
RESULT 38
AAL61333/c
ID   AAL61333 standard; DNA; 20 BP.
XX
AC   AAL61333;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126479.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        981 AAAAATGTGAAGCAGCATGC 1000
              ||||||||||||||||||||
Db         20 AAAAATGTGAAGCAGCATGC 1


RESULT 39
AAL61334/c
ID   AAL61334 standard; DNA; 20 BP.
XX
AC   AAL61334;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126483.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;
```

```
  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1067 ATGCAGGGAGAAAACTGAAC 1086
              ||||||||||||||||||||
Db         20 ATGCAGGGAGAAAACTGAAC 1


RESULT 40
AAL61362/c
ID   AAL61362 standard; DNA; 20 BP.
XX
AC   AAL61362;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145309.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 9 A; 9 C; 1 G; 1 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        726 GAGCTGTGTGTTGTTTGTGG 745
              ||||||||||||||||||||
Db         20 GAGCTGTGTGTTGTTTGTGG 1


RESULT 41
AAL61363/c
ID   AAL61363 standard; DNA; 20 BP.
XX
AC   AAL61363;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145310.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
```

```
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 7 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match          0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        734 TGTTGTTTGTGGAGACAGAG 753
              ||||||||||||||||||||
Db         20 TGTTGTTTGTGGAGACAGAG 1


RESULT 42
AAL61383/c
ID   AAL61383 standard; DNA; 20 BP.
XX
AC   AAL61383;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145330.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match          0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1525 TGTCTCCAGATAGACAATAC 1544
              ||||||||||||||||||||
Db         20 TGTCTCCAGATAGACAATAC 1


RESULT 43
AAL61390/c
ID   AAL61390 standard; DNA; 20 BP.
XX
AC   AAL61390;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145337.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
```

```
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1692 CACGCTGAGATGCTGATGTC 1711
              ||||||||||||||||||||
Db         20 CACGCTGAGATGCTGATGTC 1


RESULT 44
AAL61329/c
ID   AAL61329 standard; DNA; 20 BP.
XX
AC   AAL61329;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126465.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        717 AAAGGGGATGAGCTGTGTGT 736
              ||||||||||||||||||||
Db         20 AAAGGGGATGAGCTGTGTGT 1


RESULT 45
AAL61330/c
ID   AAL61330 standard; DNA; 20 BP.
XX
AC   AAL61330;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126471.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
```

```
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        861 GTGATGGATATGTACATGCG 880
              ||||||||||||||||||||
Db         20 GTGATGGATATGTACATGCG 1


RESULT 46
AAL61356/c
ID   AAL61356 standard; DNA; 20 BP.
XX
AC   AAL61356;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145303.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        553 ATTCCAACCTGGGTTTCTAC 572
              ||||||||||||||||||||
Db         20 ATTCCAACCTGGGTTTCTAC 1


RESULT 47
AAL61377/c
ID   AAL61377 standard; DNA; 20 BP.
XX
AC   AAL61377;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145324.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
```

```
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1342 TTCGTTCAGCTGAGATTTTC 1361
              ||||||||||||||||||||
Db         20 TTCGTTCAGCTGAGATTTTC 1


RESULT 48
AAL61380/c
ID   AAL61380 standard; DNA; 20 BP.
XX
AC   AAL61380;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145327.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1411 GAAATAGTGGTATCTCTGAT 1430
              ||||||||||||||||||||
Db         20 GAAATAGTGGTATCTCTGAT 1


RESULT 49
AAL61339/c
ID   AAL61339 standard; DNA; 20 BP.
XX
AC   AAL61339;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126506.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

```
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1688 TCACCACGCTGAGATGCTGA 1707
              ||||||||||||||||||||
Db         20 TCACCACGCTGAGATGCTGA 1

RESULT 50
AAL61368/c
ID   AAL61368 standard; DNA; 20 BP.
XX
AC   AAL61368;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145315.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1033 GTGACTTGCGACAAGTGACC 1052
              ||||||||||||||||||||
Db         20 GTGACTTGCGACAAGTGACC 1

RESULT 51
AAL61369/c
ID   AAL61369 standard; DNA; 20 BP.
XX
AC   AAL61369;
XX
DT   22-SEP-2003  (first entry)
XX
```

```
DE   Human FXR antisense oligonucleotide, ISIS 145316.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1039 TGCGACAAGTGACCTCGACA 1058
              ||||||||||||||||||||
Db         20 TGCGACAAGTGACCTCGACA 1


RESULT 52
AAL61373/c
ID   AAL61373 standard; DNA; 20 BP.
XX
AC   AAL61373;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145320.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1178 AGAAGAATTCAGTGCAGAAG 1197
              ||||||||||||||||||||
Db         20 AGAAGAATTCAGTGCAGAAG 1
```

```
RESULT 53
AAL61381/c
ID   AAL61381 standard; DNA; 20 BP.
XX
AC   AAL61381;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145328.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Example 15; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 2 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 5.6;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1429 ATGAATATATAACACCTATG 1448
              ||||||||||||||||||||
Db         20 ATGAATATATAACACCTATG 1

RESULT 54
ABL40671/c
ID   ABL40671 standard; DNA; 24 BP.
XX
AC   ABL40671;
XX
DT   17-JUN-2002  (first entry)
XX
DE   Human Fe-S protein 9.57 cDNA isolating RT-PCR primer 2.
XX
KW   Fe-S protein 9.57; human; cancer; HIV infection; cytostatic; anti-HIV;
KW   gene therapy; RT-PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   CN1325892-A.
XX
PD   12-DEC-2001.
XX
PF   31-MAY-2000; 2000CN-00116241.
XX
PR   31-MAY-2000; 2000CN-00116241.
XX
PA   (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-227561/29.
XX
PT   Polypeptide-human Fe-S protein 9.57 and polynucleotide for coding it.
XX
PS   Example 2; Page 16 (Disclosure); 32pp; Chinese.
XX
CC   The invention relates to a novel human Fe-S protein 9.57. The protein can
CC   be expressed by standard DNA recombination. The Fe-S protein 9.57 and
CC   encoding polynucleotides are useful for treating diseases such as cancer
CC   and HIV infection. The present sequence represents the human Fe-S protein
CC   9.57 cDNA isolating RT-PCR primer
XX
SQ   Sequence 24 BP; 6 A; 2 C; 1 G; 15 T; 0 U; 0 Other;

  Query Match             0.9%;  Score 19.4;  DB 1;  Length 24;
  Best Local Similarity   95.2%;  Pred. No. 8.4;
  Matches   20;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1164 AATAAAATTTTAAAAGAAGAA 1184
              |||||||||| ||||||||||
Db         21 AATAAAATTTAAAAAGAAGAA 1

RESULT 55
AAF55665
ID   AAF55665 standard; DNA; 23 BP.
XX
AC   AAF55665;
XX
DT   29-MAY-2001  (first entry)
XX
DE   Probe for human peroxisome proliferator-activated receptor gamma cDNA.
XX
KW   Human; peroxisome proliferator-activated receptor gamma; PPAR-gamma;
KW   orphan receptor; cancer; probe; ss.
XX
OS   Homo sapiens.
XX
PN   US6200802-B1.
```

XX
PD 13-MAR-2001.
XX
PF 08-OCT-1993; 93US-00134557.
XX
PR 08-OCT-1993; 93US-00134557.
XX
PA (ARCH-) ARCH DEV CORP.
XX
PI Greene ME, Blumberg B;
XX
DR WPI; 2001-234517/24.
XX
PT Novel isolated and purified polynucleotide encoding human peroxisome
PT proliferator-activated receptor gamma polypeptide useful in diagnostics,
PT drug design and therapeutics.
XX
PS Example 1; Col 34; 29pp; English.
XX
CC The present sequence represents a probe for cDNA encoding a human
CC peroxisome proliferator-activated receptor gamma (PPAR-gamma)
CC polypeptide. PPAR are orphan receptors, and may play a role in
CC proliferative and differentiation aspects of cancer. The PPAR-gamma
CC polynucleotide is useful for detecting a mRNA transcript that encodes
CC PPAR polypeptide. It is also useful for detecting hybrid formation. The
CC PPAR-gamma polypeptide is useful in diagnostics, drug design and
CC therapeutics
XX
SQ Sequence 23 BP; 3 A; 0 C; 7 G; 6 T; 0 U; 7 Other;

Query Match 0.9%; Score 19; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 9.7;
Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 783 TGTGAGGGGTGTAAAGGTTTCTT 805
||:||:|| ||:||:|| ||:||
Db 1 TGYGARGGNTGYAARGGNTTYTT 23

RESULT 56
ABZ98123
ID ABZ98123 standard; DNA; 20 BP.
XX
AC ABZ98123;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MCP4 oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13365; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 23;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 985 ATGTGAAGCAGCATGCAGAT 1004
||||||||||||:|||
Db 1 ATGTGAAGCAGCAAGTAGAT 20

RESULT 57
ABZ98075
ID ABZ98075 standard; DNA; 20 BP.
XX
AC ABZ98075;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MCP4 oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13317; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 23;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 985 ATGTGAAGCAGCATGCAGAT 1004
||||||||||||| | ||||
Db 1 ATGTGAAGCAGCAAGTAGAT 20

RESULT 58
ACC70407/c
ID ACC70407 standard; DNA; 21 BP.
XX
AC ACC70407;
XX
DT 11-AUG-2003 (first entry)
XX
DE PCR primer used to amplify susceptible-specific AFLP marker SA598.
XX
KW Sequence characterized amplified region; SCAR; AFLP marker SA598;
KW marker-assisted selection; rice; gall midge; gall midge resistance gene;
KW PCR; primer; ss.
XX
OS Oryza sp.
XX
PN WO2003033736-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-IN000212.
XX
PR 17-OCT-2001; 2001IN-DE001065.
XX
PA (ITGE-) INT CENT GENETIC ENG & BIOTECHNOLOGY.
XX
PI Sardesai N, Kumar A, Nair S, Mohan M;
XX
DR WPI; 2003-421324/39.
XX
PT New combination of sequence characterized amplified region primers
PT showing polymorphisms between resistant and susceptible plants to gall
PT midge, useful in marker-assisted selection of rice varieties.
XX
PS Claim 1; Page 4; 31pp; English.
XX
CC The specification describes a combination of sequence characterized
CC amplified region (SCAR) primers for use in marker-assisted selection of
CC rice varieties which are susceptible to attack by gall midge. The method
CC is useful in marker-assisted selection in rice as they show polymorphisms
CC between resistant and susceptible plants to gall midge. PCR primers
CC ACC70406-07 were used to amplify the susceptible-specific AFLP marker
CC SA598. This marker is present in a single copy number in susceptible
CC varieties. SCAR primers developed from this marker are able to
CC distinguish between susceptible and resistant phenotypes in different
CC crosses carrying different gall midge resistance genes
XX
SQ Sequence 21 BP; 5 A; 5 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.8%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 24;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1396 TGGAAGAAAGAATTCGAAAT 1415
| |||||||||||| |||||
Db 21 TTGAAGAAAGAATTAGAAAT 2

RESULT 59
AAF89442
ID AAF89442 standard; DNA; 19 BP.
XX
AC AAF89442;
XX
DT 14-AUG-2001 (first entry)
XX
DE Human genetic marker PCR primer SEQ ID NO: 31.
XX
KW Genetic marker; genetic disease diagnosis; cystic fibrosis; haemophilia;
KW sickle cell disease; muscular dystrophy; Huntington's disease;
KW retinoblastoma; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200134839-A1.
XX
PD 17-MAY-2001.
XX
PF 03-NOV-2000; 2000WO-US030493.
XX
PR 12-NOV-1999; 99US-0165301P.
XX
PA (DUNL/) DUNLOP C L M.
PA (WEIS/) WEISEL J M.
XX
PI Dunlop CLM, Weisel JM;
XX
DR WPI; 2001-329096/34.
XX
PT Detecting multiple genetic markers in one assay, useful to simultaneously
PT detect a number of genetic disorders, comprises generating extension
PT products and separating them on the basis of melting behavior is.
XX
PS Claim 44; Page 33; 40pp; English.
XX
CC The present invention describes a method of inentifying the presence of a
CC plurality of genetic markers in a subject, involving generating extension
CC products using PCR primers flanking the plurality of markers, separating
CC the extension products depending on their melting temperatures, and
CC analysing them to determine the presence or absence of each genetic
CC marker. This can be used in the diagnosis of genetic diseases, including
CC familial hypercholesterolaemia, cystic fibrosis, Tay-Sachs, thalassaemia,
CC sickle cell disease, phenylketonuria, galactosaemia, fragile X syndrome,
CC haemophilia A, myotonic dystrophy, medium chain acyl-CoA dehydrogenase,
CC maturity onset diabetes, cystinuria, methylmolonic acidaemia, urea cycle
CC disorders, hereditary fructose intolerance, hereditary haemochromatosis,
CC neonatal thrombocytopenia, Gaucher's disease, tyrosinaemia, Wilson's

CC disease, acaptonuria, hypolactasia, Baker's disease, argininaemia,
CC adenomatous polyposis coli, hereditary nonpolyposis colorectal cancer,
CC Huntington's disease, adult polycystic kidney disease, alpha-1-
CC antitrypsin deficiency, Duchenne muscular dystrophy, Marfan's syndrome,
CC neurofibromatosis, osteogenesis imperfecta, retinoblastoma, Freidrich's
CC ataxia, haemoglobinopathies, Leber's hereditary optic neuropathy, MCAD,
CC Canavan's disease, retinitis pigmentosa, Bloom syndrome, Fanconi anaemia
CC or Neimann Pick disease. The present sequence is one of the PCR primers
CC of the invention
XX
SQ Sequence 19 BP; 3 A; 0 C; 10 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 26;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 784 GTGAGGGGTGTAAAGGTT 801
||||||||||||| ||||
Db 2 GTGAGGGGTGTAATGGTT 19

RESULT 60
AAD50206
ID AAD50206 standard; DNA; 19 BP.
XX
AC AAD50206;
XX
DT 24-MAR-2003 (first entry)
XX
DE Human glucocerebrosidase (GBA)-3 specific PCR primer #2.
XX
KW Human; cystic fibrosis; Tay-sachs; familial hypercholesterolaemia; FH;
KW fragile X syndrome; haemophilia A; diabetes; cystinuria; tyrosinaemia;
KW urea cycle disorder; hereditary fructose intolerance; Baker's disease;
KW Wilson's disease; alcaptonuria; adult polycystic kidney disease; MCAD;
KW Huntington's disease; myotonic dystrophy; retinitis pigmentosa; cancer;
KW Gauchers disease; Canavan's disease; galactosaemia; thrombocytopaenia;
KW thalassaemia; sickle cell disease; phenylketonuria; Marfan's syndrome;
KW haemoglobinopathy; Bloom syndrome; Neimann Pick's disease; PCR; primer;
KW glucocerebrosidase; GBA; ss.
XX
OS Homo sapiens.
XX
PN WO200290374-A1.
XX
PD 14-NOV-2002.
XX
PF 06-MAY-2002; 2002WO-US014562.
XX
PR 08-MAY-2001; 2001US-00851501.
XX
PA (AMBR-) AMBRY GENETICS CORP.
XX
PI Dunlop CLM, Weisel JM;
XX
DR WPI; 2003-103498/09.
XX
PT Identifying the presence or absence of a mutation or polymorphism in a
PT subject, useful for diagnosing genetic diseases, comprises generating
PT extension products and analyzing the melting behavior of the mixed DNA
PT sample.
XX
PS Claim 56; Page 43; 49pp; English.
XX
CC The invention relates to a method for identifying the presence or absence
CC of a mutation or polymorphism in a plurality of genes. The method is used
CC for identifying the presence or absence of a mutation or polymorphism in
CC a subject, or the presence or absence of several genetic markers in a
CC subject for diagnosing genetic diseases, e.g. cystic fibrosis, Tay-sachs,
CC familial hypercholesterolaemia (FH), thalassaemia, sickle cell disease,
CC phenylketonuria, galactosaemia, fragile X syndrome, haemophilia A,
CC myotonic dystrophy, medium-chain acyl CoA dehydrogenase, maturity onset
CC diabetes, cystinuria, methylmolonic acidaemia, urea cycle disorders,
CC hereditary fructose intolerance, hereditary haemachromatosis, neonatal
CC thrombocytopaenia, Gauchers disease, tyrosinaemia, Wilson's disease,
CC alcaptonuria, hypolactasia, Baker's disease, argininaemia adenomatous
CC polyposis coli (APC), adult polycystic kidney disease, Duchenne muscular
CC dystrophy, alpha-1-antitrypsin deficiency, hereditary non-polyposis
CC colececal cancer, Huntington's disease, neurofibromatosis, Marfan's
CC syndrome, osteogenesis imperfecta, retinoblastoma, Freidrich's ataxia,
CC haemoglobinopathies, MCAD, Canavan's disease, Leber's hereditary optic
CC neuropathy, retinitis pigmentosa, Bloom syndrome, Fanconi's anaemia, or
CC Neimann Pick's disease. The present sequence is human glucocerebrosidase
CC (GBA) specific PCR primer used to illustrate the method of the invention
XX
SQ Sequence 19 BP; 3 A; 0 C; 10 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 26;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 784 GTGAGGGGTGTAAAGGTT 801
||||||||||||| ||||
Db 2 GTGAGGGGTGTAATGGTT 19

RESULT 61
ABT44411/c
ID ABT44411 standard; DNA; 20 BP.
XX
AC ABT44411;
XX
DT 06-NOV-2003 (first entry)
XX
DE Chimeric antisense oligonucleotide ISIS 192386 to inhibit human ESRB.
XX
KW Oestrogen receptor beta; ERSB; steroid hormone; female sexual maturation;
KW bone maintenance; cardiovascular system; ER beta; oestrogen receptor 2;
KW ERS2; Alzheimer's; uterine leiomyomata; cytostatic; kidney neoplasm; ss;
KW cellular proliferation; cancer; human; antisense; chimeric.
XX
OS Chimeric - Homo sapiens.
XX
PN WO2003050133-A1.
XX
PD 19-JUN-2003.
XX
PF 06-DEC-2002; 2002WO-US039200.
XX
PR 07-DEC-2001; 2001US-00005058.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Dobie KW, Roach MP, Koller E;
XX
DR WPI; 2003-577284/54.
XX
PT New antisense oligonucleotides for modulating estrogen receptor beta gene
PT expression, particularly useful for treating cancers, specifically
PT leiomyoma, pancreatic cancer, prostate cancer, breast cancer, bone cancer
PT or lymphoma.
XX
PS Claim 3; Page 81; 160pp; English.
XX
CC This invention relates to a novel antisense compounds that modulate the
CC expression of oestrogen receptor beta (ERSB). Oestrogen is a steroid
CC hormone that exerts a wide range of effects throughout the human body
CC being primarily involved in female sexual maturation. Additionally,
CC however, oestrogen targets male reproductive tissues, is known to be
CC important in bone maintenance and plays a protective role in the
CC cardiovascular system. This hormone receptor, ERSB (also known as ER
CC beta, oestrogen receptor 2 and ERS2) has been mapped to chromosome 14q22-
CC q24, a region known to be associated with early onset of Alzheimer's
CC disease, uterine leiomyomata and neoplasms of the kidney. Furthermore,
CC ERSB has been localised to metastatic cells indicating an involvement in
CC cellular proliferation. Accordingly, the selective inhibition of ERSB by

```
CC   the cytostatic antisense oligonucleotides of this invention could provide
CC   a therapeutic target for the treatment of cancer, as well as other ERSB-
CC   related disorders. This oligonucleotide sequence is the chimeric human
CC   antisense oligo used to inhibit expression of human ERSB, the aim of the
CC   invention. Note that it has two terminal five nucleotide 2'-methoxyethyl
CC   (2'-MOE) wings separated by a ten deoxynucleotide gap. The
CC   oligonucleotide backbone is phosphorothioate throughout
XX
SQ   Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 27;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1171 TTTTAAAAGAAGAATTCA 1188
              ||||||||||||| |||||
Db         19 TTTTAAAAGAAGCATTCA 2


RESULT 62
ABN09961
ID   ABN09961 standard; DNA; 17 BP.
XX
AC   ABN09961;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9953.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 9953; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 37;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1072 GGGAGAAAACTGAACTC 1088
              |||||||||||||  |||
Db          1 GGGAGAAAACTGAGCTC 17


RESULT 63
ADC24242/c
ID   ADC24242 standard; DNA; 18 BP.
XX
AC   ADC24242;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human NOV1b reverse PCR primer SEQ ID NO:49.
XX
KW   human; NOVX; cardiant; antiarteriosclerotic; hypotensive; vasotropic;
KW   dermatological; anorectic; immunosuppressive; cytostatic;
KW   antiinfertility; haemostatic; anti-HIV; antiasthmatic; antiinflammatory;
KW   neuroprotective; anabolic; nootropic; antiparkinsonian; gene therapy;
KW   cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
KW   pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
KW   transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW   prostate cancer; diabetes; metabolic disorder; neoplasm; adenocarcinoma;
KW   fertility; haemophilia; graft versus host disease; AIDS;
KW   bronchial asthma; Crohn's disease; multiple sclerosis;
KW   infectious disease; anorexia; neurodegenerative disorder;
KW   Alzheimer's disease; Parkinson's disease; immune disorder;
KW   haematopoietic disorder; dyslipidaemia; wasting disorder; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003076584-A2.
XX
PD   18-SEP-2003.
XX
PF   06-MAR-2003; 2003WO-US006951.
XX
PR   06-MAR-2002; 2002US-0361974P.
PR   19-MAR-2002; 2002US-0365477P.
PR   22-MAR-2002; 2002US-0366928P.
PR   06-AUG-2002; 2002US-0401661P.
PR   05-MAR-2003; 2003US-00401661.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Burgess CE,  Edinger SR,  Gerlach VL,  Ji W,  Kekuda R;
PI   Li L,  Macdougall JR,  Miller CE,  Millet I,  Patturajan M,  Pena CEA;
```

PI Rieger DK, Sciore P, Shenoy SG, Smithson G, Spytek KA, Stone DJ;
PI Voss EZ, Zhong M;
XX
DR WPI; 2003-722330/68.
XX
PT New NOVX polypeptides and nucleic acids, useful for diagnosing or
PT treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
PT obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
PT multiple sclerosis.
XX
PS Example C; SEQ ID NO 49; 229pp; English.
XX
CC The present invention describes novel human proteins, designated NOVX
CC proteins. The NOVX sequences have cardiant, antiarteriosclerotic,
CC hypotensive, vasotropic, dermatological, anorectic, immunosuppressive,
CC cytostatic, antiinfertility, haemostatic, anti-HIV, antiasthmatic,
CC antiinflammatory, neuroprotective, anabolic, nootropic and
CC antiparkinsonian activities, and can be used in gene therapy. The NOVX
CC sequences can be used as a therapeutic in the manufacture of a medicament
CC for treating a syndrome associated with a human disease, such as a
CC pathology associated with NOVX. The NOVX proteins and nucleic acids
CC encoding them are useful for diagnosing or treating pathologies, diseases
CC or conditions associated with NOVX sequences, including cardiomyopathy,
CC atherosclerosis, hypertension, congenital heart defects, pulmonary
CC stenosis, scleroderma, obesity, metabolic disturbances associated with
CC obesity, transplantation, adrenoleukodystrophy, congenital adrenal
CC hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm,
CC adenocarcinoma, fertility, haemophilia, graft versus host disease, AIDS,
CC bronchial asthma, Crohn's disease, multiple sclerosis, infectious
CC disease, anorexia, neurodegenerative disorders (e.g. Alzheimer's disease,
CC or Parkinson's disease), immune disorders, haematopoietic disorders,
CC dyslipidaemias, and wasting disorders associated with chronic diseases.
CC The proteins can also be used as immunogens to produce antibodies and as
CC vaccines. The sequences may further be used in chromosome mapping,
CC identifying individual from minute biological samples (tissue typing),
CC and in forensic identification of a biological sample. The present
CC sequence represents a PCR primer for a human NOVX sequence, which is used
CC in an example from the present invention.
XX
SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 38;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1569 AAGCTTCAGGAGCCACT 1585
              ||||| ||||||||||
Db         17 AAGCTGCAGGAGCCACT 1
```

RESULT 64
AAV66781
ID AAV66781 standard; DNA; 18 BP.
XX
AC AAV66781;
XX
DT 02-FEB-1999 (first entry)
XX
DE CAPS marker PCR primer 20B4L-1.6 rev.
XX
KW LSD1; plant pathogen response; apoptosis; programmed cell death;
KW disease resistance; herbicide resistance; transgenic plant;
KW crop protection; co-dominant amplified polymorphic sequence; CAPS marker;
KW 20B4L-1.6; PCR; primer; ss.
XX
OS Synthetic.
OS Arabidopsis thaliana.
XX
PN WO9837755-A1.
XX
PD 03-SEP-1998.
XX
PF 27-FEB-1998; 98WO-US004077.
XX
PR 28-FEB-1997; 97US-0039063P.
XX
PA (UYNC-) UNIV NORTH CAROLINA.
XX
PI Dangl JL, Dietrich RA, Richberg MH, Epple PM;
XX
DR WPI; 1998-531501/45.
XX
PT New isolated Arabidopsis genes - useful for producing transgenic plants
PT which show resistance to cell death caused by pathogens or herbicides.
XX
PS Example 4; Page 14; 88pp; English.
XX
CC Primers 20B4L-1.6 rev and 20B4L-1.6 for (see AAV66780) are designed for
CC the PCR amplification of the agamous (AG) co-dominant amplified
CC polymorphic sequence (CAPS) marker ch42. New PCR based RFLP (CAPS)
CC markers, including 20B4L-1.6, were derived during cloning of the
CC Arabidopsis thaliana lsd1 gene. Wild-type LSD1 (see AAW72366-67) has an
CC effect in regulating the initial response of plants to pathogens and the
CC subsequent spread of plant cell death engendered by infection. Transgenic
CC plants expressing LSD1 mutant genes that affect resistance to herbicides
CC or plant pathogens that normally result in plant cell death are claimed
XX
SQ Sequence 18 BP; 5 A; 1 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        919 AGATGGGAATGTTGG 933
              |||||||||||||||
Db          4 AGATGGGAATGTTGG 18
```

RESULT 65
ABL40671
ID ABL40671 standard; DNA; 24 BP.
XX
AC ABL40671;
XX
DT 17-JUN-2002 (first entry)
XX
DE Human Fe-S protein 9.57 cDNA isolating RT-PCR primer 2.
XX
KW Fe-S protein 9.57; human; cancer; HIV infection; cytostatic; anti-HIV;
KW gene therapy; RT-PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN CN1325892-A.
XX
PD 12-DEC-2001.
XX
PF 31-MAY-2000; 2000CN-00116241.
XX
PR 31-MAY-2000; 2000CN-00116241.
XX
PA (BODE-) BODE GENE DEV CO LTD SHANGHAI.
XX
PI Mao Y, Xie Y;
XX
DR WPI; 2002-227561/29.
XX
PT Polypeptide-human Fe-S protein 9.57 and polynucleotide for coding it.
XX
PS Example 2; Page 16 (Disclosure); 32pp; Chinese.
XX
CC The invention relates to a novel human Fe-S protein 9.57. The protein can
CC be expressed by standard DNA recombination. The Fe-S protein 9.57 and
CC encoding polynucleotides are useful for treating diseases such as cancer
CC and HIV infection. The present sequence represents the human Fe-S protein
CC 9.57 cDNA isolating RT-PCR primer

```
XX
SQ   Sequence 24 BP; 6 A; 2 C; 1 G; 15 T; 0 U; 0 Other;

  Query Match             0.7%;  Score 14.6;  DB 1;  Length 24;
  Best Local Similarity   81.0%;  Pred. No. 64;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        410 TTCTTTTTCTGAAAATTTATT 430
              ||||| || | ||| ||||||
Db          1 TTCTTCTTTTTAAATTTTATT 21


RESULT 66
AAS56770
ID   AAS56770 standard; RNA; 16 BP.
XX
AC   AAS56770;
XX
DT   16-JAN-2002  (first entry)
XX
DE   BR2 protein ribozyme sequence tag RNA #5.
XX
KW   Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW   cytostatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
KW   inhibitor dominant negative 4; breast basic conserved protein 1; BBC1;
KW   BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200170982-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US009559.
XX
PR   23-MAR-2000; 2000US-00536058.
XX
PA   (IMMU-) IMMUSOL INC.
PA   (BEGE/) BEGER C.
XX
PI   Beger C,  Barber J,  Wong-Staal F;
XX
DR   WPI; 2001-611503/70.
XX
PT   Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT   cancer and diagnosing the presence of neoplastic cells in biological
PT   sample.
XX
PS   Disclosure; Page 26; 97pp; English.
XX
CC   Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC   ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC   and primers used in the methods of the invention. Hybridisation of
CC   ribozymes to their targets results in cleavage of the RNA target. The
CC   ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
CC   1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC   mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
CC   dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC   CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC   diagnosing cancer and other proliferative disorders. The severity of an
CC   incidence of cancer can be lessened by regulating tumour proliferation
CC   through modulation of BRCA-1 expression. The sequences of the invention
CC   are useful in the development of anti-cancer drugs
XX
SQ   Sequence 16 BP; 8 A; 2 C; 1 G; 0 T; 5 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   62.5%;  Pred. No. 54;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1358 TTTCAATAAGAAACTT 1373
               :: |||:|||||||::
Db           1 UUACAAUAAGAAACUU 16


RESULT 67
AAS56813
ID   AAS56813 standard; DNA; 16 BP.
XX
AC   AAS56813;
XX
DT   16-JAN-2002  (first entry)
XX
DE   Target validation ribozyme TV32 DNA.
XX
KW   Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW   cytostatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
KW   inhibitor dominant negative 4; breast basic conserved protein 1; BBC1;
KW   BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200170982-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US009559.
XX
PR   23-MAR-2000; 2000US-00536058.
XX
PA   (IMMU-) IMMUSOL INC.
PA   (BEGE/) BEGER C.
XX
PI   Beger C,  Barber J,  Wong-Staal F;
XX
DR   WPI; 2001-611503/70.
XX
PT   Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT   cancer and diagnosing the presence of neoplastic cells in biological
PT   sample.
XX
PS   Example 6; Page 65; 97pp; English.
XX
CC   Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC   ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC   and primers used in the methods of the invention. Hybridisation of
CC   ribozymes to their targets results in cleavage of the RNA target. The
CC   ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
CC   1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC   mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
CC   dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC   CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC   diagnosing cancer and other proliferative disorders. The severity of an
CC   incidence of cancer can be lessened by regulating tumour proliferation
CC   through modulation of BRCA-1 expression. The sequences of the invention
CC   are useful in the development of anti-cancer drugs
XX
SQ   Sequence 16 BP; 8 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        1358 TTTCAATAAGAAACTT 1373
               || ||||||||||||||
Db           1 TTACAATAAGAAACTT 16


RESULT 68
ADD20023
ID   ADD20023 standard; DNA; 16 BP.
XX
AC   ADD20023;
XX
DT   15-JAN-2004  (first entry)
XX
```

DE Oreochromis niloticus microsatellite primer SEQ ID NO:658.
XX
KW single nucleotide polymorphism; SNP; fish; Salmo salar;
KW Orechromis niloticus; Atlantic halibut; microsatellite; cod;
KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
KW detection; primer; ss.
XX
OS Synthetic.
OS Oreochromis niloticus.
XX
PN WO2003060160-A2.
XX
PD 24-JUL-2003.
XX
PF 17-JAN-2003; 2003WO-IB000112.
XX
PR 18-JAN-2002; 2002US-0349950P.
PR 16-AUG-2002; 2002US-0404200P.
XX
PA (GENO-) GENOMAR ASA.
XX
PI Lie O, Slettan A, Hoyum M, Lingaas F;
XX
DR WPI; 2003-627388/59.
XX
PT Novel isolated nucleic acid molecule comprising single nucleotide
PT polymorphism associated with fish, useful for forming PCR primers which
PT are used for detecting single nucleotide polymorphisms in fish nucleic
PT acids.
XX
PS Claim 18; SEQ ID NO 658; 233pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) comprising a
CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
CC (i), or its complement under highly stringent hybridisation conditions.
CC Also described: (1) an isolated oligonucleotide (II) comprising at least
CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
CC a primer pair (III) suitable for use in PCR, comprising two (II) capable
CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites; and determining (M1) the
CC origin of fish sample comprising providing a parentage genotype database
CC comprising a collection of candidate parent genotypes, where each of the
CC candidate parent genotype represents a distinct origin, and comparing a
CC sample genotype to the parentage genotype database, where a match between
CC the sample genotype and one of the candidate parent genotype identifies
CC to the origin of the sample. (M1) is useful for determining the origin of
CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
CC detecting nucleic acid molecule comprising SNP in a sample, which
CC involves contacting the sample containing nucleic acids with one or more
CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
CC useful for detecting nucleic acid molecule comprising a polymorphic
CC sequence in a sample, comprising contacting the sample containing nucleic
CC acids with one or more (II) which is derived from O. niloticus
CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
CC sites or seabass polymorphic sites, and identifying a nucleic acid that
CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
CC comprising a microsatellite sequence in sample. The present sequence is
CC used in the exemplification of the present invention.
XX
SQ Sequence 16 BP; 3 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 849 GGGGGCAACTGTGTGA 864
|| |||||||||||||
Db 1 GGCGGCAACTGTGTGA 16

RESULT 69
AAQ38874
ID AAQ38874 standard; DNA; 17 BP.
XX
AC AAQ38874;
XX
DT 19-JUL-1993 (first entry)
XX
DE DNA primer for construction of vector with multicloning site.
XX
KW Antisense RNA; negative feedback regulation; Escherichia coli; ss.
XX
OS Synthetic.
XX
PN JP05041992-A.
XX
PD 23-FEB-1993.
XX
PF 24-OCT-1991; 91JP-00277708.
XX
PR 24-OCT-1990; 90JP-00284408.
XX
PA (OJIP) OJI CORN STARCH CO LTD.
PA (OJIP) OJI PAPER CO.
XX
DR WPI; 1993-103612/13.
XX
PT E.coli vector with intensified restriction enzyme site - contg. a drug
PT resistant gene originating from a Gram positive bacterium linked upstream
PT of the origin of replication of Col E1 plasmid.
XX
PS Disclosure; Page 27; 47pp; Japanese.
XX
CC This linker DNA is used in the construction of vectors containing a
CC unique drug-resistance gene from a Gram-positive bacterium, upstream of
CC the ColE1 ori. The copy number of the vectors is controlled by
CC transcription of antisense RNA
XX
SQ Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1293 GAAGACCAGATTGCTT 1308
||||| ||||||||||
Db 2 GAAGATCAGATTGCTT 17

RESULT 70
AAT81501/c
ID AAT81501 standard; RNA; 17 BP.
XX
AC AAT81501;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 2701).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX

```
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 76; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 10 A; 0 C; 1 G; 0 T; 6 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              ||||||||||| ||||
Db         17 TTTTTATAAAACTATT 2


RESULT 71
AAT81502/c
ID   AAT81502 standard; RNA; 17 BP.
XX
AC   AAT81502;
XX
DT   14-DEC-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 2702).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 76; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 10 A; 0 C; 1 G; 0 T; 6 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              ||||||||||| ||||
Db         16 TTTTTATAAAACTATT 1


RESULT 72
AAX71613
ID   AAX71613 standard; RNA; 17 BP.
XX
AC   AAX71613;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human KDR VEGF receptor hammerhead ribozyme substrate #625.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 116; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
```

```
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 56;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1612 AGATTCACCAGCCTGA 1627
              |||::| ||||||:||
Db          2 AGAUUCUCCAGCCUGA 17


RESULT 73
AAA21474
ID   AAA21474 standard; RNA; 17 BP.
XX
AC   AAA21474;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:4700.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 210; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 5 A; 0 C; 2 G; 0 T; 10 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 56;
  Matches    6;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1454 TTTTTATAAAAGTATT 1469
              :::::|:|||||: ::
Db          2 UUUUUAUAAAAGUGUU 17


RESULT 74
AAA20929
ID   AAA20929 standard; RNA; 17 BP.
XX
AC   AAA20929;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:4155.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 176; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
```

```
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 56;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        798 GGTTTCTTCAGGAGAA 813
              ||:::|::|| |||||
Db          2 GGUUUCUUCAAGAGAA 17


RESULT 75
AAA20930
ID   AAA20930 standard; RNA; 17 BP.
XX
AC   AAA20930;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:4156.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 176; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 6 A; 2 C; 4 G; 0 T; 5 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 56;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        798 GGTTTCTTCAGGAGAA 813
              ||:::|::|| |||||
Db          1 GGUUUCUUCAAGAGAA 16


RESULT 76
ABN09962
ID   ABN09962 standard; DNA; 17 BP.
XX
AC   ABN09962;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9954.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
```

```
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 9954; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1073 GGAGAAAACTGAACTC 1088
              ||||||||||||| |||
Db          1 GGAGAAAACTGAGCTC 16


RESULT 77
ABN09960
ID   ABN09960 standard; DNA; 17 BP.
XX
AC   ABN09960;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9952.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 9952; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1072 GGGAGAAAACTGAACT 1087
              |||||||||||||| ||
Db          2 GGGAGAAAACTGAGCT 17


RESULT 78
ABQ63861
ID   ABQ63861 standard; DNA; 17 BP.
XX
AC   ABQ63861;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 574.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
```

PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 232; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CTATAATGCACTGACC 782
||| ||||||||||||
Db 2 CTACAATGCACTGACC 17

RESULT 79
ABQ63862
ID ABQ63862 standard; DNA; 17 BP.
XX
AC ABQ63862;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 575.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.

XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 233; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CTATAATGCACTGACC 782
||| ||||||||||||
Db 1 CTACAATGCACTGACC 16

RESULT 80
ACC52120/c
ID ACC52120 standard; DNA; 17 BP.
XX
AC ACC52120;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #887.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX

PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 245; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1220 AATGGCAACCAATCAT 1235
||||||||||||| ||
Db 17 AATGGCAACCAATGAT 2

RESULT 81
ABT36349/c
ID ABT36349 standard; DNA; 17 BP.
XX
AC ABT36349;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 1986.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 265; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 655 CTGAGGTAGCAGAGAT 670
||| ||||||||||||
Db 17 CTGTGGTAGCAGAGAT 2

RESULT 82
ABT39375/c
ID ABT39375 standard; DNA; 17 BP.
XX
AC ABT39375;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5012.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 619; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 1 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        815 CATTACCAAAAACGCT 830
              ||||||||||||||| |
Db         17 CATTACCAAAAACGAT 2
```

RESULT 83
ACC64384
ID ACC64384 standard; DNA; 17 BP.
XX
AC ACC64384;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 1631.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 221; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 1 A; 1 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 56;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy        726 GAGCTGTGTGTTGTTT 741
              || |||||||||||||
Db          1 GATCTGTGTGTTGTTT 16
```

RESULT 84
ADB44143/c
ID ADB44143 standard; DNA; 17 BP.
XX
AC ADB44143;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #4466.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 554; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis

```
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 56;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1342 TTCGTTCAGCTGAGAT 1357
              || ||||||||||||
Db         17 TTTGTTCAGCTGAGAT 2


RESULT 85
ABX77487/c
ID   ABX77487 standard; DNA; 18 BP.
XX
AC   ABX77487;
XX
DT   09-APR-2003  (first entry)
XX
DE   Human lrba gene 3' splice donor site for Exon 49.
XX
KW   LPS responsive CHS1/beige-like anchor gene; lrba; cancer;
KW   tumour growth inhibitor; cytostatic; gene therapy; tumour; melanoma;
KW   chronic myelogenous leukaemia; adenocarcinoma; lymphoblastic leukaemia;
KW   lung carcinoma; ds; human; mouse.
XX
OS   Homo sapiens.
XX
PN   WO200278614-A2.
XX
PD   10-OCT-2002.
XX
PF   02-APR-2002; 2002WO-US010350.
XX
PR   02-APR-2001; 2001US-0280107P.
XX
PA   (UYSF-) UNIV SOUTH FLORIDA.
XX
PI   Kerr WG,  Wang J;
XX
DR   WPI; 2003-103233/09.
XX
PT   A new isolated LPS-responsive and Beige-like Anchor polypeptide useful
PT   for inhibiting growth of tumors in a patient.
XX
PS   Example 5; Page 45; 79pp; English.
XX
CC   This invention relates to a novel isolated LPS-responsive and Beige- like
CC   Anchor (Irba) polypeptide which may be used to inhibit tumour growth. The
CC   invention also comprises an interfering RNA sequence which may be used to
CC   suppress lrba function and inhibit tumour growth. The polypeptide and
CC   small interfering RNA (siRNA) molecules of the invention may have
CC   cytostatic activity and may be used in gene therapy. Also disclosed is a
CC   method for inhibiting tumour growth in a patient comprising administering
CC   to the patient an agent that suppresses Irba function in the patient. The
CC   agent may be a polynucleotide fragment of an Irba gene or its variant, or
CC   a polypeptide fragment of an Irba gene or its variant or an RNA sequence
CC   that interferes with the expression of the Irba gene. The method of the
CC   invention may be used to treat a patient who is suffering from a tumour
CC   or a cancer, such as breast, prostate, melanoma, cervical or colorectal
CC   cancer, chronic myelogenous leukemia, adenocarcinoma, lymphoblastic
CC   leukemia or lung carcinoma. The present sequence represents a DNA
CC   sequence used within the scope of the invention
XX
SQ   Sequence 18 BP; 3 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 58;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1615 TTCACCAGCCTGAAAA 1630
              |||| ||||||||||
Db         18 TTCAACAGCCTGAAAA 3


RESULT 86
ABT37667
ID   ABT37667 standard; DNA; 17 BP.
XX
AC   ABT37667;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 3304.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 420; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 66;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        975 CTGAGAAAAAATGT 988
              ||||||||||||||
Db          4 CTGAGAAAAAATGT 17
```

RESULT 87
AAT81545
ID AAT81545 standard; RNA; 17 BP.
XX
AC AAT81545;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 2874).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
PR 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX
DR WPI; 1996-010927/01.
XX
PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
PS Claim 1; Page 78; 128pp; English.
XX
CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 72;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1268 ACCAGGATTTCAGACTT 1284
              || || |:::|||||::
Db          1 ACUAGUAUUUCAGACUU 17
```

RESULT 88
AAT81546
ID AAT81546 standard; RNA; 17 BP.
XX
AC AAT81546;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 2875).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
PR 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX
DR WPI; 1996-010927/01.
XX
PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
PS Claim 1; Page 78; 128pp; English.
XX
CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 4 A; 3 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 72;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1269 CCAGGATTTCAGACTTT 1285
              | || |:::|||||:::
Db          1 CUAGUAUUUCAGACUUU 17
```

RESULT 89
AAT81503/c
ID AAT81503 standard; RNA; 17 BP.
XX
AC AAT81503;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 2703).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.

XX
PR 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX
DR WPI; 1996-010927/01.
XX
PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
PS Claim 1; Page 76; 128pp; English.
XX
CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 9 A; 0 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1452 AGTTTTTATAAAAGTAT 1468
              | |||||||||||| |||
Db         17 ATTTTTTATAAAACTAT 1
```

RESULT 90
AAX69956/c
ID AAX69956 standard; RNA; 17 BP.
XX
AC AAX69956;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human flt1 VEGF receptor hammerhead ribozyme substrate #1251.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 84; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 8 A; 4 C; 0 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1450 TTAGTTTTTATAAAAGT 1466
              || |||| |||||||||
Db         17 TTGGTTTGTATAAAAGT 1
```

RESULT 91
AAX69815
ID AAX69815 standard; RNA; 17 BP.
XX
AC AAX69815;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human flt1 VEGF receptor hammerhead ribozyme substrate #1110.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 80; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

```
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 10 A; 3 C; 0 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 72;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1159 TAACAAATAAAATTTTA 1175
              :||||||:||||  ::|
Db          1 UAACAAAUAAAACCUUA 17


RESULT 92
AAX69488
ID   AAX69488 standard; RNA; 17 BP.
XX
AC   AAX69488;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #783.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 70; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 72;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1101 CAGACTCTTCTACATTT 1117
              | ||| |::|:|||::: 
Db          1 CUGACCCUUCUACAUUU 17


RESULT 93
AAV97512/c
ID   AAV97512 standard; RNA; 17 BP.
XX
AC   AAV97512;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 2562.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 74; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        718 AAGGGGATGAGCTGTGT 734
              ||||| |||||||| ||
Db         17 AAGGGCATGAGCTGCGT 1


RESULT 94
AAA20415/c
ID   AAA20415 standard; RNA; 17 BP.
XX
AC   AAA20415;
XX
```

```
DT   19-JUN-2000  (first entry)
XX
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:3641.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 144; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 3 A; 3 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1147 TGCCTCAGGAAATAACA 1163
              || ||||||| ||||||
Db         17 TGACTCAGGACATAACA 1

RESULT 95
```

```
AAA21302/c
ID   AAA21302 standard; RNA; 17 BP.
XX
AC   AAA21302;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:4528.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 199; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 8 A; 3 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1423 TCTCTGATGAATATATA 1439
```

```
                    |||||| ||||| ||||
Db          17 TCTCTGTTGAATGTATA 1
```

RESULT 96
AAV91254/c
ID AAV91254 standard; RNA; 17 BP.
XX
AC AAV91254;
XX
DT 18-FEB-1999 (first entry)
XX
DE Human C-raf target site nucleotide position 2095.
XX
KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO9850530-A2.
XX
PD 12-NOV-1998.
XX
PF 05-MAY-1998; 98WO-US009249.
XX
PR 09-MAY-1997; 97US-0046059P.
PR 09-JUN-1997; 97US-0049002P.
PR 03-JUL-1997; 97US-0051718P.
PR 22-AUG-1997; 97US-0056808P.
PR 02-OCT-1997; 97US-0061321P.
PR 02-OCT-1997; 97US-0061324P.
PR 05-NOV-1997; 97US-0064866P.
PR 19-DEC-1997; 97US-0068212P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
PI Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR WPI; 1999-009494/01.
XX
PT Identifying new catalytic nucleic acid that modulates selected processes
PT - especially ribozymes that cleave Raf RNA for treating cancer,
PT restenosis, and also new ribozymes and modified nucleoside triphosphates
PT used as antiviral agents and synthons.
XX
PS Claim 177; Page 151; 259pp; English.
XX
CC A method has been developed for the identification of a nucleic acid
CC capable of modulating a process in a biological system. The method
CC comprises: (a) introducing into the system a random library of nucleic
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC in systems where modulation has occurred and/or determining the sequence
CC of at least part of the SBDs in such systems. Nucleic acid molecules with
CC endonuclease activity and catalytic activity, from the present invention,
CC are used to modulate gene expression in plant and mammalian cells and to
CC cleave target nucleic acid, particularly for treating systemic diseases
CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC ascites and infection. They may also be used to detect genetic drift and
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC with RNA-cleaving activity that modulate expression of the Raf gene, are
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC generally any condition associated with the level of c-raf. Introduction
CC of sugar/phosphate modifications increases stability against nuclease and
CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC method, specifically for modulating the expression of a Raf gene
XX
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;

```
  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        578 GCAGCCTGAAGAGTGGT 594
              |||||||||||  |||
Db         17 GCAGCCTGAAGACAGGT 1
```

RESULT 97
AAA80154/c
ID AAA80154 standard; DNA; 17 BP.
XX
AC AAA80154;
XX
DT 20-NOV-2000 (first entry)
XX
DE Hepatitis B virus related oligonucleotide probe #417.
XX
KW Hepatitis B virus; HBV; Hepatitis A virus; HAV; probe; detection;
KW mutation; high-density gene chip; ss.
XX
OS Hepatitis B virus.
XX
PN CN1252452-A.
XX
PD 10-MAY-2000.
XX
PF 24-SEP-1999; 99CN-00114460.
XX
PR 24-SEP-1999; 99CN-00114460.
XX
PA (UYDO-) UNIV DONGNAN.
XX
PI Sun X, Lu Z, Wang Y;
XX
DR WPI; 2000-443233/39.
XX
PT High-density gene chip making process.
XX
PS Example 1; Fig 15; 19pp; Chinese.
XX
CC The present invention describes a method which comprises making a high-
CC density gene chip, specifically for making high-density micro-array of
CC oligonucleotide probes. An oligonucleotide probe selecting process to
CC seek preferentially length variable and coverage variable probes is
CC provided to ensure identical cross melting temperature of probes to the
CC maximum limit, and this can make the cross control of gene chip
CC relatively simple and raise the reliability of the gene chip detecting
CC results. The process proposes a specific probe selection method for
CC detecting target sequence directly, detecting mutation in both specific
CC and non-specific sites and a probe overall arrangement scheme. AAA79738
CC to AAA80201 represent oligonucleotide probe sequences which are used in
CC examples from the present invention
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

```
  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1640 CTTTGCCTGTCTCCTGG 1656
              |||||||||  ||||  ||
Db         17 CTTTGCCTGACTCCGGG 1
```

RESULT 98
AAF05300
ID AAF05300 standard; DNA; 17 BP.
XX
AC AAF05300;
XX

DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #2519.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 18; Page 113; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 7 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 AAAGGTTTCTTCAGGAG 811
||| ||||||||| |||
Db 1 AAAAGTTTCTTCAAGAG 17

RESULT 99
AAH95461/c
ID AAH95461 standard; RNA; 17 BP.
XX
AC AAH95461;
XX
DT 09-OCT-2001 (first entry)
XX
DE Human Chk1 ribozyme substrate SEQ ID NO: 886.
XX
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157206-A2.
XX
PD 09-AUG-2001.
XX
PF 02-FEB-2001; 2001WO-US003504.
XX
PR 03-FEB-2000; 2000US-0179983P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (FATT/) FATTAEY A R.
XX
PI Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
XX
DR WPI; 2001-496922/54.
XX
PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT useful for treating colorectal, lung, breast or prostate cancers.
XX
PS Claim 4; Page 72; 115pp; English.
XX
CC The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 800 TTTCTTCAGGAGAAGCA 816
|||||||| |||||||
Db 17 TTTCTTCACTAGAAGCA 1

RESULT 100
ABK02291
ID ABK02291 standard; RNA; 17 BP.
XX
AC ABK02291;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO DNAzyme #203.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX

```
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 115; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a DNAzyme molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 72;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        606 ATATATGAACTCAGGCG 622
              |:| | ||||:||||||
Db          1 AUAAAGGAACUCAGGCG 17


RESULT 101
ABK02491/c
ID   ABK02491 standard; RNA; 17 BP.
XX
AC   ABK02491;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #163.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 134; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match              0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        567 TTCTACCCCCAGCAGCC 583
              || |||| |||||||||
Db         17 TTTTACCTCCAGCAGCC 1
```

```
RESULT 102
ABK40655/c
ID   ABK40655 standard; DNA; 17 BP.
XX
AC   ABK40655;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human beta1-adrenoceptor antisense oligonucleotide #77.
XX
KW   ss; antisense; beta1 adrenoceptor; beta1-AR; vasotropic; hypotensive;
KW   cardiant; hypertension; hypertrophy; cardiac ischaemia;
KW   cardiovascular disease; cardiac dysfunction.
XX
OS   Homo sapiens.
XX
PN   WO200204623-A2.
XX
PD   17-JAN-2002.
XX
PF   11-JUL-2001; 2001WO-US021759.
XX
PR   11-JUL-2000; 2000US-00614034.
XX
PA   (UYFL ) UNIV FLORIDA.
XX
PI   Phillips MI,  Zhang Y;
XX
DR   WPI; 2002-164644/21.
XX
PT   Novel antisense oligonucleotides that specifically bind to mRNA encoding
PT   beta 1-adrenoreceptor polypeptide, useful for treating cardiac
PT   dysfunction, hypertension, hypertrophy and other cardiovascular diseases
PT   in humans.
XX
PS   Claim 48; Page 19; 186pp; English.
XX
CC   The invention relates to an isolated antisense oligonucleotide of 9-35
CC   nucleotides in length, which specifically binds to a portion of an mRNA
CC   expressed from a gene encoding a mammalian beta1-adrenoceptor (AR)
CC   polypeptide and alters the translation of the mRNA into the beta1-AR
CC   polypeptide in a host cell expressing the mRNA. Also included are a
CC   recombinant vector comprising the antisense oligonucleotide, and a host
CC   cell comprising the vector. A composition comprising the antisense
CC   oligonucleotides is useful in the manufacture of a medicament for use in
CC   treating or ameliorating hypertension, hypertrophy and cardiac ischaemia
CC   in a mammal. A composition comprising the antisense oligonucleotides is
CC   also useful for reducing the level of beta1-AR polypeptide, the
CC   transcription of beta1-AR polypeptide-specific mRNA in a mammalian host
CC   cell, particularly human cell, and for decreasing blood pressure in a
CC   mammal, where the antisense oligonucleotide is operably linked to a
CC   promoter capable of expressing the oligonucleotide in the cell. A
CC   composition comprising a selected nucleic acid segment that comprises a
CC   full-length, or is a full length beta1-adrenoceptor antisense
CC   polynucleotide operatively linked to a promoter capable of expressing the
CC   polynucleotide in a cell is also useful for reducing the level of beta_1-
CC   adrenoceptor polypeptide in a mammalian host cell. The antisense
CC   oligonucleotide is also useful for other cardiovascular diseases and
CC   cardiac dysfunction in humans. The present sequence is a beta1-AR mRNA
CC   targetting antisense oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 2 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGCG 701
              ||| | ||||||||||||
Db         17 AGCTCGGCATGGGCGCG 1
```

```
RESULT 103
ABN09964
ID   ABN09964 standard; DNA; 17 BP.
XX
AC   ABN09964;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9956.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 9956; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
```

```
SQ   Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1075 AGAAAACTGAACTCACC 1091
              ||||||||||  ||| ||
Db          1 AGAAAACTGAGCTCTCC 17


RESULT 104
ABN09963
ID   ABN09963 standard; DNA; 17 BP.
XX
AC   ABN09963;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9955.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 9955; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1074 GAGAAAACTGAACTCAC 1090
              ||||||||||| ||| |
Db          1 GAGAAAACTGAGCTCTC 17


RESULT 105
ABN02266/c
ID   ABN02266 standard; DNA; 17 BP.
XX
AC   ABN02266;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2258.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2258; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
```

```
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1017 GAAGACAGTGAAGGTCG 1033
              || |||||||||||| |
Db         17 GAGGACAGTGAAGGTGG 1

RESULT 106
ABK18302
ID   ABK18302 standard; RNA; 17 BP.
XX
AC   ABK18302;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 949.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW   angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW   Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW   Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW   amberzyme.
XX
OS   Homo sapiens.
XX
PN   WO200188124-A2.
XX
PD   22-NOV-2001.
XX
PF   16-MAY-2001; 2001WO-US015866.
XX
PR   16-MAY-2000; 2000US-00572021.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (GLAX ) GLAXO GROUP LTD.
XX
PI   Jarvis T,  Von Carlowitz I,  Mcswiggen JA,  Mclaughlin F,  Randi AM;
XX
DR   WPI; 2002-082995/11.
XX
PT   Novel polynucleotide which down regulates expression of Ets-related gene,
PT   useful for treating cancer, diabetic retinopathy, macular degeneration,
PT   arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS   Claim 4; Page 76; 149pp; English.
XX
CC   The invention relates to a nucleic acid molecule (I) which down regulates
CC   expression of an Ets-related gene (ERG). (I) is useful for treating
CC   conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC   tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC   vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC   Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC   syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC   treating a patient having a condition associated with the level of ERG,
CC   by contacting cells of the patient with (I) under conditions suitable for
CC   the treatment. The method comprises the use of one or more therapies
CC   under conditions suitable for the treatment. Leukaemia or tumour
CC   angiogenesis is treated by administering (I) to the patient in
CC   conjunction with one or more of other therapies such as radiation or
CC   chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC   cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC   ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC   cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC   diseases related to the expression of ERG, and as diagnostic tool to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of ERG RNA in a cell. (I) is useful for specifically
CC   targeting genes that share homology with ERG gene or ERG fusion genes.
CC   ABK17354-ABK22719 represent nucleic acids, including antisense and
CC   enzymatic nucleic acid molecules which regulate expression of ERG, and
CC   related PCR primers of the invention
XX
SQ   Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 72;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1479 AAAATGACTCAAGAGGA 1495
              ||| :| |:||||||||
Db          1 AAAGUGCCUCAAGAGGA 17

RESULT 107
ABK17696
ID   ABK17696 standard; RNA; 17 BP.
XX
AC   ABK17696;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human ERG hammerhead ribozyme target sequence, Seq ID No 343.
XX
KW   Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW   ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW   vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW   tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW   neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW   angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW   Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW   Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW   amberzyme.
XX
OS   Homo sapiens.
XX
PN   WO200188124-A2.
XX
PD   22-NOV-2001.
XX
PF   16-MAY-2001; 2001WO-US015866.
XX
PR   16-MAY-2000; 2000US-00572021.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (GLAX ) GLAXO GROUP LTD.
XX
```

PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 65; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 9 A; 2 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 72;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1248 GTAGAATTCACAAAAAA 1264
              |:||||::|| ||| ||
Db          1 GUAGAAUUCAGAAACAA 17
```

RESULT 108
ABK17827/c
ID ABK17827 standard; RNA; 17 BP.
XX
AC ABK17827;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 474.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 67; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1357 TTTTCAATAAGAAACTT 1373
              ||||||.||||.|||||
Db         17 TTTTCATTAAGCAACTT 1
```

RESULT 109
ABT38914/c
ID ABT38914 standard; DNA; 17 BP.
XX
AC ABT38914;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 4551.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX

PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 566; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1082 TGAACTCACCCCAGATC 1098
              || |||||| |||||||
Db         17 TGCACTCACACCAGATC 1
```

RESULT 110
ABT39538
ID ABT39538 standard; DNA; 17 BP.
XX
AC ABT39538;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5175.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 639; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        713 GATCAAAGGGGATGAGC 729
              |||||| | ||||||||
Db          1 GATCAAGGAGGATGAGC 17
```

RESULT 111
ABT38532
ID ABT38532 standard; DNA; 17 BP.
XX
AC ABT38532;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 4169.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX

PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 521; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 668 GATGCCTGTAACAAAGA 684
||| ||||||||| |||
Db 1 GATCCCTGTAACACAGA 17

RESULT 112
ABT34842
ID ABT34842 standard; DNA; 17 BP.
XX
AC ABT34842;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 479.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 90; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 713 GATCAAAGGGGATGAGC 729
||||||||| ||||| |
Db 1 GATCAAAGGTGATGACC 17

RESULT 113
ACA09096
ID ACA09096 standard; RNA; 17 BP.
XX
AC ACA09096;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating amberzyme substrate #259.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.

XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-00864785.
XX
PR 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
PA (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX
DR WPI; 2003-340953/32.
XX
PT Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS Claim 3; Page 56; 72pp; English.
XX
CC The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 7 A; 3 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 72;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 803 CTTCAGGAGAAGCATTA 819
|:: || |||||||::|
Db 1 CUUAAGCAGAAGCAUUA 17

RESULT 114
ABZ20919
ID ABZ20919 standard; DNA; 17 BP.
XX
AC ABZ20919;
XX
DT 26-MAR-2003 (first entry)
XX
DE MT4-MMP catalytic domain antibody related oligonucleotide #4.
XX
KW MT4-MMP; catalytic domain; antibody; inflammation; cancer; PCR;
KW membrane type-matrix metalloproteinase; antiinflammatory; antirheumatoid;
KW antiarthritic; rheumatoid arthritis; cytostatic; primer; ss.
XX
OS Unidentified.
XX
PN WO2002101046-A1.
XX
PD 19-DEC-2002.
XX
PF 11-JUN-2002; 2002WO-JP005788.
XX
PR 11-JUN-2001; 2001JP-00176256.
XX
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
PI Miki I, Ohta S, Shitara K, Furuya A;
XX
DR WPI; 2003-148808/14.
XX
PT Monoclonal antibody specifically binding to natural or solubilized MT4-
PT MMP, applicable in diagnosis and remedies for MT4-MMP participated
PT diseases e.g. inflammations and cancer particularly rheumatoid arthritis.
XX
PS Disclosure; Page 50; 63pp; Japanese.
XX
CC The present invention relates to a monoclonal antibody which binds
CC specifically to the MT4-MMP (membrane type-matrix metalloproteinase)
CC catalytic domain. The antibody is applicable in diagnosis and remedies
CC for MT4-MMP participated diseases e.g. inflammations and cancer
CC particularly rheumatoid arthritis. The present sequence is an
CC oligonucleotide shown in the exemplification of the invention
XX
SQ Sequence 17 BP; 3 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 859 GTGTGATGGATATGTAC 875
||||||||||||| | |
Db 1 GTGTGATGGATATCTGC 17

RESULT 115
ACC65419/c
ID ACC65419 standard; DNA; 17 BP.
XX
AC ACC65419;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 2666.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 342; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1274 ATTTCAGACTTTGGACC 1290
|| |||||||||||| |
Db 17 ATGTCAGACTTTGGATC 1

RESULT 116
ADB40369
ID ADB40369 standard; DNA; 17 BP.
XX
AC ADB40369;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #692.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 113; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 8 A; 4 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 72;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1125 GATTCATATAACAAACA 1141
||| ||| |||||||||
Db 1 GATCCATTTAACAAACA 17

RESULT 117
ADB40537
ID ADB40537 standard; DNA; 17 BP.
XX
AC ADB40537;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #860.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 132; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and

```
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1095 GATCAACAGACTCTTCT 1111
              ||||||||| ||| |||
Db          1 GATCAACAGCCTCCTCT 17


RESULT 118
ADE30808/c
ID   ADE30808 standard; DNA; 17 BP.
XX
AC   ADE30808;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Cholesterol homeostasis/adipogenesis related DNA seq id 195.
XX
KW   expression vector; anorectic; antiarteriosclerotic; cardiant;
KW   antidiabetic; elevated cholesterol; elevated lipid; adipogenesis;
KW   obesity; athersclerosis; diabetes mellitus;
KW   coronary artery heart disease; cholesterol homeostasis; ss;
KW   differntial expression.
XX
OS   Homo sapiens.
XX
PN   US2003180764-A1.
XX
PD   25-SEP-2003.
XX
PF   08-JAN-2003; 2003US-00339793.
XX
PR   09-JAN-2002; 2002US-0347286P.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Shang J,  Bowen B;
XX
DR   WPI; 2003-830986/77.
XX
PT   Polynucleotides differentially regulated in response to cholesterol and
PT   adipogenesis are useful to detect and treat associated conditions such as
PT   obesity, athersclerosis, diabetes mellitus and coronary artery heart
PT   disease.
XX
PS   Claim 8; SEQ ID NO 195; 59pp; English.
XX
CC   The invention describes a composition comprising at least one expression
CC   vector comprising a polynucleotide of the invention. The composition has
CC   anorectic, antiarteriosclerotic, cardiant and antidiabetic properties.
CC   The invention is used to detect and treat conditions associated with
CC   elevated cholesterol and lipid or during adipogenesis, particularly
CC   obesity, athersclerosis, diabetes mellitus or coronary artery heart
CC   disease. This sequence represents a polynucleotide differentially
CC   expressed during cholesterol homeostasis and adipogenesis.
XX
SQ   Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1082 TGAACTCACCCCAGATC 1098
              || |||||| |||||||
Db         17 TGCACTCACACCAGATC 1


RESULT 119
AAT37715/c
ID   AAT37715 standard; mRNA; 15 BP.
XX
AC   AAT37715;
XX
DT   13-NOV-1996  (first entry)
XX
DE   Apo(a) mRNA (nt. pos. 11254) hammerhead ribozyme target sequence.
XX
KW   Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW   hammerhead ribozyme; target sequence; diagnosis; treatment;
KW   lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW   restenosis; heart disease; monkey; ss.
XX
OS   Cebus apella.
XX
PN   WO9609392-A1.
XX
PD   28-MAR-1996.
XX
PF   21-SEP-1995;   95WO-US011995.
XX
PR   23-SEP-1994;   94US-00311760.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Newton RS,  Ramharack R;
XX
DR   WPI; 1996-188454/19.
XX
PT   Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT   treatment of conditions related to Lp(a) levels, e.g. atherosclerosis,
PT   myocardial infarction, and heart diseases.
XX
PS   Claim 3; Page 21; 37pp; English.
XX
CC   A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC   (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC   complementary to the present sequence (nucleotide position 11254). The
CC   ribozyme blocks to some extent apo(a) expression, and can therefore be
CC   used to diagnose or treat conditions related to lipoprotein (a) levels,
CC   e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC   disease. PCR was used to generate a substrate for T7 RNA polymerase
CC   transcription from monkey apo(a) cDNA clones. Labelled transcripts were
CC   synthesised in vitro to form 2 templates. The oligonucleotides and
CC   labelled transcripts were annealed, RNaseH added and the mixts.
CC   incubated. After a designated time the reactions were stopped, and RNA
CC   sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC   cleaved was determined by autoradiographic quantification, and the most
CC   accessible ribozyme target sites chosen
XX
SQ   Sequence 15 BP; 4 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 78;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        801 TTCTTCAGGAGAAGC 815
              ||||||| ||||||
Db         15 TTCTTCAGAAGAAGC 1


RESULT 120
AAV48847/c
ID   AAV48847 standard; DNA; 15 BP.
```

```
XX
AC   AAV48847;
XX
DT   15-OCT-1998  (first entry)
XX
DE   ErbB-2 gene antisense oligonucleotide ErbB-2-N-56.
XX
KW   ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 4; Fig 6c; 286pp; English.
XX
CC   AAV48709-886 represent antisense oligonucleotides directed against the
CC   ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in
CC   significant redcution in ErbB-2 protein expression, while
CC   oligonucleotides AAV48792-886 had little effect. The oligonucleotides
CC   exemplify the invention. The specification describes oligonucleotides
CC   that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC   can each form three hydrogen bonds to cytosine; do not contain four
CC   consecutive nucleotides able to form three H-bonds each to four
CC   consecutive cytosines; do not contain two sequences of three consecutive
CC   nucleotides each able to form three H-bonds to three consecutive
CC   cytosines, and the ratio between residues able to form two H-bonds each
CC   (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC   oligonucleotides are used to modulate expression of genes, particularly
CC   the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC   proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC   kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC   oligonucleotides can also be used to analyse function of proteins (by
CC   altering their expression or activity) and therapeutically, e.g. in cases
CC   of cancer or (targeting TGF) for stimulating the immune system
XX
SQ   Sequence 15 BP; 10 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 78;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTTTA 1459
              | ||||||||||||||
Db         15 TCTGTTTAGTTTTTA 1

RESULT 121
AAF47996/c
ID   AAF47996 standard; DNA; 15 BP.
XX
AC   AAF47996;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #1416.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 7; Page 53; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 6 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 78;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        788 GGGGTGTAAAGGTTT 802
              ||||| |||||||||
Db         15 GGGGTTTAAAGGTTT 1

RESULT 122
ABL31461/c
ID   ABL31461 standard; DNA; 15 BP.
XX
AC   ABL31461;
XX
DT   21-MAR-2002  (first entry)
XX
DE   Human HLA genotyping oligonucleotide SEQ ID NO 950.
XX
KW   Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW   immunogenetic; transplantation; genetic disease; ss.
```

XX
OS Homo sapiens.
XX
PN WO200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP004662.
XX
PR 01-JUN-2000; 2000JP-00164798.
XX
PA (NISN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
DR WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
PS Claim 10; Page 273; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 15 BP; 7 A; 1 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 78;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1640 CTTTGCCTGTCTCCT 1654
||||.||||||||||
Db 15 CTTTCCCTGTCTCCT 1

RESULT 123
AAI64950/c
ID AAI64950 standard; DNA; 16 BP.
XX
AC AAI64950;
XX
DT 04-DEC-2001 (first entry)
XX
DE Human Cream1 protein coding sequence intron 11/exon 12 junction.
XX
KW Human; Cream1; repeat; transcriptional control factor; Rb;
KW retinoblastoma protein; intron-exon junction; ds.
XX
OS Homo sapiens.
XX
PN CN1303861-A.
XX
PD 18-JUL-2001.
XX
PF 07-JAN-2000; 2000CN-00111426.
XX
PR 07-JAN-2000; 2000CN-00111426.
XX
PA (SHAN-) SHANGHAI INST CYTOBIOLOGY CHINESE ACAD.
XX
PI Zhu X, Yan X, Qian M;
XX
DR WPI; 2001-566148/64.
XX
PT New retinoblastoma protein binding protein, its preparation and
PT application.
XX
PS Disclosure; Fig 3B; 35pp; Chinese.
XX
CC The present invention relates to the coding sequence of human Cream1,
CC which is a protein containing a repetitive 86 amino acid motif. The
CC protein is a transcriptional control factor, and is a conjugate of
CC retinoblastoma protein (Rb). The present sequence is the an intron-exon
CC junction in the coding sequence of the invention
XX
SQ Sequence 16 BP; 4 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 777 CTGACCTGTGAGGGG 791
||||||||||| |||
Db 15 CTGACCTGTGAAGGG 1

RESULT 124
AAV10983
ID AAV10983 standard; RNA; 13 BP.
XX
AC AAV10983;
XX
DT 25-MAR-2003 (revised)
DT 14-JUL-1998 (first entry)
XX
DE Human ribozyme target sequence from HLA-B exon 4 #2.
XX
KW Ribozyme; target; human lymphocyte antigen; HLA-B; MHC allele;
KW major histocompatability complex; cleavage; suppression; transplant;
KW incompatibility; autoimmune disease; juvenile diabetes;
KW rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO9704087-A1.
XX
PD 06-FEB-1997.
XX
PF 18-JUL-1996; 96WO-EP003173.
XX
PR 18-JUL-1995; 95EP-00111256.
XX
PA (KRUP/) KRUPP G.
PA (MARG/) MARGET M.
PA (WEST/) WESTPHAL E.
PA (MUEL/) MUELLER-RUCHHOLTZ W.
XX
PI Krupp G, Marget M, Westphal E, Mueller-Ruchholtz W;
XX
DR WPI; 1997-132628/12.
XX
PT Ribozyme that cleaves specific MHC allele(s) - used to inhibit graft
PT versus host reactions, to overcome blood incompatibility and to treat
PT auto:immune disease.
XX
PS Claim 5; Fig 1; 76pp; German.
XX
CC AAV10915-V11123 are target sequences for a novel ribozyme which cleaves
CC specific alleles from the major histocompatability complex (MHC). This
CC ribozyme contains a catalytic region and a hybridisation region which is
CC complementary to all mRNA transcribed from vertebrate genes of a specific
CC family of closely related MHC alleles or to mRNA from a single MHC
CC allele, and is able to cleave such mRNA. The mRNA has a target region

```
CC   which in case is essentially conserved in all genes of the family but
CC   differs from genes of all other MHC alleles to such a degree that no
CC   cleavage of mRNA transcribed from these other alleles occurs. This allows
CC   the selective reduction or inhibition of expression of all genes of a
CC   family or of a single gene. This ribozyme can be used for permanent or
CC   transient suppression of expression of MHC alleles, in vivo or in vitro.
CC   Specific applications are to prevent guest vs. host or host vs. guest
CC   reactions, to prevent blood incompatibilities (partic. of the ABO, rhesus
CC   and Kell systems) and to treat autoimmune diseases such as juvenile
CC   diabetes and rheumatoid arthritis. The use of this ribozyme avoids the
CC   need for immunosuppressants in transplant patients. It provides very
CC   specific reduction of particular HLA molecules that cause incompatibility
CC   between donor and recipient. (Updated on 25-MAR-2003 to correct PA
CC   field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 13 BP; 1 A; 4 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   61.5%;  Pred. No. 84;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        560 CCTGGGTTTCTAC 572
              ||:|||:::|:||
Db          1 CCUGGGUUUCUAC 13


RESULT 125
ABC82063/c
ID   ABC82063 standard; DNA; 13 BP.
XX
AC   ABC82063;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 82080 for detecting SNP TSC0020752.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 82080; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1448 GTTTAGTTTTTAT 1460
              |||||||||||||
Db         13 GTTTAGTTTTTAT 1


RESULT 126
ABF77671
ID   ABF77671 standard; DNA; 13 BP.
XX
AC   ABF77671;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 177668 for detecting SNP TSC0005430.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 177668; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1252 AATTCACAAAAAA 1264
              |||||||||||||
Db          1 AATTCACAAAAAA 13
```

```
RESULT 127
ABF42907/c
ID   ABF42907 standard; DNA; 13 BP.
XX
AC   ABF42907;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 142904 for detecting SNP TSC0035843.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 142904; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1165 ATAAAATTTTAAA 1177
              |||||||||||||
Db         13 ATAAAATTTTAAA 1


RESULT 128
ABF60108
ID   ABF60108 standard; DNA; 13 BP.
XX
AC   ABF60108;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 160105 for detecting SNP TSC0040306.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 160105; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db          1 TGTTTAGTTTTTA 13


RESULT 129
ABF90851
ID   ABF90851 standard; DNA; 13 BP.
XX
AC   ABF90851;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 190848 for detecting SNP TSC0046944.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 190848; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1160 AACAAATAAAATT 1172
||||||||||||||
Db 1 AACAAATAAAATT 13

RESULT 130
ABC01400/c
ID ABC01400 standard; DNA; 13 BP.
XX
AC ABC01400;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 1391 for detecting SNP TSC0000491.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 1391; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAA 1168
||||||||||||||
Db 13 AAATAACAAATAA 1

RESULT 131
ABH40300/c
ID ABH40300 standard; DNA; 13 BP.
XX
AC ABH40300;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240277 for detecting SNP TSC0058601.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 240277; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;

```
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1162 CAAATAAAATTTT 1174
              |||||||||||||
Db         13 CAAATAAAATTTT 1

RESULT 132
ABC18409
ID   ABC18409 standard; DNA; 13 BP.
XX
AC   ABC18409;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 18416 for detecting SNP TSC0003901.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 18416; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1157 AATAACAAATAAA 1169
              |||||||||||||
Db          1 AATAACAAATAAA 13

RESULT 133
ABC82062
ID   ABC82062 standard; DNA; 13 BP.
XX
AC   ABC82062;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 82079 for detecting SNP TSC0020752.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 82079; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1448 GTTTAGTTTTTAT 1460
              |||||||||||||
Db          1 GTTTAGTTTTTAT 13

RESULT 134
ABC08004
ID   ABC08004 standard; DNA; 13 BP.
XX
AC   ABC08004;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 7995 for detecting SNP TSC0002255.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
```

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 7995; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1451 TAGTTTTTATAAA 1463
||||||||||||
Db 1 TAGTTTTTATAAA 13

RESULT 135
ABC37607/c
ID ABC37607 standard; DNA; 13 BP.
XX
AC ABC37607;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37624 for detecting SNP TSC0011703.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 37624; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1446 ATGTTTAGTTTTT 1458
|||||||||||||
Db 13 ATGTTTAGTTTTT 1

RESULT 136
ABC64450
ID ABC64450 standard; DNA; 13 BP.
XX
AC ABC64450;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 64467 for detecting SNP TSC0017002.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 64467; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

```
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1116 TTTATTATGGATT 1128
              |||||||||||||
Db          1 TTTATTATGGATT 13


RESULT 137
ABC39964
ID   ABC39964 standard; DNA; 13 BP.
XX
AC   ABC39964;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 39981 for detecting SNP TSC0012181.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 39981; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 0 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1547 AAAGGATAGAGAG 1559
              |||||||||||||
Db          1 AAAGGATAGAGAG 13


RESULT 138
ABC79783/c
ID   ABC79783 standard; DNA; 13 BP.
XX
AC   ABC79783;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 79800 for detecting SNP TSC0020264.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 79800; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        735 GTTGTTTGTGGAG 747
              |||||||||||||
Db         13 GTTGTTTGTGGAG 1


RESULT 139
ABC39965/c
ID   ABC39965 standard; DNA; 13 BP.
XX
AC   ABC39965;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 39982 for detecting SNP TSC0012181.
XX
```

```
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 39982; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1547 AAAGGATAGAGAG 1559
             |||||||||||||
Db         13 AAAGGATAGAGAG 1


RESULT 140
ABF20975/c
ID   ABF20975 standard; DNA; 13 BP.
XX
AC   ABF20975;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 120972 for detecting SNP TSC0030183.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 120972; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 4 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1395 TTGGAAGAAAGAA 1407
             |||||||||||||
Db         13 TTGGAAGAAAGAA 1


RESULT 141
ABF53585/c
ID   ABF53585 standard; DNA; 13 BP.
XX
AC   ABF53585;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 153582 for detecting SNP TSC0038830.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 153582; 29pp + Sequence Listing; German.
XX
```

```
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        736 TTGTTTGTGGAGA 748
              |||||||||||||
Db         13 TTGTTTGTGGAGA 1


RESULT 142
ABF94684
ID   ABF94684 standard; DNA; 13 BP.
XX
AC   ABF94684;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 194681 for detecting SNP TSC0047884.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 194681; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 0 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1170 ATTTTAAAAGAAG 1182
              |||||||||||||
Db          1 ATTTTAAAAGAAG 13


RESULT 143
ABF77670/c
ID   ABF77670 standard; DNA; 13 BP.
XX
AC   ABF77670;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 177667 for detecting SNP TSC0005430.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 177667; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1252 AATTCACAAAAAA 1264
              |||||||||||||
Db         13 AATTCACAAAAAA 1


RESULT 144
ABF60109/c
```

```
ID   ABF60109 standard; DNA; 13 BP.
XX
AC   ABF60109;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 160106 for detecting SNP TSC0040306.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 160106; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
             |||||||||||||
Db         13 TGTTTAGTTTTTA 1

RESULT 145
ABC18408/c
ID   ABC18408 standard; DNA; 13 BP.
XX
AC   ABC18408;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 18415 for detecting SNP TSC0003901.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 18415; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1157 AATAACAAATAAA 1169
             |||||||||||||
Db         13 AATAACAAATAAA 1

RESULT 146
ABC79782
ID   ABC79782 standard; DNA; 13 BP.
XX
AC   ABC79782;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 79799 for detecting SNP TSC0020264.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
```

DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 79799; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 735 GTTGTTTGTGGAG 747
||||||||||||||
Db 1 GTTGTTTGTGGAG 13

RESULT 147
ABC07509/c
ID ABC07509 standard; DNA; 13 BP.
XX
AC ABC07509;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 7500 for detecting SNP TSC0002171.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 7500; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1163 AAATAAAATTTTA 1175
||||||||||||||
Db 13 AAATAAAATTTTA 1

RESULT 148
ABF20974
ID ABF20974 standard; DNA; 13 BP.
XX
AC ABF20974;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 120971 for detecting SNP TSC0030183.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 120971; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 0 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1395 TTGGAAGAAAGAA 1407
              |||||||||||||
Db          1 TTGGAAGAAAGAA 13


RESULT 149
ABF42906
ID   ABF42906 standard; DNA; 13 BP.
XX
AC   ABF42906;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 142903 for detecting SNP TSC0035843.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 142903; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 0 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1165 ATAAAATTTTAAA 1177
              |||||||||||||
Db          1 ATAAAATTTTAAA 13


RESULT 150
ABF88708/c
ID   ABF88708 standard; DNA; 13 BP.
XX
AC   ABF88708;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188705 for detecting SNP TSC0046458.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 188705; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 0 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1107 CTTCTACATTTTA 1119
              |||||||||||||
Db         13 CTTCTACATTTTA 1


RESULT 151
ABF86380
ID   ABF86380 standard; DNA; 13 BP.
XX
AC   ABF86380;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 186377 for detecting SNP TSC0045896.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
```

```
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 186377; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 0 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1164 AATAAAATTTTAA 1176
              |||||||||||||
Db          1 AATAAAATTTTAA 13


RESULT 152
ABC01401
ID   ABC01401 standard; DNA; 13 BP.
XX
AC   ABC01401;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 1392 for detecting SNP TSC0000491.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 1392; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAA 1168
              |||||||||||||
Db          1 AAATAACAAATAA 13


RESULT 153
ABC64451/c
ID   ABC64451 standard; DNA; 13 BP.
XX
AC   ABC64451;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 64468 for detecting SNP TSC0017002.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 64468; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
```

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1116 TTTATTATGGATT 1128
||||||||||||||
Db 13 TTTATTATGGATT 1

RESULT 154
ABF86381/c
ID ABF86381 standard; DNA; 13 BP.
XX
AC ABF86381;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 186378 for detecting SNP TSC0045896.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 186378; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1164 AATAAAATTTTAA 1176
||||||||||||||
Db 13 AATAAAATTTTAA 1

RESULT 155
ABC07508
ID ABC07508 standard; DNA; 13 BP.
XX
AC ABC07508;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 7499 for detecting SNP TSC0002171.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 7499; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1163 AAATAAAATTTTA 1175
||||||||||||||
Db 1 AAATAAAATTTTA 13

RESULT 156
ABF51767/c
ID ABF51767 standard; DNA; 13 BP.
XX
AC ABF51767;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 151764 for detecting SNP TSC0038341.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151764; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1456 TTTATAAAAGTAT 1468
              |||||||||||||
Db         13 TTTATAAAAGTAT 1


RESULT 157
ABF90850/c
ID   ABF90850 standard; DNA; 13 BP.
XX
AC   ABF90850;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 190847 for detecting SNP TSC0046944.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 190847; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AACAAATAAAATT 1172
              |||||||||||||
Db         13 AACAAATAAAATT 1


RESULT 158
ABC08005/c
ID   ABC08005 standard; DNA; 13 BP.
XX
AC   ABC08005;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 7996 for detecting SNP TSC0002255.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 7996; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
```

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1451 TAGTTTTTATAAA 1463
              |||||||||||||
Db         13 TAGTTTTTATAAA 1

RESULT 159
ABF51766
ID   ABF51766 standard; DNA; 13 BP.
XX
AC   ABF51766;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 151763 for detecting SNP TSC0038341.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151763; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1456 TTTATAAAAGTAT 1468
              |||||||||||||
Db          1 TTTATAAAAGTAT 13

RESULT 160
ABH40301
ID   ABH40301 standard; DNA; 13 BP.
XX
AC   ABH40301;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 240278 for detecting SNP TSC0058601.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 240278; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1162 CAAATAAAATTTT 1174
              |||||||||||||
Db          1 CAAATAAAATTTT 13

RESULT 161
ABC37606
ID   ABC37606 standard; DNA; 13 BP.
XX
```

```
AC   ABC37606;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 37623 for detecting SNP TSC0011703.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 37623; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1446 ATGTTTAGTTTTT 1458
              |||||||||||||
Db          1 ATGTTTAGTTTTT 13


RESULT 162
ABF88709
ID   ABF88709 standard; DNA; 13 BP.
XX
AC   ABF88709;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188706 for detecting SNP TSC0046458.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 188706; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 3 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1107 CTTCTACATTTTA 1119
              |||||||||||||
Db          1 CTTCTACATTTTA 13


RESULT 163
ABF94685/c
ID   ABF94685 standard; DNA; 13 BP.
XX
AC   ABF94685;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 194682 for detecting SNP TSC0047884.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 194682; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 2 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1170 ATTTTAAAAGAAG 1182
||||||||||||||
Db 13 ATTTTAAAAGAAG 1

RESULT 164
ABF53584
ID ABF53584 standard; DNA; 13 BP.
XX
AC ABF53584;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 153581 for detecting SNP TSC0038830.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 153581; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 736 TTGTTTGTGGAGA 748
||||||||||||||
Db 1 TTGTTTGTGGAGA 13

RESULT 165
AAQ92723
ID AAQ92723 standard; DNA; 14 BP.
XX
AC AAQ92723;
XX
DT 13-FEB-1996 (first entry)
XX
DE c-erbB-2 antisense nucleic acid #66.
XX
KW Antisense nucleic acid; c-erbB-2; inhibition; fibroblast; neoplasm;
KW p185-erbB-2 protein tyrosine kinase; tumour; breast cancer; detection;
KW immune disease; angiogenesis; ss.
XX
OS Synthetic.
XX
PN WO9517507-A1.
XX
PD 29-JUN-1995.
XX
PF 09-DEC-1994; 94WO-EP004094.
XX
PR 23-DEC-1993; 93EP-00120710.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Brysch W, Schlingensiepen K, Schlingensiepen R, Schlingensiepen G;
XX
DR WPI; 1995-240669/31.
XX
PT New anti:sense nucleic acid against C-erbB-2 - for treating or preventing
PT neoplasms, immune disease and angiogenesis, also for diagnosis.
XX
PS Claim 1; Page 35; 55pp; English.
XX
CC The sequences given in AAQ92658-762 are antisense nucleic acids which
CC hybridise with part of the mRNA and/or DNA encoding c-erbB-2. These
CC antisense nucleic acids are able to inhibit the expression of the p185-
CC erbB-2 protein tyrosine kinase activity and cell growth in a number of
CC tumour cells including breast cancer cells. Untransformed normal
CC fibroblasts are not growth inhibited by anti-c-erbB-2 antisense compounds
CC suggesting that p185-erbB-2 plays a pathogenic role in the growth of the
CC above mentioned tumours. These antisense oligonucleotides may be used in
CC the prevention and treatment of neoplasms, immune diseases and/or
CC diseases involving pathological angiogenesis when associated with c-erbB-
CC 2 expression. They may also be used to detect expression of the relevant
CC genes
XX
SQ Sequence 14 BP; 3 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1632 CCTCAACACTTTG 1644
||||||||||||||

```
Db          2 CCTCAACACTTTG 14

RESULT 166
AAV48848/c
ID   AAV48848 standard; DNA; 14 BP.
XX
AC   AAV48848;
XX
DT   15-OCT-1998  (first entry)
XX
DE   ErbB-2 gene antisense oligonucleotide ErbB-2-N-57.
XX
KW   ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 4; Fig 6c; 286pp; English.
XX
CC   AAV48709-886 represent antisense oligonucleotides directed against the
CC   ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in
CC   significant redcution in ErbB-2 protein expression, while
CC   oligonucleotides AAV48792-886 had little effect. The oligonucleotides
CC   exemplify the invention. The specification describes oligonucleotides
CC   that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC   can each form three hydrogen bonds to cytosine; do not contain four
CC   consecutive nucleotides able to form three H-bonds each to four
CC   consecutive cytosines; do not contain two sequences of three consecutive
CC   nucleotides each able to form three H-bonds to three consecutive
CC   cytosines, and the ratio between residues able to form two H-bonds each
CC   (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC   oligonucleotides are used to modulate expression of genes, particularly
CC   the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC   proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC   kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC   oligonucleotides can also be used to analyse function of proteins (by
CC   altering their expression or activity) and therapeutically, e.g. in cases
CC   of cancer or (targeting TGF) for stimulating the immune system
XX
SQ   Sequence 14 BP; 9 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match              0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 88;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         13 TGTTTAGTTTTTA 1

RESULT 167
AAV48849/c
ID   AAV48849 standard; DNA; 14 BP.
XX
AC   AAV48849;
XX
DT   15-OCT-1998  (first entry)
XX
DE   ErbB-2 gene antisense oligonucleotide ErbB-2-N-58.
XX
KW   ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 4; Fig 6c; 286pp; English.
XX
CC   AAV48709-886 represent antisense oligonucleotides directed against the
CC   ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in
CC   significant redcution in ErbB-2 protein expression, while
CC   oligonucleotides AAV48792-886 had little effect. The oligonucleotides
CC   exemplify the invention. The specification describes oligonucleotides
CC   that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC   can each form three hydrogen bonds to cytosine; do not contain four
CC   consecutive nucleotides able to form three H-bonds each to four
CC   consecutive cytosines; do not contain two sequences of three consecutive
CC   nucleotides each able to form three H-bonds to three consecutive
CC   cytosines, and the ratio between residues able to form two H-bonds each
CC   (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC   oligonucleotides are used to modulate expression of genes, particularly
CC   the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC   proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC   kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC   oligonucleotides can also be used to analyse function of proteins (by
CC   altering their expression or activity) and therapeutically, e.g. in cases
CC   of cancer or (targeting TGF) for stimulating the immune system
XX
SQ   Sequence 14 BP; 9 A; 2 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match              0.6%;  Score 13;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 88;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1447 TGTTTAGTTTTTA 1459
              |||||||||||||
Db         14 TGTTTAGTTTTTA 2

RESULT 168
AAX66868
ID   AAX66868 standard; RNA; 15 BP.
XX
AC   AAX66868;
XX
DT   20-JUL-1999  (first entry)
```

```
XX
DE   Mouse CD40 hammerhead ribozyme target SEQ ID NO:3500.
XX
KW   Arthritic condition; graft tolerance; immune response; target; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW   stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW   rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW   diagnosis; ss.
XX
OS   Mus sp.
XX
PN   WO9618736-A2.
XX
PD   20-JUN-1996.
XX
PF   22-NOV-1995;   95WO-US015516.
XX
PR   13-DEC-1994;   94US-00354920.
PR   23-DEC-1994;   94US-00363253.
PR   23-DEC-1994;   94US-00363254.
PR   17-FEB-1995;   95US-00390850.
PR   20-APR-1995;   95US-00426124.
PR   02-MAY-1995;   95US-00432874.
PR   04-MAY-1995;   95US-00434509.
PR   07-JUL-1995;   95US-0000951P.
PR   07-JUL-1995;   95US-0000974P.
PR   07-AUG-1995;   95US-00512861.
PR   05-OCT-1995;   95US-00541365.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Beigelman L,  Stinchcomb DT,  Jarvis T,  Draper K,  Pavco P;
PI   Mcswiggen J,  Gustofson J,  Usman N,  Wincott F,  Matulic-Adamic J;
PI   Karpeisky A,  Thompson JD,  Modak A,  Burgin A;
XX
DR   WPI; 1996-300653/30.
XX
PT   Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT   the treatment of arthritis, induction of graft tolerance or treatment of
PT   auto-immune diseases.
XX
PS   Claim 10; Page 210; 307pp; English.
XX
CC   The present invention describes a novel enzymatic nucleic acid (ENA)
CC   having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC   ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC   ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC   can inhibit collagenase and stromelysin production in the synovial
CC   membrane of joints for the treatment or prevention of arthritis,
CC   particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC   be used to treat antigen presenting cells of a donor to induce tolerance
CC   in a recipient to an alloantigen of a donor. They can also be used for
CC   enhancing graft tolerance or for treating autoimmune disease, and for
CC   treating allergies and other inflammatory conditions. The ENA's can also
CC   be used in diagnosis. Ribozyme therapy impacts on the expression of
CC   stromelysin without introducing the non-specific effects upon gene
CC   expression which accompany treatment with retinoids and dexamethasone.
CC   The concentration of ribozyme required to affect a therapeutic treatment
CC   is lower than that required of antisense molecules, and is highly
CC   specific. The present sequence is used in the exemplification of the
CC   present invention
XX
SQ   Sequence 15 BP; 1 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   61.5%;  Pred. No. 92;
  Matches    8;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 CTGGGTTTCTACC 573
              |:|||:::|:|||
Db          1 CUGGGUUUCUACC 13
```

```
RESULT 169
AAZ62853
ID   AAZ62853 standard; RNA; 15 BP.
XX
AC   AAZ62853;
XX
DT   28-MAR-2000  (first entry)
XX
DE   Substrate for HH ribozyme HCV-9065 which cleaves HCV RNA at nt. 9065.
XX
KW   Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW   cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW   autoimmune disease; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO9955847-A2.
XX
PD   04-NOV-1999.
XX
PF   26-APR-1999;   99WO-US009027.
XX
PR   27-APR-1998;   98US-0083217P.
PR   18-SEP-1998;   98US-0100842P.
PR   25-FEB-1999;   99US-00257608.
PR   23-MAR-1999;   99US-00274553.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Mcswiggen JA,  Roberts E,  Pavco PA,  Macejak D;
XX
DR   WPI; 2000-062023/05.
XX
PT   Novel ribozymes for the treatment of diseases and conditions related to
PT   hepatitis C infection.
XX
PS   Claim 1; Page 65; 123pp; English.
XX
CC   The present sequence represents the preferred target sequence of an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC   the descriptor line. The HCV sequence was screened for optimal ribozyme
CC   target sites using a computer folding algorithm and regions of the mRNA
CC   which did not form secondary folding structures and contained potential
CC   ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC   target these sites and their activities optimised by either varying the
CC   length of the binding arms or by modification to prevent degradation by
CC   nucleases. The ribozymes of the invention inhibit gene expression and/or
CC   viral replication, and are used to treat diseases associated with
CC   Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC   hepatocellular carcinoma. The ribozymes may be used in combination with
CC   interferon to treat HCV infection, other infectious diseases, autoimmune
CC   diseases, and cancer
XX
SQ   Sequence 15 BP; 5 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 92;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 170
ABN80545
ID   ABN80545 standard; DNA; 15 BP.
XX
AC   ABN80545;
XX
DT   19-JUL-2002  (first entry)
XX
```

DE Human P450(cytochrome) oxidoreductase allele specific probe #11.
XX
KW Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;
KW single nucleotide polymorphism; flavoprotein; enzyme; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200226768-A2.
XX
PD 04-APR-2002.
XX
PF 01-OCT-2001; 2001WO-US030877.
XX
PR 29-SEP-2000; 2000US-0236449P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Kazemi A, Kliem SE, Lanz EM, Messer C, Tanguay DA;
XX
DR WPI; 2002-394236/42.
XX
PT New genetic variants comprising haplotypes of the P450 (cytochrome)
PT oxidoreductase (POR) isogene, useful in improving the efficiency of drug
PT screening protocols for compounds targeting POR.
XX
PS Claim 14; Page 14; 141pp; English.
XX
CC The present invention provides the protein, gene and cDNA sequences of
CC human P450(cytochrome) oxidoreductase POR, and single nucleotide
CC polymorphisms (SNPs) identified therein. The sequences can be used to
CC haplotype the POR gene of an individual, and to establish whether POR is
CC a suitable target for drugs to treat cancer and disorders associated with
CC impaired protein synthesis in cells. The present sequence is an allele
CC specific probe for the coding sequences of the invention
XX
SQ Sequence 15 BP; 4 A; 3 C; 5 G; 2 T; 0 U; 1 Other;

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy        743 TGGAGACAGAGCCTC 757
              ||||||| ||| |||
Db          1 TGGAGACRGAGACTC 15
```

RESULT 171
ABL45821/c
ID ABL45821 standard; DNA; 15 BP.
XX
AC ABL45821;
XX
DT 26-APR-2002 (first entry)
XX
DE Human EDG6 gene allele specific probe SEQ ID NO: 15.
XX
KW Human; endothelial differentiation, G-protein coupled receptor 6; EDG6;
KW haplotype; cancer; angiogenesis; inflammation; chromosome 19p13.3;
KW cytostatic; antiinflammatory; gene therapy; SNP;
KW single nucleotide polymorphism; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200206446-A2.
XX
PD 24-JAN-2002.
XX
PF 17-JUL-2001; 2001WO-US022523.
XX
PR 17-JUL-2000; 2000US-0218727P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Kliem SE, Koshy B;
XX
DR WPI; 2002-171804/22.
XX
PT New genetic variants of endothelial differentiation, G-protein coupled
PT receptor-6 gene for studying expression, function of the gene and
PT expressing EDG6 protein for use in screening drugs to treat cancer,
PT inflammation.
XX
PS Claim 16; Page 13; 111pp; English.
XX
CC The present invention provides the gene, protein and cDNA sequences of
CC the human endothelial differentiation, G-protein coupled receptor 6
CC (EDG6). Also identified are single nucleotide polymorphisms (SNPs) found
CC within the sequences. The sequences can be used in the identification of
CC the haplotype of an individual, and in the treatment of cancer,
CC angiogenesis and inflammation. The present sequence is an allele specific
CC probe for the EDG6 gene, which is found on chromosome 19p13.3
XX
SQ Sequence 15 BP; 1 A; 5 C; 4 G; 4 T; 0 U; 1 Other;

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy        578 GCAGCCTGAAGAGTG 592
              |||||| :|||||||
Db         15 GCAGCCCRAAGAGTG 1
```

RESULT 172
ABX00704
ID ABX00704 standard; RNA; 15 BP.
XX
AC ABX00704;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #486 for HCV hammerhead ribozyme #486.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytostatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 35; 80pp; English.
XX

```
CC   The present invention relates to enzymatic nucleic acids which
CC   specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC   enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC   (HP) motif where the binding arms comprise sequences complementary to one
CC   of the substrate sequences defined in the specification. The HCV
CC   ribozymes are useful for modulating the expression and/or replication of
CC   HCV. They can be used to treat cirrhosis, liver failure and/or
CC   hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC   a condition associated with HCV infection in conjunction with one or more
CC   other drug therapies, particularly type I interferon, especially
CC   interferon alpha, beta or gamma or consensus interferon. The present
CC   sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC   Some of the sequence data for this patent did not form part of the
CC   printed specification. The complete sequence data for this patent was
CC   obtained in electronic format directly from the USPTO web site at
CC   seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 15 BP; 5 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

  Query Match             0.6%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   84.6%;  Pred. No. 92;
  Matches   11;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1146 ATGCCTCAGGAAA 1158
              |:|||:|||||||
Db          2 AUGCCUCAGGAAA 14


RESULT 173
AAT90604
ID   AAT90604 standard; RNA; 16 BP.
XX
AC   AAT90604;
XX
DT   07-APR-1998  (first entry)
XX
DE   Hepatitis C virus recognition sequence 14 for ribozyme cleavage.
XX
KW   Recognition sequence; HCV; ribozyme; 5' untranslated region;
KW   nucleocapsid coding region; hairpin ribozyme; RNA cleavage; treatment;
KW   HCV infection; HCV contamination; ss.
XX
OS   Hepatitis C virus.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .4
FT                   /*tag=  a
FT                   /note= "complementary to the CR12 ribozyme"
FT   misc_feature    6
FT                   /*tag=  b
FT                   /note= "cleavage site corresponding to position 2469 of
FT                   the (+) strand, counting from 5' end"
FT   misc_feature    9. .16
FT                   /*tag=  c
FT                   /note= "complementary to the CR12 ribozyme"
XX
PN   WO9732018-A2.
XX
PD   04-SEP-1997.
XX
PF   27-FEB-1997;   97WO-US003304.
XX
PR   29-FEB-1996;   96US-00608862.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Barber JR,  Welch PJ,  Tritz R,  Yei S,  Yu M;
XX
DR   WPI; 1997-470461/43.
XX
PT   Ribozyme(s) directed against hepatitis C virus - for prevention and
PT   treatment of viral infection, and detection of HCV contamination of
PT   blood.
XX
PS   Example 1; Page 17; 98pp; English.
XX
CC   AAT90591-620 represent recognition sequences found in the positive (+)
CC   strand of the Hepatitis C virus (HCV) RNA. The sequences are recognised
CC   by novel ribozymes which inhibit replication, infectivity or gene
CC   expression of HCV. The present sequence is located within the NS1 gene.
CC   Hairpin ribozymes of the present invention were designed based on
CC   sequences adjacent to the GUC sequence recognition feature. The ribozymes
CC   are directed against conserved regions of the genome and so should be
CC   active against many strains of HCV. The ribozymes, when optionally
CC   expressed from a vector, cleave the RNA of HCV and so are useful for
CC   treatment and prevention of HCV infection. They can also be used to
CC   detect HCV contamination of blood or for clinical diagnosis
XX
SQ   Sequence 16 BP; 3 A; 2 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||:| ||||::|
Db          1 AUAGGGUCAGCGGUUG 16


RESULT 174
AAZ97721
ID   AAZ97721 standard; DNA; 16 BP.
XX
AC   AAZ97721;
XX
DT   15-SEP-2003  (revised)
DT   26-APR-2000  (first entry)
XX
DE   HIV-1 protease gene probe SEQ ID NO:211.
XX
KW   Human immunodeficiency virus; HIV; protease; probe; detection;
KW   drug selected mutation; hybridisation; genotyping; infection;
KW   drug resistance; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9967428-A2.
XX
PD   29-DEC-1999.
XX
PF   22-JUN-1999;   99WO-EP004317.
XX
PR   24-JUN-1998;   98EP-00870143.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Stuyver L;
XX
DR   WPI; 2000-147219/13.
XX
PT   Detection of drug-selected mutations in the HIV protease gene used to
PT   treat HIV infections.
XX
PS   Claim 3; Page 37; 76pp; English.
XX
CC   The present invention describes the detection of drug-selected mutations
CC   in the HIV protease gene. The method of detection allows the simultaneous
CC   characterisation of a range of codons involved in drug resistance using
CC   sets of probes optimised to function together in a reverse-hybridisation
CC   assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC   in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC   protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC   AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC   and AAZ97516 represents an HIV protease probe used in an example from the
CC   present invention. The method, probes and primers can be used for the
CC   detection of drug-selected mutations in the HIV protease gene. The method
```

```
CC   allows the simultaneous characterisation of a range of codons involved in
CC   drug resistance. The method may also be used for HIV protease genotyping
CC   assays. The probes are able to discriminate between wild type and mutated
CC   protease sequences. The method allows rapid and reliable detection of
CC   drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC   field)
XX
SQ   Sequence 16 BP; 6 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1452 AGTTTTTATAAAAGTA 1467
              || |||||| ||||||
Db          1 AGGTTTTATCAAAGTA 16


RESULT 175
AAA13421
ID   AAA13421 standard; RNA; 16 BP.
XX
AC   AAA13421;
XX
DT   17-JUL-2000  (first entry)
XX
DE   Hepatitis C virus hairpin ribozyme recognition sequence SEQ ID NO:21.
XX
KW   Hepatitis C virus; HCV; hairpin ribozyme; cleavage; recognition site;
KW   infection; virucide; hepatotropic; antiinflammatory;
KW   replication inhibitor; gene expression inhibitor; ss.
XX
OS   Hepatitis C virus.
XX
PN   US6043077-A.
XX
PD   28-MAR-2000.
XX
PF   20-OCT-1997;   97US-00954210.
XX
PR   29-FEB-1996;   97US-00608862.
PR   27-FEB-1997;   97WO-US003304.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Yei S,  Yu M,  Barber JR,  Welch PJ;
XX
DR   WPI; 2000-270342/23.
XX
PT   Ribozyme capable of inhibiting replication, infectivity or gene
PT   expression of hepatitis C virus, useful for treating or preventing
PT   hepatitis C virus infection.
XX
PS   Example 1; Col 12; 57pp; English.
XX
CC   The present invention describes ribozymes (I) capable of inhibiting
CC   replication, infectivity or gene expression of a hepatitis C virus (HCV),
CC   directed to target sequences AAA13438 to AAA13444, AAA13454 and AAA13465.
CC   (I) have virucide, hepatotropic and antiinflammatory activities. (I), or
CC   vectors comprising nucleotide sequences encoding (I), are useful for
CC   interfering with the replication or gene expression of HCV in a human
CC   cells. (I) are useful for diagnosis, prevention and treatment of HCV
CC   infection or disease in a mammals especially humans. Nucleotide sequences
CC   encoding (I) are useful for preventing hepatitis C viral infection in a
CC   cell. AAA13401 to AAA13405 represent examples of the briefest
CC   requirements for hairpin ribozyme; AAA13406 and AAA13407 represent PCR
CC   primers used in the amplification of the HCV capsid sequence; AAA13408 to
CC   AAA13467 represent HCV hairpin ribozyme recognition sites; and AAA13468
CC   to AAA13473 represent oligonucleotides used in the construction of HCV
CC   hairpin ribozymes, all these sequences are used in the exemplification of
CC   the present invention
XX
SQ   Sequence 16 BP; 3 A; 2 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||:| ||||::|
Db          1 AUAGGGUCAGCGGUUG 16


RESULT 176
ABK40647/c
ID   ABK40647 standard; DNA; 16 BP.
XX
AC   ABK40647;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human beta1-adrenoceptor antisense oligonucleotide #69.
XX
KW   ss; antisense; beta1 adrenoceptor; beta1-AR; vasotropic; hypotensive;
KW   cardiant; hypertension; hypertrophy; cardiac ischaemia;
KW   cardiovascular disease; cardiac dysfunction.
XX
OS   Homo sapiens.
XX
PN   WO200204623-A2.
XX
PD   17-JAN-2002.
XX
PF   11-JUL-2001; 2001WO-US021759.
XX
PR   11-JUL-2000; 2000US-00614034.
XX
PA   (UYFL ) UNIV FLORIDA.
XX
PI   Phillips MI,  Zhang Y;
XX
DR   WPI; 2002-164644/21.
XX
PT   Novel antisense oligonucleotides that specifically bind to mRNA encoding
PT   beta 1-adrenoreceptor polypeptide, useful for treating cardiac
PT   dysfunction, hypertension, hypertrophy and other cardiovascular diseases
PT   in humans.
XX
PS   Claim 48; Page 19; 186pp; English.
XX
CC   The invention relates to an isolated antisense oligonucleotide of 9-35
CC   nucleotides in length, which specifically binds to a portion of an mRNA
CC   expressed from a gene encoding a mammalian beta1-adrenoceptor (AR)
CC   polypeptide and alters the translation of the mRNA into the beta1-AR
CC   polypeptide in a host cell expressing the mRNA. Also included are a
CC   recombinant vector comprising the antisense oligonucleotide, and a host
CC   cell comprising the vector. A composition comprising the antisense
CC   oligonucleotides is useful in the manufacture of a medicament for use in
CC   treating or ameliorating hypertension, hypertrophy and cardiac ischaemia
CC   in a mammal. A composition comprising the antisense oligonucleotides is
CC   also useful for reducing the level of beta1-AR polypeptide, the
CC   transcription of beta1-AR polypeptide-specific mRNA in a mammalian host
CC   cell, particularly human cell, and for decreasing blood pressure in a
CC   mammal, where the antisense oligonucleotide is operably linked to a
CC   promoter capable of expressing the oligonucleotide in the cell. A
CC   composition comprising a selected nucleic acid segment that comprises a
CC   full-length, or is a full length beta1-adrenoceptor antisense
CC   polynucleotide operatively linked to a promoter capable of expressing the
CC   polynucleotide in a cell is also useful for reducing the level of beta_1-
CC   adrenoceptor polypeptide in a mammalian host cell. The antisense
CC   oligonucleotide is also useful for other cardiovascular diseases and
CC   cardiac dysfunction in humans. The present sequence is a beta1-AR mRNA
CC   targetting antisense oligonucleotide of the invention
XX
SQ   Sequence 16 BP; 2 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
```

```
  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        685 AGCCCCGCATGGGCGC 700
              ||| | ||||||||||
Db         16 AGCTCGGCATGGGCGC 1


RESULT 177
ABX74340
ID   ABX74340 standard; RNA; 16 BP.
XX
AC   ABX74340;
XX
DT   24-MAR-2003  (first entry)
XX
DE   Hepatitis C recognition sequence for ribozyme CR12.
XX
KW   Hairpin ribozyme; ss; hepatitis C infection; HCV; gene therapy; virucide.
XX
OS   Hepatitis C virus.
XX
PN   US6458567-B1.
XX
PD   01-OCT-2002.
XX
PF   01-NOV-1999;   99US-00431419.
XX
PR   29-FEB-1996;   96US-00608862.
PR   20-OCT-1997;   97US-00954210.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Barber JR,  Welch PJ,  Tritz R,  Yei S,  Yu M;
XX
DR   WPI; 2003-155536/15.
XX
PT   New ribozyme having the ability to inhibit replication, infectivity or
PT   gene expression of a Hepatitis C Virus (HCV), useful for treating or
PT   preventing HCV infection.
XX
PS   Example 1; Col 12; 48pp; English.
XX
CC   The invention relates to a new ribozyme with the ability to inhibit
CC   replication, infectivity or gene expression of a Hepatitis C Virus (HCV)
CC   by cleaving the positive strand genomic RNA of HCV at a sequence having
CC   16 bp. Also included are a nucleic acid encoding the ribozyme, a host
CC   cell containing the ribozyme or vector, a vector comprising a promoter
CC   operably linked to the nucleic acid, producing a ribozyme, interfering
CC   with HCV replication or gene expression in a cell infected in a cell
CC   culture with HCV or a composition comprising the ribozyme and a carrier
CC   or diluent. The ribozyme is useful for treating or preventing HCV
CC   infection. The present sequence is an HCV +ve strand recognition sequence
CC   for a ribozyme of the invention
XX
SQ   Sequence 16 BP; 3 A; 2 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1314 AAAGGGTCTGCGGTTG 1329
              | ||||:| ||||::|
Db          1 AUAGGGUCAGCGGUUG 16


RESULT 178
ACF58014/c
ID   ACF58014 standard; DNA; 28 BP.
XX
AC   ACF58014;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Mouse npFXRa RNA expression analysing RT-PCR primer.
XX
KW   Nuclear receptor; npFXRb; npFXR-beta; cholesterol; triglyceride; RT-PCR;
KW   bile acid; lanosterol; fertility control; npFXRa; primer; ss.
XX
OS   Mus sp.
XX
PN   WO2003087140-A1.
XX
PD   23-OCT-2003.
XX
PF   07-MAR-2003; 2003WO-EP002357.
XX
PR   13-APR-2002; 2002EP-00008454.
XX
PA   (LION-) LION BIOSCIENCE AG.
XX
PI   Deuschle U,  Jackson D,  Kober I,  Kranz H,  Kremoser C,  Otte K;
PI   Remmel B;
XX
DR   WPI; 2003-833703/77.
XX
PT   New nucleic acid molecule coding for the non-primate nuclear receptor
PT   npFXRb, useful for the analysis of agents that modulate cholesterol, bile
PT   acids, and triglyceride synthesis.
XX
PS   Example 1; Page 44; 0pp; English.
XX
CC   The invention relates to a novel non-primate nuclear receptor npFXRb
CC   (npFXR-beta) or its splice variants. Host cells comprising the npFXRb
CC   nucleic acids or the npFXRb transgenic animals are useful for identifying
CC   agents that are capable of modulating the cellular function of the non-
CC   primate nuclear receptor of npFXRb or its splice variants, preferably for
CC   the analysis of agents that modulate cholesterol, bile acids, and
CC   triglyceride synthesis. The agent is useful for modulating the synthesis
CC   of lanosterol or cholesterol from lanosterol or bile acids or
CC   triglycerides in non-primate animals, modulating developmental processes
CC   in non-primate animals, and/or modulating the wool fat synthesis in sheep
CC   or lamas. The agent is preferably useful for the fertility control of non
CC   -primate animals, including mice, rats, rabbits, frogs, birds, fish, or
CC   non-vertebrates. Sequences ACF58014-15 represent RT-PCR primers for
CC   analysis of murine npFXRa RNA expression
XX
SQ   Sequence 28 BP; 5 A; 2 C; 10 G; 11 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 12.8;  DB 1;  Length 28;
  Best Local Similarity   70.8%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy        944 GTTAACTGAAATTCAGTGTAAATC 967
              ||||||  | ||||||   | |||
Db         26 GTTAACAAACATTCAGCCAACATC 3


RESULT 179
ABC04480
ID   ABC04480 standard; DNA; 13 BP.
XX
AC   ABC04480;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 4471 for detecting SNP TSC0001638.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4471; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;

```
  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1446 ATGTTTAGTTTTT 1458
              |||||||||||:
Db          1 ATGTTTAGTTTTY 13
```

RESULT 180
ABC39927
ID ABC39927 standard; DNA; 13 BP.
XX
AC ABC39927;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 39944 for detecting SNP TSC0012177.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 39944; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 1 Other;

```
  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1156 AAATAACAAATAA 1168
              :|||||||||||:
Db          1 RAATAACAAATAA 13
```

RESULT 181
ABC16033
ID ABC16033 standard; DNA; 13 BP.
XX
AC ABC16033;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16040 for detecting SNP TSC0003517.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 16040; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

```
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1157 AATAACAAATAAA 1169
              :|||||||||||||
Db          1 RATAACAAATAAA 13


RESULT 182
ABF51058/c
ID   ABF51058 standard; DNA; 13 BP.
XX
AC   ABF51058;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 151055 for detecting SNP TSC0038138.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151055; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1104 ACTCTTCTACATT 1116
              :|||||||||||||
Db         13 RCTCTTCTACATT 1


RESULT 183
ABH59876/c
ID   ABH59876 standard; DNA; 13 BP.
XX
AC   ABH59876;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 259853 for detecting SNP TSC0009042.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 259853; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        761 ATACCACTATAAT 773
              :|||||||||||||
Db         13 RTACCACTATAAT 1


RESULT 184
ABC39926/c
ID   ABC39926 standard; DNA; 13 BP.
XX
AC   ABC39926;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 39943 for detecting SNP TSC0012177.
```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 39943; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 1 Other;

Query Match 0.6%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 99;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1156 AAATAACAAATAA 1168
:||||||||||||
Db 13 RAATAACAAATAA 1

RESULT 185
ABH31369
ID ABH31369 standard; DNA; 13 BP.
XX
AC ABH31369;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 231346 for detecting SNP TSC0056414.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 231346; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 0.6%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 99;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1160 AACAAATAAAATT 1172
:||||||||||||
Db 1 RACAAATAAAATT 13

RESULT 186
ABF89184/c
ID ABF89184 standard; DNA; 13 BP.
XX
AC ABF89184;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 189181 for detecting SNP TSC0046569.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 189181; 29pp + Sequence Listing; German.

```
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1431 GAATATATAACAC 1443
              :||||||||||||
Db         13 RAATATATAACAC 1


RESULT 187
ABF51059
ID   ABF51059 standard; DNA; 13 BP.
XX
AC   ABF51059;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 151056 for detecting SNP TSC0038138.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151056; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1104 ACTCTTCTACATT 1116
              :||||||||||||
Db          1 RCTCTTCTACATT 13


RESULT 188
ABH28233
ID   ABH28233 standard; DNA; 13 BP.
XX
AC   ABH28233;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 228210 for detecting SNP TSC0055644.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 228210; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1155 GAAATAACAAATA 1167
              :||||||||||||
Db          1 RAAATAACAAATA 13


RESULT 189
```

```
ABF62626
ID   ABF62626 standard; DNA; 13 BP.
XX
AC   ABF62626;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 162623 for detecting SNP TSC0040908.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 162623; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 2 G; 7 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1117 TTATTATGGATTC 1129
              ||||||||||||:
Db          1 TTATTATGGATTY 13


RESULT 190
ABH57534
ID   ABH57534 standard; DNA; 13 BP.
XX
AC   ABH57534;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 257511 for detecting SNP TSC0005086.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 257511; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTT 1457
              ||||||||||||:
Db          1 TATGTTTAGTTTY 13


RESULT 191
ABH57535/c
ID   ABH57535 standard; DNA; 13 BP.
XX
AC   ABH57535;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 257512 for detecting SNP TSC0005086.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
```

```
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 257512; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1445 TATGTTTAGTTTT 1457
              ||||||||||||:
Db         13 TATGTTTAGTTTY 1


RESULT 192
ABH59877
ID   ABH59877 standard; DNA; 13 BP.
XX
AC   ABH59877;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 259854 for detecting SNP TSC0009042.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 259854; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       761 ATACCACTATAAT 773
             :||||||||||||
Db         1 RTACCACTATAAT 13


RESULT 193
ABF11960/c
ID   ABF11960 standard; DNA; 13 BP.
XX
AC   ABF11960;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111957 for detecting SNP TSC0027944.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111957; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
```

```
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 ATAACAAATAAAA 1170
              :|||||||||||||
Db         13 RTAACAAATAAAA 1


RESULT 194
ABH28232/c
ID   ABH28232 standard; DNA; 13 BP.
XX
AC   ABH28232;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 228209 for detecting SNP TSC0055644.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 228209; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1155 GAAATAACAAATA 1167
              :|||||||||||||
Db         13 RAAATAACAAATA 1


RESULT 195
ABF62627/c
ID   ABF62627 standard; DNA; 13 BP.
XX
AC   ABF62627;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 162624 for detecting SNP TSC0040908.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 162624; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1117 TTATTATGGATTC 1129
              ||||||||||||:
Db         13 TTATTATGGATTY 1


RESULT 196
ABH41465/c
ID   ABH41465 standard; DNA; 13 BP.
XX
AC   ABH41465;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241442 for detecting SNP TSC0007988.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
```

```
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241442; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1456 TTTATAAAAGTAT 1468
              |||||||||||:
Db         13 TTTATAAAAGTAY 1


RESULT 197
ABC71778/c
ID   ABC71778 standard; DNA; 13 BP.
XX
AC   ABC71778;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 71795 for detecting SNP TSC0018570.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 71795; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1252 AATTCACAAAAAA 1264
              :||||||||||||
Db         13 RATTCACAAAAAA 1


RESULT 198
ABH41464
ID   ABH41464 standard; DNA; 13 BP.
XX
AC   ABH41464;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 241441 for detecting SNP TSC0007988.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 241441; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
```

```
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1456 TTTATAAAAGTAT 1468
              ||||||||||||:
Db          1 TTTATAAAAGTAY 13


RESULT 199
ABH31368/c
ID   ABH31368 standard; DNA; 13 BP.
XX
AC   ABH31368;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 231345 for detecting SNP TSC0056414.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 231345; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1160 AACAAATAAAATT 1172
              :||||||||||||
Db         13 RACAAATAAAATT 1


RESULT 200
ABF11961
ID   ABF11961 standard; DNA; 13 BP.
XX
AC   ABF11961;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111958 for detecting SNP TSC0027944.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111958; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 1 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1158 ATAACAAATAAAA 1170
              :||||||||||||
Db          1 RTAACAAATAAAA 13


RESULT 201
ABC71779
ID   ABC71779 standard; DNA; 13 BP.
XX
AC   ABC71779;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 71796 for detecting SNP TSC0018570.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 71796; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 0.6%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 99;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1252 AATTCACAAAAAA 1264
:||||||||||||
Db 1 RATTCACAAAAAA 13

RESULT 202
ABC16032/c
ID ABC16032 standard; DNA; 13 BP.
XX
AC ABC16032;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16039 for detecting SNP TSC0003517.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 16039; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 1 G; 9 T; 0 U; 1 Other;

Query Match 0.6%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 99;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1157 AATAACAAATAAA 1169
:||||||||||||
Db 13 RATAACAAATAAA 1

RESULT 203
ABC04481/c
ID ABC04481 standard; DNA; 13 BP.
XX
AC ABC04481;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 4472 for detecting SNP TSC0001638.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4472; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic

```
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1446 ATGTTTAGTTTTT 1458
              |||||||||||:
Db         13 ATGTTTAGTTTTY 1


RESULT 204
ABF89185
ID   ABF89185 standard; DNA; 13 BP.
XX
AC   ABF89185;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 189182 for detecting SNP TSC0046569.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 189182; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 2 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 99;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1431 GAATATATAACAC 1443
              :|||||||||||
Db          1 RAATATATAACAC 13


RESULT 205
AAS98725
ID   AAS98725 standard; DNA; 15 BP.
XX
AC   AAS98725;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #91.
XX
KW   Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
KW   cytostatic; gene therapy; malignant histiocytosis; isogene;
KW   myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
KW   genotype; human; allele specific oligonucleotide; ASO; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200179225-A2.
XX
PD   25-OCT-2001.
XX
PF   12-APR-2001; 2001WO-US012044.
XX
PR   12-APR-2000; 2000US-0196411P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Chew A,  Choi JY,  Koshy B;
XX
DR   WPI; 2002-075058/10.
XX
PT   Novel polymorphic variants of colony stimulating factor 1 receptor useful
PT   in studying expression and function of the protein, useful for screening
PT   candidate drugs to treat diseases e.g. inflammatory disorders.
XX
PS   Claim 15; Page 16; 164pp; English.
XX
CC   The invention describes a novel isolated polynucleotide (I) comprising a
CC   sequence which is a polymorphic variant (PV) of a reference sequence for
CC   colony stimulating factor 1 receptor (CSF1R) gene, found on The
CC   polypeptide are useful for improving the discovery and development of
CC   drugs for treating diseases associated with CSF1R activity, e.g.,
CC   malignant histiocytosis, myeloid malignancies, and inflammatory disorders
CC   and the haplotypes can be used to validate CSF1R as a candidate target
CC   for treating a specific condition or disease predicted to be associated
CC   with CSF1R activity. Genotyping the CSF1R gene of an individual can also
CC   be used in developing diagnostic tests and therapeutic treatments. (I) is
CC   useful in studying the expression and function of CSF1R, and in
CC   expressing CSF1R protein for use in screening for candidate drugs to
CC   treat diseases related to CSF1R activity and in studying the effect of
CC   the variation on the biological activity of CSF1R as well as on the
CC   binding affinity of candidate drugs targeting CSF1R. Antibodies are
CC   useful in a variety of diagnostic and prognostic formats and therapeutic
CC   methods. A transgenic animal is useful in studying expression of the
CC   CSF1R isogenes in vivo, for in vivo screening and testing of drugs
CC   targeted against CSF1R protein, and for testing the efficacy of
CC   therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
CC   are useful as probes and primers, and for assaying a polymorphism in the
CC   target region. Without requiring any a priori knowledge of the phenotypic
CC   effect of any particular CSF1R or haplotype the invention provides a
CC   method for identifying lead compounds that are more likely to show
CC   efficacy in clinical trials. This sequence is an allele specific
CC   oligonucleotide primer used for detecting CSF1R gene polymorphisms,
```

```
CC   described in the method of the invention
XX
SQ   Sequence 15 BP; 4 A; 2 C; 6 G; 2 T; 0 U; 1 Other;

  Query Match             0.6%;  Score 12.6;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GCCTGAAGAGTGG 593
              ||||||||||||:|
Db          3 GCCTGAAGAGTRG 15


RESULT 206
AAL61360
ID   AAL61360 standard; DNA; 20 BP.
XX
AC   AAL61360;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145307.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 74; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             0.6%;  Score 12.2;  DB 1;  Length 20;
  Best Local Similarity   82.4%;  Pred. No. 1.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         23 ACCTCATTGTCTCCCCG 39
              |||||| | ||||||  |
Db          4 ACCTCAGTTTCTCCCTG 20


RESULT 207
AAL61335
ID   AAL61335 standard; DNA; 20 BP.
XX
AC   AAL61335;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126487.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
```

```
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 12;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1196 AGAAAATTTTCT 1207
              ||||||||||||
Db          4 AGAAAATTTTCT 15


RESULT 208
AAL61331
ID   AAL61331 standard; DNA; 20 BP.
XX
AC   AAL61331;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126474.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 73; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             0.5%;  Score 11.6;  DB 1;  Length 20;
  Best Local Similarity   77.8%;  Pred. No. 1.7e+02;
  Matches   14;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        374 CATTGAACATTCCCATTT 391
              ||   |||||||||| |
Db          1 CAGCCAACATTCCCATCT 18


RESULT 209
AAL61332
ID   AAL61332 standard; DNA; 20 BP.
XX
AC   AAL61332;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 126476.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
```

DR WPI; 2003-468767/44.
XX
PT New antisense oligonucleotides for modulating human farnesoid X receptor
PT (FXR) expression, useful for treating conditions associated with FXR in
PT humans, e.g. cardiovascular disease, atherosclerosis or
PT hypercholesterolemia.
XX
PS Claim 3; Page 73; 127pp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC inhibiting the expression of human FXR in cells or tissues. It is
CC particularly useful for treating or preventing a disease or condition
CC associated with FXR in a human, e.g. cardiovascular disease,
CC atherosclerosis or hypercholesterolaemia. The antisense compound is
CC useful for diagnostics, therapeutics, prophylaxis, or as research
CC reagents or kits. It is also used in gene therapy. The present sequence
CC is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC is used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 11.6; DB 1; Length 20;
Best Local Similarity 77.8%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 943 TGTTAACTGAAATTCAGT 960
| | |||||| ||||||
Db 1 TTTACACTGAATTTCAGT 18

RESULT 210
AAL61320/c
ID AAL61320 standard; DNA; 27 BP.
XX
AC AAL61320;
XX
DT 22-SEP-2003 (first entry)
XX
DE Human farnesoid X receptor (FXR) DNA specific forward PCR primer.
XX
KW Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW retinoid X receptor-interacting protein 14; RIP14; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003044167-A2.
XX
PD 30-MAY-2003.
XX
PF 13-NOV-2002; 2002WO-US036691.
XX
PR 15-NOV-2001; 2001US-00002491.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Watt AT;
XX
DR WPI; 2003-468767/44.
XX
PT New antisense oligonucleotides for modulating human farnesoid X receptor
PT (FXR) expression, useful for treating conditions associated with FXR in
PT humans, e.g. cardiovascular disease, atherosclerosis or
PT hypercholesterolemia.
XX
PS Example 13; Page 71; 127pp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC inhibiting the expression of human FXR in cells or tissues. It is
CC particularly useful for treating or preventing a disease or condition
CC associated with FXR in a human, e.g. cardiovascular disease,
CC atherosclerosis or hypercholesterolaemia. The antisense compound is
CC useful for diagnostics, therapeutics, prophylaxis, or as research
CC reagents or kits. It is also used in gene therapy. The present sequence
CC is human FXR DNA specific PCR primer. This sequence is used in the
CC exemplification of the invention
XX
SQ Sequence 27 BP; 11 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 11.6; DB 1; Length 27;
Best Local Similarity 65.4%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 240 TCTCTTAGTTTCCTGGATTTCTTCTG 265
| ||| ||| | | ||||| |||
Db 27 TTTCTCAGTCGCTTAGATTTACACTG 2

Search completed: April 8, 2004, 15:22:29
Job time : 6 secs